¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>ªYÄ£¥ÍÂå
¥«³õ­º¨£·sÃÄ ±ÂÅv½Í¤¤     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Ghung120110149413  µoªí®É¶¡:2020/6/24 ¤U¤È 02:11:23
¥«³õ­º¨£·sÃÄ(¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸) Àø®Ä¤ÀªR p=0.009

6634 ªYÄ£

ªÑ¥»: 3.832»õ

¥D­n·~°È:

¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo

¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤)

¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤)

Ä~Äò©¹¤U¬Ý...!

=============================================================================

²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ)

¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢

²£«~Àu¶Õ:

1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ«

2.¥«³õ­º¨£·sÃÄ(First-in-class)

3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x

4.µL¦w¥þ©Ê°ÝÃD

¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C

Ävª§¤O:

1.¦h­«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢

2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A­°§C¨x¯×

3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x

¬ãµo¶¥¬q:

1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á

2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ

Àø®Ä¤ÀªR¡G

1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n

2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009)

=============================================================================

²£«~02¡GSNP-630

¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢

²£«~Àu¶Õ:

1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE)

2.¥«³õ­º¨£·sÃÄ(First-in-class)

3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x

4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~

¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C

Ävª§¤O:

1.¦h­«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢

2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A­°§C¨x¯×

3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡

4.µL¦w¥þ©Ê°ÝÃD

¬ãµo¶¥¬q:

1.Á{§É«e

2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C

3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C

Àø®Ä¤ÀªR¡G

1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05

=============================================================================

²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯)

¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯)

²£«~Àu¶Õ:

1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê

2.¸Ñ¨M­¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs)

3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q

¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ

Ävª§¤O:

1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«

2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^

3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O

¬ãµo¶¥¬q:

1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç

2.¤w¥Ó½ÐUSFDA¼Ï&#32445;Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D

3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç

=============================================================================

²£«~04¡GSNP-830/ SNP-840

¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B­««×¯kµh)

²£«~Àu¶Õ:

1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è

2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q

¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ

Ävª§¤O:

1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è

2.½Æ¤è¤w¥Ñ¬ü°êFDA­n¨D­°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä

3.¦³¨Ï¥Î±M§Q¡A¥i­×§ï©Î§R°£FDA¨x¬rĵ»y

4.¥i¼W¥[¤AñQÓi×ô¾¯¶q

¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A­°§C¦¨Å}°Æ§@¥Î

5.¤GªÌ¾Ü¤@±ÂÅv

6.¥i¼W¥[¥«¦û²v

¬ãµo¶¥¬q:

1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç

SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ý­n¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç

µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ

=============================================================================

*****************************************************************************

SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G

1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005

1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005

=============================================================================

*****************************************************************************

¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G

1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv

2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv

3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿­±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv

=============================================================================

*****************************************************************************

¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@­p¹º

§Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó

¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ù­È±o´Á«Ý¡A¦³¾÷·|¬O ¤U¤@­Ó ¦X¤@ ÄƪÑ

-----------------------------------------------------------------------------

¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×)

·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/10 ¤W¤È 08:24:13²Ä 2416 ½g¦^À³
»¡¸Ñª¼ÃD§÷ªºªÑ»ù°ª§C«ÜÃø«Ü¶Ë¸£µ¬¡A­Ó¤Hªº»{ª¾®t²§¡A¨ä°ª§Cµ²ªG´N¬O¤j¤j¤£¦P¡A§Ú¶É¦V¥HÁ`¥«­Èµû»ù¡A¼vÅT¦]¤l:ÃĪ«²{ªp(Á{§É´ÁP1~P3,Ävª§ªÌµ¥)¡A¥«³õ¤j¤p(ÃÄ»ù,±wªÌ¼Æµ¥)...¡A«hÁö¤£¤¤¥ç¤£»·¨o¡C

¥H¤U­Ó¤H²L¨£¶È°µ°Ñ¦Ò:

1.¥H«e°ò¨È»P¯E¹©ªº¸Ñª¼¥«­È?(3®a³£¬OÀù¯gÃĪ«)

2.²{¦bÃĵØÃĪº¥«­È?

«ä¦Ò¤H®a¯d¤U(¤j³g)ªº³¡¦ì¬Oµ¥¤°»ò¡A±ÂÅvª÷ÃD§÷»P¯Ç¤JMSCIªk¤H©Ô©ï???

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/9/10 ¤W¤È 04:41:02²Ä 2415 ½g¦^À³
Nelson¡A§Ú¤]¦³¥_·¥¬P¡A¤£¹L¥u¬Oª±ª±¡AÁȸѪ¼¦æ±¡¡C

¦Ñ°­®w¦s888ÅÜ333¡A¦b178½æ¥X¦^¥»(¤£³g)¡A³Ñ¤U333½ä¸Ñª¼¸ò¥¼¨Ó(¤j³g)¡A¬O¦Ñ°­¤½¶}¶K¤åªº¡C§Ú¨º¸Ì¶Ã»¡¡H

-------------

DK¤j¡ARoger¤j¡A

¦b¡yªYÃÄ¡z°Q½×¨ä¥LªÑ²¼¡A§Ú§¹¥þ¨S¦³°ÝÃD¡I­Ó¤H¤]«D±`³ßÅwÅ¥¨ì¥H¤£¦Pªº¨¤«×¤Î°T®§¨Ó¤ÀªR¦Û¤vªº§ë¸ê¼Ðªº¬O§_¦³§Ú¨S¬Ý¨ìªº¼ç¦b­·ÀI¡H¡I

¦ý¬O§ÚµLªk»{¦P Peter Lin ©ó 9 ¤ë 7 ¤é¡A¹ï¡y¥_·¥¬P¡z¥H¤Uªºµû½×¡I¦]¬°¦³®Ú¾Ú¶Ü¡H¶º¥i¥H¶Ã¦Y¡A¸Ü¤£¯à¶ÃÁ¿¡I .. ¤§«eªº¤@­Óµû½×¡A¤]¦³¥¢°¾»á¡G

¡y¦A¨Ó»¡¤@¤U¥_·¥¬P¡A¬Ý·|¤£·|º¦¡H

¦Ñ°­¤£³g¥ý½æ60%²{ªÑ¥ý¦^¥»¡A³Ñ¤Uªº¤j³g40%«ùªÑ½ä¡C

¥i¼¦ªº´²¤á¡C¡z

¡yªYÃÄ¡z¸ò¡y¥_·¥¬P¡z¡A§Ú³£¦³«ùªÑ¡I ¡K ¦P®É¡A§Ú¤]«Ü¬Ý¦n¡yªYÃÄ¡zªº¼ç¤O¡I ¡K §Æ±æ¥xÆW¡y¦n¡zªº¥Í§Þ¤½¥q¥i¥H¦@¦n¡I ¥[ªo⛽️

¯¬ ¤¤¬î¨Î¸`§Ö¼Ö¡I §ë¸ê¶¶§Q¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gnelson10149051  µoªí®É¶¡:2022/9/9 ¤U¤È 11:04:01²Ä 2414 ½g¦^À³
DK¤j¡ARoger¤j¡A

¦b¡yªYÃÄ¡z°Q½×¨ä¥LªÑ²¼¡A§Ú§¹¥þ¨S¦³°ÝÃD¡I­Ó¤H¤]«D±`³ßÅwÅ¥¨ì¥H¤£¦Pªº¨¤«×¤Î°T®§¨Ó¤ÀªR¦Û¤vªº§ë¸ê¼Ðªº¬O§_¦³§Ú¨S¬Ý¨ìªº¼ç¦b­·ÀI¡H¡I

¦ý¬O§ÚµLªk»{¦P Peter Lin ©ó 9 ¤ë 7 ¤é¡A¹ï¡y¥_·¥¬P¡z¥H¤Uªºµû½×¡I¦]¬°¦³®Ú¾Ú¶Ü¡H¶º¥i¥H¶Ã¦Y¡A¸Ü¤£¯à¶ÃÁ¿¡I .. ¤§«eªº¤@­Óµû½×¡A¤]¦³¥¢°¾»á¡G

¡y¦A¨Ó»¡¤@¤U¥_·¥¬P¡A¬Ý·|¤£·|º¦¡H

¦Ñ°­¤£³g¥ý½æ60%²{ªÑ¥ý¦^¥»¡A³Ñ¤Uªº¤j³g40%«ùªÑ½ä¡C

¥i¼¦ªº´²¤á¡C¡z

¡yªYÃÄ¡z¸ò¡y¥_·¥¬P¡z¡A§Ú³£¦³«ùªÑ¡I ¡K ¦P®É¡A§Ú¤]«Ü¬Ý¦n¡yªYÃÄ¡zªº¼ç¤O¡I ¡K §Æ±æ¥xÆW¡y¦n¡zªº¥Í§Þ¤½¥q¥i¥H¦@¦n¡I ¥[ªo⛽️

¯¬ ¤¤¬î¨Î¸`§Ö¼Ö¡I §ë¸ê¶¶§Q¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/9/9 ¤W¤È 09:43:08²Ä 2413 ½g¦^À³
¦pªG¦³³W©w¤£¯à°Q½×§O¤äªÑ²¼¡A¨º§Ú¹Dºp¡C¦ý§Úı±oÀ³¸Ó°Q½×¬ì¾Ç¡A¥»ªOªº¦Ñ¤Í³£·|º¡¼Ö·Nªº§a~~¥u¬O¾×¨ì§O¤Hªº°]¸ô¡C

§Ú°ê³»¡B¥_·¥¤]³£¦³(§Ú«Üµuµø¡B¨Sº¦§Ú´N¤£²n¡C)·sÄ£¤]­n³QªB¤Í¯º

¥_·¥º¦°±¤F¡A¥i¥H®ð®ø¤F

¸Ü»¡¦^¨Ó¡A²{¦b·sÃĪº«Ü¦h¨£¸Ñ¡A¤£³£¬OR¤j¤§«e´N´£¨Ñªº¸ê°T¶Ü?§Ú¤]¤£¨£R¤j»¡§O¤H¦b§Û¥L(³æµM¤]¦³¥i¯à¬O§O¤H¦Û¦æ´M§ä¨ìªº¸ê°T¨Ó¤À¨É)

¬O¤£¬O~~~~~~~===>«ùÄò¤U¥h

=============

ªGµMÁ¿§O¤äªÑ¡AªYÄ£¤~·|º¦¡C😂😂😂

=========

·|­û¡Gdk10140377 µoªí®É¶¡:2022/8/31 ¤U¤È 12:05:12²Ä 2361 ½g¦^À³

¦pªG°Q½×§O¤ä¡A·sÃÄ·|º¦============>´N¤@ª½°Q½×§O¤ä§a@@

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/9 ¤W¤È 09:29:58²Ä 2412 ½g¦^À³
¦X¤@¨«¦b«e­±¡A±q¦X²z»ù¤G¦Ê¤¸¨ì²{¦b¤W¬Ý¤dª÷®×¨Ò¡FªYÄ£¬OºC½Ä¥X¨Ó½}¤F¡A¬Û«H«¥ªYÄ£¤@©w¤]¬O¤dª÷¤p©j¡IºCµo¨|ªº¤Ï¦Óªø§ó°ª¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/9 ¤W¤È 06:18:17²Ä 2411 ½g¦^À³
2022.9.9Æp¥Û¥Í§Þ ·~ÁZ¼É¼W807­¿

...¦X¤@..¨ä¡u¶Ë¤f¥~¥Î¨Å»IBonvadis¡v..³o¶µ²£«~¹w­p©ú¦~­º©u³z¹L±ÂÅv¦X§@¹Ù¦ñ¡A¥¿¦¡¦b¬ü°ê¥«³õ¾P°â...

ªYÄ£¥ÍÂå±Mª`¯×ªÕ¨xª¢ªvÀø»â°ì¡A¯×ªÕ¨xª¢·sÃÄSNP-630¤wÀò±o¦h°ê±M§Q¡A¥B¥¿¦b¶i¦æ¤HÅéÁ{§É¸ÕÅç¡A¥¼¨Ó¦³¾÷·|±ÂÅv°ê»Ú¤j¼t¡C

·s»D¸ÑŪµ²½×:¦X¤@ON101«Ü§Ö·|¤½¥¬±ÂÅv¡A¯à¤£¯à±a°Ê·sÃĪÑ(ªYÄ£)ªmÄËÃzªí? «ø¥Ø¥H«Ý~

---------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/7 ¤U¤È 09:19:29²Ä 2393 ½g¦^À³

...¦]¬°±µ¤U¨Óªº­«ÀYÀ¸¡A³o2®aªº±ÂÅvª÷¥´¯}¥x·LÅ骺6.7»õ¬ü¤¸¡A§Ú¬O»{¬°¨S¦³Äa©À¡A°ªÃB±ÂÅvª÷À³¸Ó·|Åý·sÃĪѪmÄËÃzªí!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/9 ¤W¤È 05:55:18²Ä 2410 ½g¦^À³
2022.8.22Ä_¨Î·s®× ¬D¾Ô·s¦Ë©Ð»ù¤ÑªáªO

©Ð¥«´º®ð¤ÏÂà°T¸¹¯B²{¡A¤£¹L¦Ë¥_¤´¦³¹w°â®×¬D¾Ô°ª»ù¡A¡u±À®×¤ý¡vÄ_¨Î¤W©P¥½¤½¶}¾P°âªº°ªÅK¯¸®Ç¡uÄ_¨Î©_½U¡v¡A¶}»ù¤W¬Ý7¦rÀY¡A¬D¾Ô·s¦Ë©Ð»ù¤ÑªáªO¡A¬Æ¦Ü³Ð¤UÄ_¨Î¾÷ºc±À®×¥v¤W·s°ª¡C

....

---------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/4/5 ¤U¤È 03:05:47²Ä 1866 ½g¦^À³

¦pªG¬O¦P°¦¯T?(¥»©ÊÃø²¾)

©R¤¤ª`©w§Ú±N³B©ó©t¿W¡A¯î²D»P±I¹æ¤¤§Ú¾Ç·|¤F§Ô­@¡A§Ú½L½õ©ó¯î­ìªº¤@¨¤¡A¾iºë»W¾U¡B«Ì®§¥H«Ý¡A²×¦³¤@¨è¡A¿E±¡»PÅé¯à·|¥þ­±Ãzµo¡A¤ä¼µ§Ú¨º«i²rªº¤@À»¡C¡m¯T¹D¡n©¹©¹¨ú±o¦¨¥\ªº´I¤H¡A¥L­Ì³£¦³µÛ³oºØ¯T¹Dºë¯«¡C´I¤H¤§©Ò¥H¯à°÷¨ú±o¦¨¥\¡A°£¤F¦³Áæ¦Ó¤£±Ë¡B¥Ã¤£¨¥±Ñªº¯T¹Dºë¯«¡A©¹©¹ÁÙ¦³³o¤­ºØ¯T©Ê«äºû¡I

¯T©Ê«äºû¤@¡B¦¨¥\¤§¹D¡A¶Q¦b°í«ù...¯T©Ê«äºû¤­¡B¤£°Ê«h¤w¡A¤@»ïÅå¤H¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/9 ¤W¤È 05:43:18²Ä 2409 ½g¦^À³
¦òÁI¡G©M®ð¥Í°]¡AµÊ®ð¦nªº¤H¡A¤£¶ÈºÖ®ð²`¡A°]¹B¤]¶Õ¤£¥i¾×!

¦hťť¤£¤@¼ËªºÁn­µ¡A±q§ïÅܦۤv®Ú²`¸¦©Tªº·Qªk¶}©l¡A¤~¦³¾÷·|§ïÅܦۤvªº¤H¥Í¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/9/8 ¤U¤È 10:38:40²Ä 2408 ½g¦^À³
·PÁ¦³±z¡C

^^

...............

nelson10149051

¦Û¥H¬°¬O¡I µL¤U­­¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gnelson10149051  µoªí®É¶¡:2022/9/8 ¤U¤È 10:29:01²Ä 2407 ½g¦^À³
¦Û¥H¬°¬O¡I µL¤U­­¡I
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/9/8 ¤U¤È 10:08:55²Ä 2406 ½g¦^À³
¨º¤@­Ó¡H³oÃ䪺ªÑ¤Í¡A¦]¬°¤Ó¼ôªYÄ£¤F¡A¨S¤°»ò¦n²á¡A§A·Qª¾¹D¤°»ò¡H¥i¥H°Ý¡I

¥t¥~¡A¦h¤F¸Ñ¤@ÂI§O¤äªÑ¦b·d¤°»ò¡A¤]¬O¤@ºØ¾Ç²ß¡C

­n·í«H®{¡A¤£¬Ý¬ì¾Ç¸ò¥«³õ¡A¨º³Ì¦n§O¸I·sÃĪѡC

...............

¤p«Ó­ô

«ç»ò¤@ª½¦³¤@­Ó¦b¨º¸õ°w¦Û¨¥¦Û»y °Q½×¨ä¥LªÑ²¼ªº¨Æ...¾÷¾¹¤H??

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¤p«Ó­ô10152857  µoªí®É¶¡:2022/9/8 ¤U¤È 09:20:53²Ä 2405 ½g¦^À³
«ç»ò¤@ª½¦³¤@­Ó¦b¨º¸õ°w¦Û¨¥¦Û»y °Q½×¨ä¥LªÑ²¼ªº¨Æ...¾÷¾¹¤H??
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/9/8 ¤U¤È 04:31:18²Ä 2404 ½g¦^À³
ªGµMÁ¿§O¤äªÑ¡AªYÄ£¤~·|º¦¡C😂😂😂
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gnelson10149051  µoªí®É¶¡:2022/9/8 ¤U¤È 04:24:50²Ä 2403 ½g¦^À³
¬Ý¤£°_¦b­I«á»¡§O¤H(¥_·¥¬P)Ãa¸Üªº¤H!! ... ¦³°ÝÃD¡A«Øijª½±µ¥h¥_·¥¬PÁ¿ ... ¥H¦Û¤v»{¬°°ª¯Åªº±¡¾Þ¥h±Ï´²¤á
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/8 ¤U¤È 01:03:49²Ä 2402 ½g¦^À³
ªYÄ£2017¦~6¤ë50¤¸¤W¿³Âd¡Aªø½u¦~¥­§¡³ø¹S²v15¦Ê¤À¤ñ¡m¼W¸ê­Yºâ¦A¥[°ª¨Ç¡n¡AªÑ»ù°_¥ñ«Ü¤j¡Aªø´Á§ë¸ê¤]»Ý§ÜÀ£¯À½è¤~¯à¨«¤U¥h¡F¤µ¦~¨â¤j¶°¹Î81¤¸¶i³õ¡A¬O¹ª»R¤]¬OªÖ©w¡Cªñ´Á¤½¥q¤w¶}ªá­nµ²ªG¡Aªø½u§ë¸ê±N°ª©ó©¹©õ15¦Ê¤À¤ñ¡Cµu½u¾Þ§@¨ë¿E¤ß±¡°_¥ñ¤j¡Bªø½uí©w¦³§Æ±æµyµyµL½ì¡F¦bªYÄ£®Ç³ò¶´X¥G³£¦³ÁȨì¿ú¡C¯¬ºÖ¤j®a¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GÂĶ©¤Ú´µ10151323  µoªí®É¶¡:2022/9/8 ¤W¤È 11:37:32²Ä 2401 ½g¦^À³
§ÜÀùÀÆ¥ú¡IµØ¤W¥ÍÂå§ÜÀù·sÃĸѪ¼¦¨¥\¡@¶Ç¤µ¦~¦³¾÷·|¨ú±oÃÄÃÒ ¡m¤Þ¥ÎªF´Ë·s»D¡n

µØ¤W¥ÍÂå¬O¥xÆW¶i¤JÁ{§É¤T´Á¸ÕÅ窺·sÃĶ}µo¤½¥q¡A¦¨¥ß©ó2013¦~¡A¨Ã»P°ê»ÚÃļt¦X§@¡A¨ú±o°ê»Ú©Ê§ÜÀù·sÃÄ¡u¦è¹F¥»Ói¡v±ÂÅv¡A§ë¤J¡u¥~©PT²Ó­M²O¤ÚÀù¡v¥H¤Î¡u±ß´Á¨ÅÀù¡v¨â¶µ¾AÀ³¯g¶}µo¡A¨Ã¦b¥h¦~ºaÀò²Ä18©¡°ê®a·s³Ð¼ú---¥ø·~·s³Ð¼ú¡C

GNTbm-38¬OµØ¤W¥ÍÂå¦Û¥D¶}µo¥Ó½Ð¥þ²yPCT±M§QªºNCE (New Chemical Entity) ¡A¬O·s¤@¥N¤fªAªíÆ[§K¬Ì½Õ±±¾¯¡A¤]¬OµØ¤W¥ÍÂåªá¶O¦h¦~®É¶¡¦Û¥D¶}µoªº·sÃÄ¡A¥D­nÀ³¥Î©ó·s¥@¥N¸~½F§K¬ÌÀøªk¡A¨ä¿W¯SªºªíÆ[¿ò¶Ç¤Î¸~½F§K¬Ì½Õ±±¾÷¨î¡A±N¦¨¬°¸~½F§K¬ÌÀøªkªº°©·FÃĪ«¡A·íGNTbm-38»P¨ä¥LÃĪ«Áp¦X¨Ï¥Î¡A±N¥iªvÀø§ó¦hºØ¤£¦P±ß´ÁÀù¯g¡AÄÝ©ó¼s´¶©Ê§ÜÀùÃĪ«¡CµØ¤W¥ÍÂå±N»P¦h®aCRO¤½¥q¦X§@¡A¶i¦æGNTbm-38ªº­ì®ÆÃÄ¡B»s¾¯¡BÃIJz¡BÃĮġB¬r²z¡BÃĪ«°Ê¤Oµ¥¬ã¨s¡A¹w­p§ë¤J2¦~®É¶¡¡A§¹¦¨¬ü°ê¡B¥xÆW¤Î¤¤°êªºIND (Investigational New Drug)¥Ó³ø¡A§Ö³t¶i¤J¤HÅéÁ{§ÉÅçÃÒ¡A¥i¤j´T´£¤ÉGNTbm-38ªº»ù­È¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/9/8 ¤W¤È 08:46:11²Ä 2400 ½g¦^À³
¤ñ¹ï¦ó¤j¤@ªº¨£¸Ñ vs°ªºÝªºªÑ»ùª£¨ì°ªºÝ

======================================

­J¤j¹ï·sÄ£ªº¨£¸Ñ vs ·sÄ£ªº¨«¶Õ==========>©ê¹ï¤j»L¤~¦³¥Î

¥[ªo½Ä§r ¤µ¤Ñ¯}°ª¨Ó½æ

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/8 ¤W¤È 08:38:23²Ä 2399 ½g¦^À³
¹ï¤ñVERUªº¤£½T©w©Ê¡A¥tÃþªº¥xÆW¤§¥ú´N¬O¡uôÈ¥J¥m¤û¨¤Ã­·í·í¡v!
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/8 ¤W¤È 08:17:11²Ä 2398 ½g¦^À³
Veru stockÃzº¦®É¡A«¥´£¥Xĵ¥Ü:¤£ª¾¹D¸ê®Æ¯u°°©Ê¡A«¥Âର«O¦u¬Ý«ÝEUA!

10¤ë6¤éFDAÃĪ«¿Ô¸ß©e­û·|°Q½×ªº­«ÂI±N¥]¬A¦b¦w¼¢¾¯¦º¤`²v°ªªº±¡ªp¤UªºªvÀø®ÄªG¤j¤p¡A¦w¥þ¼Æ¾Ú®wªº¦³­­¤j¤p¡A¥H¤Î½T©wÀÀijªº¤H¸s¡C

[¦w¼¢¾¯¦º¤`²v°ª]¬OªÅ¤èªº§ðÀ»µJÂI¡A¤µ¤Ñ¬Ý°_¨Ó¯u¤£¹³ªÅ¥Þ¨Ó­·!

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/13 ¤U¤È 05:09:16²Ä 2312 ½g¦^À³

Veru stock³o2¤éÃzº¦¡A¦³½g¸ê®Æ¥i¬Ý¤@¤U!

2022.7.18 Veru ªºP3¸ÕÅç¥X²{·sªº¦MÀI«H¸¹¡Aªí©ú FDA ¥i¯à·|©Úµ´

whitediamondresearch.com/research/new-red-flags-emerge-from-verus-phase-3-covid-trial-suggesting-an-fda-rejection-is-likely/

¦w¼¢¾¯²Õªº§C¦å®ñ¹¡©M«×

±q¤w¤½§Gªº¦w¼¢¾¯²Õ°ò½u¦å®ñ¹¡©M«×(OS)½d³ò¨Ó¬Ý¡A§Ú­Ìª¾¹D52¦W¦w¼¢¾¯±wªÌ¤¤³Ì§CªºOS¬OVeru¦P¦æµû¼f½×¤å¤¤ªº48¡C³oÅãµM¬O¤@­Ó¯f±o«Ü­«ªº¯f¤H¡A¤£ºÞªvÀø¦p¦ó¡A¥Lªº©R¹B´X¥G³£¬O²³©Ò©Pª¾ªº¡C

[Sabizabulin ªvÀø²Õ¾¨ºÞ±wªÌ¼Æ¶q¼W¥[¤F¤@­¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84¡C]

[Sabizabulin ªvÀø²Õ¾¨ºÞ±wªÌ¼Æ¶q¼W¥[¤F¤@­¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84¡C]

...

¦w¼¢¾¯²Õ¤¤¦³ 11.5% ªº±wªÌ¬O WHO 6 ±wªÌ¡A¦Ó Sabizabulin ²Õ¥u¦³ 5.1%¡C³o¬O Veru «ù¤[¹B®ðªº¤@­Ó¨Ò¤l¡A

[³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C][³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C][³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C]

µ²½×:¤£ª¾¹D¸ê®Æ¯u°°©Ê¡A«¥Âର«O¦u¬Ý«ÝEUA!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/8 ¤W¤È 06:16:12²Ä 2397 ½g¦^À³
2021.11.17 ¯f¬rÅv«Â¦ó¤j¤@¡mTVBS¤j®vÁ¿°ó¡n¶}Á¿ µû°ªºÝ¨ú±oºò«æ±ÂÅv¡u«D±`¨u¨£¡v

news.tvbs.com.tw/health/1636861

...¦Ü©ó°ªºÝ¬Ì­]³q¹L§Ú°êEUA (ºò«æ¨Ï¥Î±ÂÅv)¤§«á¡A¿ð¿ð¥¼Àò±o°ê»Ú»{ÃÒ¡A¦ó¤j¤@¤]´£¥X¨£¸Ñ¡C¥L»{¬°°ªºÝ³oºØ­«²Õ³J¥Õ¬Ì­]­n¶i¦æ²Ä¤T´ÁÁ{§É¹êÅç¤~²Å¦X¬ì¾Ç.......

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/6/8 ¤U¤È 12:24:18²Ä 1191 ½g¦^À³

¬°¦ó¥xÆW3®a·s«a¬Ì­]¥þÀ£¦b­«组³J¥Õ¬Ì­]¡A¤£°µmRNA¬Ì­]? »¡¬ï´N¬O§Þ³N¤£¨ì¦ì¡C

·í°ê¤H¼J¯º¤j³°°êÃÄ»P¬ì¿³ªº·À¬¡¬Ì­]®É¡A®í¤£ª¾¤j³°²Ä1¤ämRNA¬Ì­]¤w¦b¾¥¦è­ô¶i¤J3´ÁÁ{§É

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/8 ¤W¤È 05:57:32²Ä 2396 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2021/6/8 ¤U¤È 12:24:18²Ä 1191 ½g¦^À³

¬°¦ó¥xÆW3®a·s«a¬Ì­]¥þÀ£¦b­«组³J¥Õ¬Ì­]¡A¤£°µmRNA¬Ì­]? »¡¬ï´N¬O§Þ³N¤£¨ì¦ì.....

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/6/23 ¤W¤È 11:13:07²Ä 1241 ½g¦^À³

µLªkµL¤Ñ¡A¤Ï¥¿¨S¤T´ÁÁ{§É¡A§Ú­Ó¤H¬O¤£·|¥´°ªºÝ»PÁp¨Èªº¬Ì­]£x!

----------------------------------------------------------------------------------------------------

2022.8.31-FDA«Å¥¬®Ö­ãBNT¤Î²ö¼w¯Ç°w¹ïBA.5¤G»ù¬Ì­]ªººò«æ¨Ï¥Î±ÂÅv(EUA)!

­«组³J¥Õ¬Ì­]¹ï¯f¬rÅܲ§ªºÀ³Åܳt«×¸ò¤£¤WmRNA¬Ì­]¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/8 ¤W¤È 05:48:15²Ä 2395 ½g¦^À³
veruªÑ»ù¬Q¤é¦A±Y21.11%¦¬½L11.51.

¦]¬°FDAÃĪ«¿Ô¸ß©e­û·|©w©ó2022.10.06¤é¶}·|°Q½×sabizabulin ªºEUA½Ð¨D¡C(ÁôÁô·Pı¨Æ¥ó¤£³æ¯Â!)

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/4 ¤W¤È 07:35:21²Ä 2373 ½g¦^À³

°ê¹©¦¬124¦W¤S¨S¦³²Î­p¾Ç·N¸q!(è¤ß¦k·QEUA)

ªÅ¤è:Veruè¤ß¦k·Q¥H150¦W±wªÌªº¼Æ¾Ú·Q®³¨ìEUA!(ª`·Nveru¬O¦]¬°ÃĪ«¡§À£­Ë©Ê¡¨ªº¦³®Ä©Ê¡A¿W¥ß¼Æ¾ÚºÊ´ú©e­û·|«Øij´£«e°±¤î¡C)

xqimg.imedao.com/18232d5f89a53cad3fcbdabd.jpg!raw.jpg (ªÅªÅ¦p¤]¨C¤£ªÅ§@ªº¹Ïªí¡A®³¨ìEUAªº8®a¡A³Ì§C¦¬ªv±wªÌ¼Æ:966¤H)

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/19 ¤W¤È 04:29:28²Ä 2325 ½g¦^À³

VERU¤µ¤Ñ¦hªÅ¥æ¾Ô¿E¯P±Y21.47%(¸³¨ÆMario Eisenberge¶g¤@½æªÑ¡A¿ðº¢¤µ¤Ñ¤ÏÀ³?)¡AªÅÀY³o»ò¸vµL§Ò¼ª?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/9/8 ¤W¤È 12:29:15²Ä 2394 ½g¦^À³
Roger¤j¡A§Ú¬O¥X¨Ó¦R¼Ñ¤@¤U»Ä§ÚÁ¿¥_·¥¬Pªº¤H¡A§O¦b·N¡C

¤µ¤Ñ¬Ý¨ì°ªºÝ¤@¸s¹F¤H¦b»Ä¦Ñ°­¡AÁ¿ªº¤]¨S¿ù¡A»¡¸Ñª¼«e§CÂI¶R¡A¤£­n°l°ªµ¥¸Ñª¼¡C»¡°ªºÝ²{¦b»ù®æ§C¡A¤~¥i¥H¶R¨Óµ¥WHO¤T´Á¡A§Ú§Ö¯º¦º¡C

¦]¬°°ªºÝWHO¤T´Á®Ú¥»¸Ñ¤£¤Fª¼¡C

150¤H½T¶E¸Ñª¼¬O¥H¨¾·P¬V¤H¼Æ¬°¦ô­p¶q¤Î­È¡A³o­Ó¼Ë¥»¤H¼ÆOK¡A¦]¬°¨¾·P¬Vªº¦ô­p¶q(­È)«Ü®e©ö±q¤p¼Ë¥»¼Æ¤¤Æ[¹î±o¨ì¡C

¦ýomicronªº­«¯g¤ñ²v¡A¤j¬ù¥u¦³¤d¤À¤§2(¨S¥´¬Ì­])~5

(¦³¥´¬Ì­])¡A¦ô­p¶q(­È)«ÜÃø±q¤p¼Ë¥»¤¤Æ[¹î±o¨ì¡C

18000ªº¤T´Á¼Ë¥»¼Æ¡A¤À±±¨î²ÕVS¹ï·Ó²Õ¡A±±¨î²Õ¦A¤À´X¤ä¬Ì­]¡A®Ú¥»§@¤£§¹ªº¡A¤×¨ä¨º¤T­Ó°ê®a³£¦~»´¤H¡A¦~»´¤H¦³¥´¨S¥´¬Ì­]ªº­«¯g¤ñ²v¡A®Ú¥»´X¥G¤@¼Ë¡A¬O­n«ç»ò±o¥X¨¾­«¯g«OÅ@¤O¤j©ó70%?

°£«DWHO§@¹ú¡A§â­«¯g¼Ð·Ç¶}«ÜÃP«Ü¼e¡C

¤£µM¥u¯à¾ô±µ¤F¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/7 ¤U¤È 09:19:29²Ä 2393 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2022/6/13 ¤U¤È 02:40:52²Ä 2071 ½g¦^À³

¦b¦X¤@FB825¥H5.3»õ¬ü¤¸±ÂÅvLEO»sÃÄ¡A­ì¥»»{¬°±µ¤U¨Ó·|¬O¥_·¥¬PADI-PEG20»P¦X¤@ON101½l³y¬ö¿ý...

--------------------------------------------------------------------------------------------------

¦p¦¹¸Ñª¼¦æ±¡ºG¿é´X¦~«eªº°ò¨È»P¯E¹©¡A²´¤UÁÙ¤£¨ì³»ÂI¤~¬O!

¦]¬°±µ¤U¨Óªº­«ÀYÀ¸¡A³o2®aªº±ÂÅvª÷¥´¯}¥x·LÅ骺6.7»õ¬ü¤¸¡A§Ú¬O»{¬°¨S¦³Äa©À¡A°ªÃB±ÂÅvª÷À³¸Ó·|Åý·sÃĪѪmÄËÃzªí!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/9/7 ¤U¤È 05:33:25²Ä 2392 ½g¦^À³
¦A¨Ó»¡¤@¤U¥_·¥¬P¡A¬Ý·|¤£·|º¦¡H

¦Ñ°­¤£³g¥ý½æ60%²{ªÑ¥ý¦^¥»¡A³Ñ¤Uªº¤j³g40%«ùªÑ½ä¡C

¥i¼¦ªº´²¤á¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/7 ¤U¤È 03:59:05²Ä 2391 ½g¦^À³
«e­±±M¤j´£¨Ñ±ÂÅvª÷Åv¯q5­¿ºâªk¯u·Ç¡I¦X¤@5¡B3»õ¬ü¤¸¦X²z»ù2¦Ê¦h¤¸¡A²{¦b¦h­Ó¶Ë¤fÃÄ¡A¤ÀªR®v¤wµû¦ô¥¦¤W¬Ý¤dª÷¡C«¥ªYÄ£­Ó¤Hµû¦ô¦³¥|¤d¤¸ªÑ»ù¹ê¤O¡A¨CÁûÃÄ¥­§¡5»õ¬ü¤¸±ÂÅv´N¬O¡C®É¶¡§Ö2¦~ºC3¢w5¦~´N§¹¦¨¡C¤j®a·í°Ñ¦Ò¡A­Y¤£»{¦P´N·í¯º¸Ü¤@«h¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/9/7 ¤U¤È 01:53:11²Ä 2390 ½g¦^À³
ı±o¤Íºô¦³¤H¦b¬Ý³oª©ªº°Q½×¡A¶¶«K°Ñ¦Ò¤Fr¤j¤§«e´£¨Ñªººô­¶¡C¤£´N±M§QÀòµý¡C·f¤W¤F¦X¤@ªº¨®¡C¶}¤ß¨S¤G¤Ñ¡A¦n¨Æªñ¤F??
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/9/6 ¤U¤È 09:08:40²Ä 2389 ½g¦^À³
¥u¯à»¡Ä@½äªA¿é¡A§Æ±æ¤£­nÅý§Ú­Ì¥¢±æ~

©µ´Á¥Ó½Ð®ø®§¬O§Ú¦Û¤v·Qªº¡A¨S¦³³o¸ê°T¡C¤U¤@ªiº¦´T·|§óÅå¤H¡A¤£¥²®ð¾k¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/6 ¤U¤È 04:34:11²Ä 2388 ½g¦^À³
©µ´Á¥Ó½Ð®ø®§¬O§Ú¦Û¤v·Qªº¡A¨S¦³³o¸ê°T¡C¤U¤@ªiº¦´T·|§óÅå¤H¡A¤£¥²®ð¾k¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/9/6 ¤U¤È 03:32:16²Ä 2387 ½g¦^À³
³o¦¸1111¨S¥X ¤µ¤Ñ´N¤Ö¤F´X¤QW¡A©µ´Á®ø®§¤@¥X¡C¥´¦^­ì§Î¤F¡C¤£¦p«Ý¦b·sÂd¡Aµ¥¨º¤@¤Ñ¯}200¥H¤W¡C

===========================

§Ú²qªYÄ£´£¤WÂd¥Ó½Ð·|©µ¦b´Á­­¨ì´Á«e¤~´£¡AÁÙ¦³¥b¦~®É¶¡¡F³o¥b¦~¤º¥i¯à¦³±ÂÅv®ø®§¡A©Ô°ª¤WÂd©âÅÒ»ù¡A¹ï´£¼·¤jªÑªF¤~¦³¨Ç¥æ«Ý¡C·íµM¥¼¨Ó¤WÂd­Y¦³2¡B300¤¸ªÑ»ù¡A¤]¤£·|¬OªYÄ£³Ì°ª»ù¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/6 ¤U¤È 12:49:03²Ä 2386 ½g¦^À³
§Ú²qªYÄ£´£¤WÂd¥Ó½Ð·|©µ¦b´Á­­¨ì´Á«e¤~´£¡AÁÙ¦³¥b¦~®É¶¡¡F³o¥b¦~¤º¥i¯à¦³±ÂÅv®ø®§¡A©Ô°ª¤WÂd©âÅÒ»ù¡A¹ï´£¼·¤jªÑªF¤~¦³¨Ç¥æ«Ý¡C·íµM¥¼¨Ó¤WÂd­Y¦³2¡B300¤¸ªÑ»ù¡A¤]¤£·|¬OªYÄ£³Ì°ª»ù¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/6 ¤W¤È 11:36:36²Ä 2385 ½g¦^À³
µu½u¦Ê¤¸5¤¸¤W¤U¡A¤é«á¦³®ø®§¥²µM«D¤Z¾_¾Ù¡I¤@ªi¤ñ¤@ªi°ª¡C­YÁA¸ÑªYÄ£»ù­È¡Aµù©w­n©t¿W¨«¤U¥h¡I¤ß±¡¥­Ã­¬Ý«ÝªÑ»ù°_°_¥ñ¥ñ¦ÛµMªi°Ê¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/9/6 ¤W¤È 10:11:18²Ä 2384 ½g¦^À³
¥u­n¦Ê¤¸¨S¤W¡A§Úı±o¨S¹ê»Ú§Q¦h¥X²{¡A¤S¦³ªºµ¥¤F
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦V«e¦æ10140498  µoªí®É¶¡:2022/9/6 ¤W¤È 09:53:22²Ä 2383 ½g¦^À³
¦^ÀÉ­×¥¿¡A¦Ê¤¸¯¸¤£¦í¡C

¦^¤F¤Ó²`¤F§a¡I

¥[ÂIªo

¤£µM¤£ª¾¹D¤S­nµ¥¦h¤[¡H

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/9/6 ¤W¤È 09:33:20²Ä 2382 ½g¦^À³
³·¤¤°e¬´¤H¤Ö ¸¨¤«¤U¥Û¤H¦h
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¤p¨k¤H10151116  µoªí®É¶¡:2022/9/5 ¤U¤È 04:43:54²Ä 2381 ½g¦^À³
¤îµhÃĵLµÇ¬r±M§Q¬O¥@¬É°ß¤@¡A«ä¦Ò²Ä¤@®aÃļt2020/12¡A²Ä¤G®aÃļt2021/5¡A¬O§_±ÂÅv¦X¬ù´N¦bµ¥«Ý³o­Ó±M§Q©O?Ä~Äò¬Ý¤U¥h
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/5 ¤U¤È 01:05:53²Ä 2380 ½g¦^À³
µLµÇ¬r±M§Qº¦¦¨¦p¦¹¡A±N¨Ó±ÂÅv®ø®§¤@©wº¦Â½¤Ñ¡I±q¡m¤p®É­Ô¡n»P¥_·¥¬P¬Û¤ñ¡AªYÄ£¬O¦h¥X10¤¸ªº¤p­ô­ô¡A²{¦b¤p¥_º¦¨ì200¤¸¡A¥i¥H¹w´ÁªYÄ£«Ü¼ÖÆ[¡I¥¼¨Ó¤WÂd¡B¥|ÁûÃÄ¥þ³¡±ÂÅv¡B¤À¼íª÷®³¤F¡A´N¬OªYÄ£¥þ³¡»ù­È®i²{¡C«O¦uµû¦ô¡AªÑ»ù500¤¸¢w2000¤¸¡C¤j®a·í°Ñ¦Ò¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GBear10152946  µoªí®É¶¡:2022/9/4 ¤W¤È 10:38:45²Ä 2379 ½g¦^À³
SNP-8 ¨t¦CÁ{§É¸ÕÅç©ó«e¦~¦Vfda¥Ó½Ð¡A½Ð°Ý¦³¤j¤j¥i¤À¨É¤@¤U«áÄò¦p¦ó¶Ü¡H©Ç¡A«ç¨S®ø®§¤F¡I
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 10:09:18²Ä 2378 ½g¦^À³
°ê¹©¥Í§Þ©e¥ÑCRO¤½¥q¦V¬ü°êFDA´£¥X¥Ó½Ð Pre-EUA Meeting Request(ºò«æ¨Ï¥Î±ÂÅv«e·|ij½Ð¨D)¡A

-------------------------------------------------------------------------------------------

¤£­n§â¥ICRO¤½¥qªº¥Ó½Ð¥N¿ì¶O¡A±bºâ¨ìFDAÀY¤W!!!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 09:57:33²Ä 2377 ½g¦^À³
[all meeting types are free of charge]

[all meeting types are free of charge]

[all meeting types are free of charge]

FDA:§K¶O §K¶O §K¶O

FDA:§K¶O §K¶O §K¶O

FDA:§K¶O §K¶O §K¶O

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/4 ¤W¤È 06:33:17²Ä 2371 ½g¦^À³

°ê¹©pre-eua meeting(eCTD Sequence Number:0025 )¡C

eCTD Sequence Number´N¬OCDERµo¥Xªº¤å¥ó¦¬µo®×¸¹¡C

FDA does not charge a fee for submitting an EUA request (or pre-EUA request)--->FDA¤£¦¬¨ú´£¥æEUA ½Ð

¨D¡]©Î EUA «e½Ð¨D¡^ªº¶O¥Î¡C

pre-EUA requestÂkÄÝ©óType B meeting¡A¬OFDA[§K¶O]¬°¨üCDER©MCBERºÊºÞªºÃÄ«~¶}µo°Ó´£¨Ñ¥¿¦¡«Øijªº½dÃ¥!

----------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/11 ¤U¤È 07:43:09²Ä 2311 ½g¦^À³

¥Ó½ÐPRE-EUA meeting»PEUA­nªá«Ü¦h¿ú¶Ü? (FDA:§K¶O §K¶O §K¶O)

FDA§K¶O¬°¨üCDER©MCBERºÊºÞªºÃÄ«~¶}µo°Ó´£¨Ñ¥¿¦¡«Øij

¸ê®Æ¶}ªù¨£¤s¼gµÛ:FDA offers formal advice at no cost to developers of medicines regulated by both [CDER ]and CBER, with the aim of supporting medicinal product development from Phase 1 through to rketing.

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 09:35:11²Ä 2376 ½g¦^À³
°ê¹©«ç»ò¤£»¡Â§¨ÓEUA¬O¦h¤Ö¤Hªº¼Æ¾Ú?

§¨Ó Bebtelovima¦¬ªv 1634¤H VS. °ê¹©antroquinonol ¦¬ªv124¤H

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤U¤È 11:06:36²Ä 2276 ½g¦^À³

®³Â§¨ÓªºBebtelovima EUA°µ¹ï·Ó¡A¥u¯à»¡¤½¥q¨S¥Í§Þ¤H¤~¤F.

°ê¹©¤G´ÁÁ{§ÉOmicron¯f¨Ò¤H¼Æ?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 08:14:39²Ä 2375 ½g¦^À³
Âd¶R¤¤¤ß±o¦³¾á·íµw°_¨Ó¡A¤Á²ö¥¢Â¾¡A9/9«á°È¥²¥h¨ç­n¨D°ê¹©¤½§i¥B¥X¨ãFDAªº®Ñ¼f·|ijªº¤ÏõX¤½¤å!

----------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/9/1 ¤W¤È 05:13:58²Ä 2365 ½g¦^À³

´CÅé¹ï¥Í§Þ·sÃĪº¥¿¥»²M·½!

1.2022.8.26 °]¸g«C¬õ¿O¡n¥Í§Þ·~ªº¦Ñ¹««Ë ec.ltn.com.tw/article/paper/1536484

2.2022.8.31 ·íÁ{§É¸ÕÅç³ø§i¹J¤W­^©úªº¥Í§Þ¦ÑÁó¡K¡K¡K

news.gbimonthly.com/tw/magazine/article_show.php?num=52732&menu=1302&p_id=104

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 08:07:36²Ä 2374 ½g¦^À³
·|­û¡Gdk10140377 µoªí®É¶¡:2022/8/31 ¤U¤È 12:05:12²Ä 2361 ½g¦^À³

¦pªG°Q½×§O¤ä¡A·sÃÄ·|º¦============>´N¤@ª½°Q½×§O¤ä§a@@

------------------------------------------------------------------------------------------------

¤µ¤Ñ´X½g¶K¤å¡A¤£¬O¦^À³DK¤j¡A¬O¤£²n¦P¾Ç·|¨ºÃ䦳¤H­J»¡¤K¹D!

¥»¤H¶È¦b»E°]ºô¶K¤å¡A¦Ü¤µ¨S¦³¦b¨ä¥LªÑ²¼°Q½×ºôµù¥U¶K¤å¹L!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 07:35:21²Ä 2373 ½g¦^À³
°ê¹©¦¬124¦W¤S¨S¦³²Î­p¾Ç·N¸q!(è¤ß¦k·QEUA)

ªÅ¤è:Veruè¤ß¦k·Q¥H150¦W±wªÌªº¼Æ¾Ú·Q®³¨ìEUA!(ª`·Nveru¬O¦]¬°ÃĪ«¡§À£­Ë©Ê¡¨ªº¦³®Ä©Ê¡A¿W¥ß¼Æ¾ÚºÊ´ú©e­û·|«Øij´£«e°±¤î¡C)

xqimg.imedao.com/18232d5f89a53cad3fcbdabd.jpg!raw.jpg (ªÅªÅ¦p¤]¨C¤£ªÅ§@ªº¹Ïªí¡A®³¨ìEUAªº8®a¡A³Ì§C¦¬ªv±wªÌ¼Æ:966¤H)

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/19 ¤W¤È 04:29:28²Ä 2325 ½g¦^À³

VERU¤µ¤Ñ¦hªÅ¥æ¾Ô¿E¯P±Y21.47%(¸³¨ÆMario Eisenberge¶g¤@½æªÑ¡A¿ðº¢¤µ¤Ñ¤ÏÀ³?)¡AªÅÀY³o»ò¸vµL§Ò¼ª?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 07:04:17²Ä 2372 ½g¦^À³
1. VERU

Step 3: pre-eua meeting( FDA¨S¦³­n¨D´£¨ÑÃB¥~¼Æ¾Ú¥B·í¤Ñ´N«ØijVERU»¼¥æEUA¥Ó½Ð¡C)

Step 4: Veru¤½§i°e¥Xeua¥Ó½Ð¡C

Step 5: Veruµ¥FDAµo¥X¥¿¦¡ªº§å­ã©Î©Úµ´EUA (¦³¬Ý¨ì°ê¥~§ë¸êªÌ»¡9¤ë15«e·|¦³µª®×?)

2.Adagio

Step 3: pre-eua meeting(FDA¤ÏõXadintrevimab¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Ê¼Æ¾Ú(Adagio¦Ûª¾EUAµL±æ¡A¼È°±Step4ªº

EUA¥Ó½Ð¡A¡§­«·s³]­p¡¨ adintrevimab¥H´£°ª¹ïOmicronªºÀø®Ä¡C)

Adagio­n¤@±ø¹D¨«¨ì¶Â¬O¥i¥Hªº¡A©¹step 4->step 5(FDAµ´¹ï§_¨MEUA)!

3.°ê¹©

Step 3: 9/9 pre-eua®Ñ¼f¡AFDA¤ÏõX·N¨£???

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/4 ¤W¤È 06:33:17²Ä 2371 ½g¦^À³
°ê¹©pre-eua meeting(eCTD Sequence Number:0025 )¡C

eCTD Sequence Number´N¬OCDERµo¥Xªº¤å¥ó¦¬µo®×¸¹¡C

FDA does not charge a fee for submitting an EUA request (or pre-EUA request)--->FDA¤£¦¬¨ú´£¥æEUA ½Ð

¨D¡]©Î EUA «e½Ð¨D¡^ªº¶O¥Î¡C

pre-EUA requestÂkÄÝ©óType B meeting¡A¬OFDA[§K¶O]¬°¨üCDER©MCBERºÊºÞªºÃÄ«~¶}µo°Ó´£¨Ñ¥¿¦¡«Øijªº½dÃ¥!

----------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/11 ¤U¤È 07:43:09²Ä 2311 ½g¦^À³

¥Ó½ÐPRE-EUA meeting»PEUA­nªá«Ü¦h¿ú¶Ü? (FDA:§K¶O §K¶O §K¶O)

FDA§K¶O¬°¨üCDER©MCBERºÊºÞªºÃÄ«~¶}µo°Ó´£¨Ñ¥¿¦¡«Øij

¸ê®Æ¶}ªù¨£¤s¼gµÛ:FDA offers formal advice at no cost to developers of medicines regulated by both [CDER ]and CBER, with the aim of supporting medicinal product development from Phase 1 through to rketing.

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/1 ¤U¤È 08:52:35²Ä 2370 ½g¦^À³
SNP-810µLµÇ¬r©Ê³o­ÓÀuÂI¡A¹ï©ó·m§ðNSAIDs¡]«DÃþ©T¾J®øª¢¤îµhÃÄ¡^ªº¥«³õ¥÷ÃB¤j¦³§U¤O!

¤îµhÃį}ÃaµÇŦ«OÅ@¾÷¨î!!!

www.commonhealth.com.tw/article/74087

½Ð·V¥Î¤îµhÃÄ¡IµÇŦ¬ì¦WÂå¨Iµh§i¥Õ

¡u¿Ë·RªºÂå¥Í¡G³o¦ì±wªÌ¦³ºC©ÊµÇ¯f¡]µÇ¯f´Á¼Æ3b¡BµÇ¥\¯à«ü¼Æ38ml/min/1.73¢T¡^¡A½Ð¤Å¶}¥ßNSAIDs¡]«DÃþ©T¾J®øª¢¤îµhÃÄ¡^¡A¦ýAspirin¤ÎAcetaminophen¥i¾A¶q¨Ï¥Î¡A¥HÁקK¼vÅTµÇ¥\¯à¡C¸Û¼°·PÁ¡C¡v

¥Î¤¤­^¤å¿Ëµ§¤â¼g«K±ø¯È¡A¬OµÇŦ¬ì¦WÂå¡B¤¤°êÂåÃĤj¾Çªþ³]Âå°|°Æ°|ªø¶À¬îÀA³Ì²`­«ªº°U¥I»P¥mÀ{¡C

¡u§Ú´N³o¼Ë¼g¡A¤@±i±i¼gµ¹«DµÇŦ¬ìÂå¥Í¬Ý¡A¡v¶À¬îÀA¥Î¤O¦a»¡¡AµÇŦ¬ìÂå¥Í¦³³d¥ô´£¿ô«DµÇŦ¬ìÂå®v¡C

¦]¬°¦o¬Ý¹L¤Ó¦h¦³ºC©ÊµÇŦ¯fªº¤H¡A¦]¬°·P«_¥þ¨­µmµh¥h¡u¦Q¤jµ©¡]ÂIºw¡^¡v¥[¤W¥´¤îµh°w¡Aµ²ªGµÇ«ü¼ÆÅÜ®t¬Æ¦Ü²£¥ÍÄY­«µÇ°IºÜ¡A¡u¦Y¤F¥ß¨è¤£µhªºÃÄ¡A¦³¥i¯à·|®`§AªºµÇ¡I¡v¶À¬îÀA»¡¡AµÇŦ¤£¦nªº¤H­n·V¥Î«DÃþ©T¾JÃþ®øª¢¤îµhÃÄ¡A¦ý¦o¼~¤ß³oÃþ¤îµhÃĦb¥xÆW¥Î±o¤Ó¯BÀÝ¡A¦]¬°¹ïµÇŦ¦³¶Ë®`ªº§t°¨°Â¹a»Ä¤¤¯óÃĦ­¤w¦b2003¦~¸T¤î¨Ï¥Î¡A¡uºC©ÊµÇ¯f«oÁÙ³o»ò¦h¡A§Ú­Ì­n«ä¦Ò¨ä¥L¥i¯àªº­ì¦]¡A¡v¦o»¡¡C

µL¿W¦³°¸¡A¿n·¥±À°ÊºC©ÊµÇ¯f¨¾ªv¡B°ª¶¯Âå¾Ç¤j¾Çªþ³]¤¤©M¬ö©ÀÂå°|°Æ°|ªø¶À©|§Ó¤]µo²{¡AÂå¬É¹ï©ó¤îµhÃĪº¨Ï¥ÎÀ³§óÂÔ·V¡C

¡u§Ú­Ì¦b¯f±w°·«O¥d¤Wµù°O¡B¦³¶K¯È´£¿ô¡AÁÙ¬O¶Ã¶}ÃÄ⋯⋯¡A¡v»¡¨ì³o¡A¥L§Ô¤£¦í®ð¼«¨ì¥Î¤O­«´¨¨Fµo3¤U¡C¤îµhÃį}ÃaµÇŦ«OÅ@¾÷¨î

«DÃþ©T¾J®øª¢¤îµhÃÄ¡]Nonsteroidal anti-inflammatory drugs¡ANSAIDs¡^¦]¦P®É¨ã¦³¤îµh¤Î§Üµoª¢®ÄªG¦Ó³Q¼sªx¨Ï¥Î©óÃö¸`ª¢¤Î¦UºØ¯kµh¤W¡A¦p¾Ç¦WÃÄIbuprofen¡BNaproxen¡BCelecoxib¡BKetoprofenµ¥¡A³oÃþÃĪ«·|§í¨î«e¦C¸¢¯ÀE¦X¦¨¡A¯}ÃaµÇŦ¦Û§Ú«OÅ@¾÷Âà¡A³y¦¨µÇ°IºÜ¡A¤]·|¯}ÃaµÇ¤pºÞ¡A¤Þµo¶¡½è©ÊµÇª¢........

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/1 ¤U¤È 08:16:14²Ä 2369 ½g¦^À³
¦¶¸³¡A

¶P³ßSNP-810¦A¼W¥þ¥@¬É°ß¤@µL[µÇ]¬r©Ê¤AñQÓi×ô±M§Q»PÂX¤j«OÅ@½d³ò¤§¬ü°ê±M§Q¡A¬JµM±ÂÅv®×¬O»P±M§Q¥Ó½Ð¶i«×¦³Ãö¡A¦¹¨è§ë¸ê¤H´÷±æªº¬O«e5¤jÃļt & «e10¤jÃļtªº±ÂÅv®×¤½§i!!!

-----------------------------------------------------------------------------------------------

Q:½Ð°Ý¬°¦ó»¡±ÂÅv»P¤HÅé´ú¸Õ¡B¼Ï¯Ã¸ÕÅçµ¥¶i«×µLÃö¡A¦Ó»P±M§Q¥Ó½Ð¶i«×¦³Ãö¡H

A:§Ú­Ì²{¦b¿n·¥¬ãµo¡A¨Ã½Í±ÂÅv¡A´Á±æ¦b³Ì¾A©yªº®É¾÷¤Î±ø¥ó¤U±ÂÅv¡C¦³¤HÅé¸ÕÅç¡B¼Ï¯Ã¸ÕÅç¥i¼W¥[½Í§PªºÄw½X¡A¤@¯ë¦Ó¨¥¡A¦ý¥²¶·¦³±M§Q¸û©ö±ÂÅv¡C±ÂÅv½Í§P²o¯A«Ü¼s¤]«Ü½ÆÂø¡A¥]¬A¹ï¼Ðªºª«½T»{¡A¬ì¾ÇÅçÃÒ¡B¹ê¦a¬d®Ö¡B±ÂÅv±ø¥ó¨ó°Óµ¥µ¥¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¤p¨k¤H10151116  µoªí®É¶¡:2022/9/1 ¤U¤È 07:53:51²Ä 2368 ½g¦^À³
¥»¤½¥qµL¨xµÇ¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k)

¨ú±o«n«D±M§Q¡A¬°¥þ¥@¬É°ß¤@¥H¥h°£¬r©Ê¥NÁª«¤§µLµÇ¬r©Ê

¤AñQÓi×ô±M§Q

1.¨Æ¹êµo¥Í¤é:111/09/01

2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q±µÀò©e¥ô±M§Q¨Æ°È©Ò³qª¾¡A¥»¤½¥qµL¨xµÇ¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810

(¦w®õ®³¯k)¨ú±o«n«D±M§Q¡A±M§Q¦WºÙ:¡uMethods and Compositions for Preventing,

Reducing or Eradicating Toxicity Caused by Acetaminophen (APAP)¡v¡A¬°¥þ¥@¬É

°ß¤@¥H¥h°£¬r©Ê¥NÁª«¤§µLµÇ¬r©Ê¤AñQÓi×ô±M§Q¡C

6.¦]À³±¹¬I:¤£¾A¥Î

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@.¥»¤½¥qµL¨xµÇ¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k) °£¥H©¹¤w®Ö­ãµL¨x¬r©Ê¤§

±M§Q¡A²{§ó¼W¥[¤FµLµÇ¬r©Ê¤§±M§Q«OÅ@¡A¤µÀò±o«n«D±M§Q¡A¡u¥Î©ó¹w¨¾¡A´î¤Ö©Î®ø°£¥Ñ

¤AñQ®ò°ò×ô¡]APAP¡^¤Þ°_ªº¬r©Êªº¤èªk©M²Õ¦Xª«¡vµ¥¤@¨t¦C±M§Q¥]§t¼sªxªº¤AñQÓi×ô°Æ

§@¥Î¹w¨¾¥\®Ä¡A¥]¬A¹w¨¾¤AñQÓi×ô¹L¶q³y¦¨ªº¨x¡BµÇ¬r©Ê¡AµL¨x¬r³¡¤À¡A¤wÀò±o¬ü°ê¡B

¼Ú¬w(38·|­û°ê)¡B¤é¥»¡BÁú°ê¡B¤¤°ê¡B¼Ú¨È±M§Q²Õ´(8·|­û°ê)¡B¤¤µØ¥Á°êµ¥±M§Q¡A¦Ó

µLµÇ¬r³¡¤À¡A°£¤µ¤éÀò±o«n«D±M§Q¥~¡A¥ç©ó¬ü°ê¡B¼Ú¬w(¦@38·|­û°ê)¡B¤é¥»¡B¤¤°ê¡B

¿D¬w¡B¯Ã¦èÄõ¡B¥[®³¤j¡B¤Ú¦è¡B¾¥¦è­ô¡B¦L«×¡B¦L¥§¡B®õ°ê¡B·s¥[©Y¡B°¨¨Ó¦è¨È¡B

µá«ß»«¡B¶V«n¡B­ô­Û¤ñ¨È¡B­»´äµ¥¥@¬É¦U°ê¤w¥Ó½Ð±M§Q¦@18¥ó¡A¥Ø«e¬Ò¿n·¥¼f®Ö¤¤¡C

¤G.¥»±M§Q¦³®Ä´Á³Ìªø¥i¦Ü¦è¤¸2044¦~¡C

¤T.SNP-810(¦w®õ®³¯k)¤w§¹¦¨¥Ó½Ð¬ü°êFDA¼Ï¯Ã¸ÕÅç©Ò»Ýªº¹«¬r²z¸ÕÅç¡Aµ²ªGÅã¥Ü

SNP-810¦³·¥¨Îªº¦w¥þ©Ê¡C

¥|.Acetaminophen(¤AñQÓi×ô)¹L¶q±N³y¦¨¨x·l®`ªº°Æ§@¥Î³Q¼s¬°ª¾±x¡AµM«æ©Ê¨x°IºÜ

¤Þ°_ªº¨xµÇ¯g­Ô¸s¥ç¥i¯à¾É­P«æ©ÊµÇ°IºÜ¡C¨Ì¾Ú2008¦~Âå¾Ç´Á¥Z¡uJournal of Medical

Toxicology ¡v«ü¥X¡A¦³¦Ê¤À¤§1¨ì2¹L¶qªA¥Î¤AñQÓi×ôªº±wªÌ·|¥X²{µÇ¥\¯à¤£¥þªº²{¶H

¡C¥»¤½¥qªø´Á±Mª`¬ãµo¤AñQÓi×ô³y¦¨ªº¬r©Ê°Æ§@¥ÎµhÂI¡AµÇ°Æ§@¥Î»P¨x°Æ§@¥Î¦P¼Ë¬°

°ª«×¦MÀI«o¸û¤Ö¬°¤H©Òª¾¡A¥»±M§Q®Ö­ã¼Ð»x¤F¥»¤½¥qSNP-810§Þ³N¹ï¤AñQÓi×ô³y¦¨ªº¨xµÇ

°Æ§@¥Î¹w¨¾®ÄªG¨½µ{¸O¡A¬°¥þ¥@¬É°ß¤@¥H¥h°£¬r©Ê¥NÁª«¤§µLµÇ¬r©Ê¤AñQÓi×ô±M§Q¡C

¤­.®Ú¾ÚFuture Market Insights 2021¦~¥«³õ²Î­p³ø§i«ü¥X¡A¥þ²yAcetaminophen(¤AñQ

Ói×ô)¤îµhÃÄ¥«³õ³W¼Ò©ó2020¦~¹ê»Ú¬ù¬°91.5»õ¬ü¤¸¡A¦Ó¥D­n¥«³õ¦p¥_¬ü¦û¤ñ¬ù33.0%¡B

¼Ú¬w¬ù26.3% ©M¨È¬w(¥]§tªF¨È©M«n¨È°ê®a)¬ù31.7%¡C­Y¥H¨C¦~¦~§¡½Æ¦X¼Wªø²v(CAGR)

4.1%­pºâ¡A©ó2031¦~¥þ²y¤îµhÃÄ¥«³õ³W¼Ò¥i¹F140.7»õ¬ü¤¸¡C°£¥»¤½¥qSNP-810(¦w®õ®³¯k

)¥~¡A¥Ø«e¥«³õ¤W©|µL¨ä¥¦Ãþ¦üµL¬r©Ê¤§acetaminophen¤§¤îµhÄvª§²£«~¡C¥Ø«e¥»¤½¥q

SNP-810·sÃĤw»P°ê»Ú¥D­n¤îµhÃĤj¼tñ­q¦³Àv¦X¬ù¡A¦³³Ì·s¶i®i¡A±NÀH®É¤½§i¡C

¤».·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A

§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¶ø¥ì´µ¯S10031727  µoªí®É¶¡:2022/9/1 ¤U¤È 04:28:18²Ä 2367 ½g¦^À³
¥»¤½¥qµL¨x¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k) ¦A¨ú±o¤@ÂX¤j«OÅ@½d³ò¤§¬ü°ê±M§Q

1.¨Æ¹êµo¥Í¤é:111/09/01

2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q±µÀò©e¥ô±M§Q¨Æ°È©Ò³qª¾¡A¥»¤½¥qµL¨x¬r¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k)

¦A¨ú±o¤@ÂX¤j«OÅ@½d³ò¬ü°ê±M§Q¡A±M§Q¦WºÙ¡uNew Acetaminophen Compound

Composition Without Side Effect To Liver¡v¡C

6.¦]À³±¹¬I:¤£¾A¥Î

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@.¥»¤½¥qµL¨x¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k)¥ý«e¤wÀò±o¬ü°ê¡B¼Ú¬w

(38·|­û°ê)¡B¤é¥»¡BÁú°ê¡B¤¤°ê¡B¼Ú¨È±M§Q²Õ´(8·|­û°ê)¡B¤¤µØ¥Á°êµ¥±M§Q¡A

¤µ¤SÀò±o¥t¤@¬ü°ê±M§Q¡A¨ä±M§Q«OÅ@½d³ò¸û«e¦¸®Ö­ã¤§¬ü°ê±M§Q½d³ò§ó¬°ÂX¤j¡A

¹ïSNP-810¤§«OÅ@§ó¬°§¹¾ã¡C

¤G.¥»±M§Q¦³®Ä´Á³Ìªø¥i¦Ü¦è¤¸2038¦~¡C

¤T.SNP-810(¦w®õ®³¯k)¤w§¹¦¨¥Ó½Ð¬ü°êFDA¼Ï¯Ã¸ÕÅç©Ò»Ýªº¹«¬r²z¸ÕÅç¡Aµ²ªGÅã¥Ü

SNP-810¦³·¥¨Îªº¦w¥þ©Ê¡C

¥|.®Ú¾ÚFuture Market Insights 2021¦~¥«³õ²Î­p³ø§i«ü¥X¡A¥þ²yAcetaminophen

(¤AñQÓi×ô)¤îµhÃÄ¥«³õ³W¼Ò©ó2020¦~¹ê»Ú¬ù¬°91.5»õ¬ü¤¸¡A¦Ó¥D­n¥«³õ¦p¥_¬ü¦û¤ñ

¬ù33.0%¡B¼Ú¬w¬ù26.3% ©M¨È¬w(¥]§tªF¨È©M«n¨È°ê®a)¬ù31.7%¡C­Y¥H¨C¦~¦~§¡½Æ¦X

¼Wªø²v(CAGR)4.1%­pºâ¡A©ó2031¦~¥þ²y¤îµhÃÄ¥«³õ³W¼Ò¥i¹F140.7»õ¬ü¤¸¡C°£¥»¤½¥q

SNP-810(¦w®õ®³¯k)¥~¡A¥Ø«e¥«³õ¤W©|µL¨ä¥¦Ãþ¦üµL¨x¬r©Ê¤§acetaminophen¤§¤îµh

Ävª§²£«~¡C¥Ø«e¥»¤½¥qSNP-810·sÃĤw»P°ê»Ú¥D­n¤îµhÃĤj¼tñ­q¦³Àv¦X¬ù¡A¦³³Ì·s

¶i®i¡A±NÀH®É¤½§i¡C

¤­.·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI

¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/1 ¤W¤È 06:02:21²Ä 2366 ½g¦^À³
2022.03.29--¬O¼´¨ìötªÑÁÙ¬O¦a¹pªÑ¡H14Àɲb­È§C¡B²{ª÷°¾§C¥Í§ÞªÑ­n¤p¤ß¡I³Ð§ë´£¿ô¡G¨â­Ó¨¤«×ÁקK½ò¹p www.businesstoday.com.tw/article/category/183016/post/202203280015/

....ªk¼wÃĦ]²{ª÷¤£¨¬ªº°ÝÃD¡A3¤ë18¤éºM¤U¿³Âd¡C

¨é°Ó´«¤H¡@¥i¯à¬O»{½ß©â»L

²{ª÷¤£¨¬¡@¥þ²y¥Í§Þ·~³q¯f

------------------------------------------------------------------------------------------------

°ê¹©¡B³Ð¯q¡B¦w¦¨¡B¤ß®®¡B¨ÈªG....¡Aªí¦C14Àɨº¤@®a¥i¯à¨B¤Jªk¼wÃÄ«á¹Ð?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/1 ¤W¤È 05:13:58²Ä 2365 ½g¦^À³
´CÅé¹ï¥Í§Þ·sÃĪº¥¿¥»²M·½!

1.2022.8.26 °]¸g«C¬õ¿O¡n¥Í§Þ·~ªº¦Ñ¹««Ë ec.ltn.com.tw/article/paper/1536484

2.2022.8.31 ·íÁ{§É¸ÕÅç³ø§i¹J¤W­^©úªº¥Í§Þ¦ÑÁó¡K¡K¡K

news.gbimonthly.com/tw/magazine/article_show.php?num=52732&menu=1302&p_id=104

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/9/1 ¤W¤È 05:01:51²Ä 2364 ½g¦^À³
FDA¥Ç¸o°»¬d Criminal Investigations ºô§}:

www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/criminal-investigations

¸Ó¤å³¹¤¤¨º¦ì±M·~ªºCRO¦n¤Í¬O¶}ª±¯º©ÎªÌ¯u¯àÁ|µo???

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/31 ¤U¤È 05:16:03²Ä 2362 ½g¦^À³

2022.8.31 ·íÁ{§É¸ÕÅç³ø§i¹J¤W­^©úªº¥Í§Þ¦ÑÁó¡K¡K¡K

news.gbimonthly.com/tw/magazine/article_show.php?num=52732&menu=1302&p_id=104

...µ¹¥xÆW«È¤áªº³ø§i¡A¥L­Ì¥i¥H¥Î¦Û¤vªº·Qªk¥h½Ķµ¹¤j²³¡C¦nÀI°Ú! ÁÙ¦n¥L­Ì¼g¤¤¤å¡AFDA¤]¬Ý¤£À´¡A¤£·|¥h§@¥Ç¸o°»¬d

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/9/1 ¤W¤È 12:11:32²Ä 2363 ½g¦^À³
¥¼¨Ó16­Ó¤ëªYÄ£§ë¸ê³ø¹S²v·|«Ü°ª¡A¤WÂd¤~¤@­¿º¦´T¡A±ÂÅv®×¦¨¨Æ¹ê¤~¥i©È¡I810¥[Á`®t«l»ù¤]¦³5»õ¬ü¤¸¡A¦X²z»ù1000¤¸¡C«á­±ÁÙ¦³3ÁûÃÄ¡I«¥ªYÄ£©ú©ú¬O¶ÂÆp¥Û¡A¥u¬O²{¦b¹³·ÑºÒ¦Ó¤w¡C¤j®a¦@«j¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/31 ¤U¤È 05:16:03²Ä 2362 ½g¦^À³
2022.8.31 ·íÁ{§É¸ÕÅç³ø§i¹J¤W­^©úªº¥Í§Þ¦ÑÁó¡K¡K¡K

news.gbimonthly.com/tw/magazine/article_show.php?num=52732&menu=1302&p_id=104

...µ¹¥xÆW«È¤áªº³ø§i¡A¥L­Ì¥i¥H¥Î¦Û¤vªº·Qªk¥h½Ķµ¹¤j²³¡C¦nÀI°Ú! ÁÙ¦n¥L­Ì¼g¤¤¤å¡AFDA¤]¬Ý¤£À´¡A¤£·|¥h§@¥Ç¸o°»¬d...

...³o¦ì¥H°êÄ_Ãħ÷¬ãµo·sÃĪº¤½¥q¦ÑÁ󳺵MÂǦ¹°í«ù¦©´Ú....

---------------------------------------------------------------------------------------------------

ÁôÁô¬ù¬ù«üªº¬OXX...

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/8/31 ¤U¤È 12:05:12²Ä 2361 ½g¦^À³
¦pªG°Q½×§O¤ä¡A·sÃÄ·|º¦============>´N¤@ª½°Q½×§O¤ä§a@@
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gnelson10149051  µoªí®É¶¡:2022/8/30 ¤U¤È 10:34:03²Ä 2360 ½g¦^À³
¶]¨ÓªYÄ£¡A°Ý¤ß®®¡A§åµû¥_·¥¬P ¡K.
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/30 ¤W¤È 11:50:00²Ä 2359 ½g¦^À³
¤§«e¦³»¡¹L¡A»¡¹ê¦bªº¡A¥_·¥¬PªºÃÄ¥u¬O¦³¥i¯àÁpÃĥΡA¦Ó¤£¬O¤@©w¥i¥H¡AÀù¯g¥ÎÃĤ£¯àÀH«K¥Îªº¡A²{¦b¥u¬O¥Î¤@­Ó¨u¨£Àù¯g§@¤T´Á¡A¥¼¨Ó·QÂX¥R¨ì¨ä¥LÀù¯g¡A¸ôÁÙªøªº«Ü¡C¥t¥~¨º­Ó¿z¯f¤H(¦³¤ÏÀ³ªº¥Ø¼Ð±Ú¸s)ªº¥Íª«¼Ð°O¬O¤°»ò¡H¤]¨S»¡²M·¡¡C§j¤Ó¤j¤Ó»·¤F¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/8/29 ¤W¤È 11:15:40²Ä 2358 ½g¦^À³
­Y¥H¥_·¥¬P¬°¨Ò¡A¥¦±q«e¦~©³´£¥X¤WÂd«e70¤¸¡A¨ì²{¦b180¤¸¡A¨¬¨¬¤@­¿»ù¡FªYÄ£¤WÂd¬Ý¨Ó¤]¥²µM¡A¤WÂd«e100¤¸¦ô¡A©ú¦~²{¦b¦Ü¤Ö200¤¸¡C¡m±ÂÅv¹ê½è¤j§Q¦h¡A§¹¥þ¨S¦³ºâ¡n
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¤p«Ó­ô10152857  µoªí®É¶¡:2022/8/28 ¤U¤È 09:05:07²Ä 2357 ½g¦^À³
¤ÀªRªº«Ü¦n,¦³¤H±N¥Í§Þ¼ç¤OötªÑÄ´³ë¬°®ü§¯,Âæb²`®ü¤§¤¤ªº¥¨Ã~µ´«D¦À¤¤ª«,·í¨eı¿ôªº®É­Ô,¨º¥²¬O¥HÅå°Ê¥@¤H¤§«º®i²{
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/8/28 ¤U¤È 12:52:58²Ä 2356 ½g¦^À³
ªYÄ£¦]ù±¥Û°òª÷¤W¿³Âdª¾¦W«×ÅÜ°ª¡A¸êª÷´é¶i«á¡A¨«¶Õ¤´¤jº¦ºCºC¦^¶^¡A¦ý¦^¶^²`«×ÁY¤p«K¦A©¹¤Wº¦¡A¨Ì¦¹¼ö«×¤£¥²¤WÂd´N¯}¦Ê¤F¡C¥¼¨ÓªYÄ£¤WÂd¡B±ÂÅv¡B¤À¼íª÷¥þ¹ê²{¤F¡A¬ù5¦~¨ì8¦~«áªÑ»ù¤W¬Ý500¤¸¨ì«Ü°ª«Ü°ª¢w¢w¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/28 ¤W¤È 08:53:45²Ä 2355 ½g¦^À³
Roger¤j¡A¨º¨Ç«n¥P¤¦¹©¯»¯uªº¬O¥á¥ú§Ú­Ì·sÃĪѤͪºÁy¡C

µ{«×¦³û{®tÆ¿¤S³g¤ß¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/27 ¤W¤È 08:35:31²Ä 2354 ½g¦^À³
°]¸g«C¬õ¿O¡n¥Í§Þ·~ªº¦Ñ¹««Ë (³oµ§150¸U¬OÂd¶Rªº»@´Ú¬ö¿ý¶Ü?)

Æ[¹î¥xÆW¤§¥ú·|¤£·|¤@±ø¹D¨«¨ì¶Â???

Step 3: 5/10 Veru»PFDA¶}pre-eua meeting

Step 4: 6/7 Veru¤½§i°e¥Xeua¥Ó½Ð¡C

Step 5: Veruµ¥FDAµo¥X¥¿¦¡ªº§å­ã©Î©Úµ´EUA (¦³¬Ý¨ì°ê¥~§ë¸êªÌ»¡9¤ë15«e·|¦³µª®×?)

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/24 ¤U¤È 03:57:02²Ä 2350 ½g¦^À³

....¦]¬°¦bpre-EUA¡A±q¹ê¾Þ¤WFDA¨Ã¤£·|ÀɧAªº±µ¤U¨ÓªºEUA¥Ó³ø¡A¦]¬°pre-EUAªº¥»·N¬O»²¾É¡A¤£¬Oµ¹µ²ªG...

....®M¦bEUAªº¬yµ{7¨B¦±

Step 3: 9¤ë9¤é Pre-EUA Meeting¬O®Ñ­±¼f¬d.(±q¹ê¾Þ¤WFDA¨Ã¤£·|ÀɧAªº±µ¤U¨ÓªºEUA¥Ó³ø)->°ê¹©·|¦A©¹Step 4->Step 5(³o¨BFDA¤~·|µo¥X¥¿¦¡ªº§å­ãEUA©Î©Úµ´EUA)

µ²½×:9¤ë9¤é§O³Q­«°TÄF¤W¨®!!!

-------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/21 ¤W¤È 08:01:08²Ä 1807 ½g¦^À³

...

³o¬OEUAªº¬yµ{7¨B¦±!

Step 3: Pre-EUA Submission

Step 4: Submission of EUA This involves submitting an EUA request to be reviewed by the FDA.

Step 5: Approve/Reject EUA After reviewing the EUA application, the FDA issues a formal approval or rejection.

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/25 ¤W¤È 05:20:20²Ä 2353 ½g¦^À³
¶K¦b¤ß®®ªO¡A5¦~«e¥v¤j(²{¦b¦n¹³¬O¤ß®®°ªºÞ?)ªº¸ê®Æ¬Û·í¸ÔºÉ(«á¤H­¼²D)¡Aª¦ª¦¥v¤j¤å¤]¦³§A¤ß¤ß©À©ÀªºBTD....

Sage : finance.yahoo.com/quote/SAGE/

Neurocrine:finance.yahoo.com/quote/NBIX/

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/24 ¤U¤È 10:12:35²Ä 1613 ½g¦^À³

¤µ¤Ñªº¤½§i¤ÀªRµ²ªG¡A¥i°Ñ¦Ò2017¦Ñ¥v¤jªº¶K¤å!

-------------------------------------------------------------------------------------------------

·|­û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/8/2 ¤U¤È 01:52:55²Ä 121 ½g¦^À³

....©Ò¥HFDA¹ªÀy³o¼Ë°µ¡A¥ý°µ­Ó348¤H¸Õ¸Õ¬Ý¡A§A«áÄò¦³§ó¦h¸ê®Æªº®É­Ô¡AÅý§A°µ¤@­Ó¤H¼Æ½Õ¾ã¡C³oºØ³]­p¤Uªº´Á¤¤¤ÀªR¥Øªº¤£¦b©ó¡u´£«e°±¤î¦¬®×¡v¡A¦Ó¬O¦b©ó¡u­n¤£­n¼W¥[¦¬®×¤H¼Æ¡v¡A¦pªGresponder¤ñ¨Ò²Å¦X¹w´Á¡Atrial´NÄ~Äò¤U¥h¤£¥Î¥[¦¬¯f¤H¡]¦ó¥²¦Û§ä³Â·Ð§â¼Æ¾Ú¥i¯à¤£¿ùªºtrial´£«e°±¤î¦¬®×¦Ó´î·l¼Æ¾Ú¡^¡H¦pªGresponder¤ñ¨Ò¤ñ¹w´Á§C¡A¨º´N¥[¦¬¯f¤H¡C348¤H¬O¸g¹L­pºâªº¼Æ¦r¡A¦pªG¶¶§Q¡A¤w¸g¤ñ1374¤H¸`¬Ù«Ü¦h¸g¶O»P®É¶¡¡A·íµL¥²­n«_ÀI¡u´£«e°±¤î¦¬®×¡v¡C¦P²z¡A¦pªG´Á¤¤¤ÀªR«á»Ý­n¥[¦¬¯f¤H¡A³o¤]¤£¬O§QªÅ¡A¦]¬°¦badaptive designsªººë¯«¤U¬O«Ü¦X²zªº½Õ¾ã¡C....

-----------------------------------------------------------------------------------------------

·|­û¡G¦Ñ¥v10140531 µoªí®É¶¡:2017/11/14 ¤U¤È 01:11:15²Ä 205 ½g¦^À³

....¦pªG¨S¦³BTD¡A§Ú¼gªº³o¨Ç¤º®e¥i¥H·í¦¨©ñX¡A¦Û§Ú¿±µÈ¡F¥¿¦]¬°§Ú­Ì¦³BTD¡A©Ò¥H§Ú¤~Ä@·Nªá³o»ò¦h®É¶¡¤¶²Ð³o¨ÇCNS¤½¥qµ¹¤j®a»{ÃÑ¡C¯¸°ª¤@ÂI¡A´N¥i¥H¬Ý»·¤@ÂI¡A¯¸¶V°ª¡A¬Ý¶V»·....

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/25 ¤W¤È 12:25:14²Ä 2352 ½g¦^À³
Roger¤j¡A¤ß®®ªºSND13´Á¤¤¡A§A«ç»ò¬Ý¡H

§Ú¸ò§A¶R¤F40±i¡A¥i¥H©ê2¦~¶Ü¡H

©ú

1.¨Æ¹êµo¥Í¤é:111/08/24

2.¤½¥q¦WºÙ:¤ß®®¥ÍÂåªÑ¥÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q¬ãµo¤¤¦¨¤Hºë¯«¤Àµõ¯g¥[¦¨ªvÀø·sÃÄNaBen(SND13)¡A±µÀò¦w¥þºÊ´ú©e­û·|

(Data Safety Monitoring Committee, DSMC)«Øij¡C

(1)Á{§É¸ÕÅç³]­p¡G

A.¸ÕÅç­pµe¦WºÙ¡G¦¨¤Hºë¯«¤Àµõ¯g¤§¥[¦¨ªvÀø(SND13)¡C

B.¸ÕÅç¥Øªº¡Gµû¦ôNaBen§ïµ½¦¨¤Hºë¯«¤Àµõ¯gªº¦³®Ä©Ê©M¦w¥þ©Ê¡C

C.¸ÕÅ綥¬q¡G¦h°ê¦h¤¤¤ß¤§¤G(b)/¤T´Á¤HÅéÁ{§É¸ÕÅç¡C

D.ÃÄ«~¦WºÙ¤Î¾AÀ³¯g¡GNaBen¡B¦¨¤Hºë¯«¤Àµõ¯g¡C

E.µû¦ô«ü¼Ð¡G±ø¥óÀË©w¤O(Conditional Power)¡A°ßDSMC¤£·|§iª¾¥»¤½¥q¥H«OÅ@Á{§É

¸ê®ÆÂùª¼¡A¤ÎÁ{§É¸ÕÅ礧§¹¾ã¥i¾a©Ê¡C

F.¸ÕÅç­pµe¨ü¸ÕªÌ¤H¼Æ¡G¹w­p¦¬®×348¤H¡A²Ä¤G¦¸ÀH¾÷¤À°tªº¨ü¸ÕªÌ182¤H§¹¦¨8¶g

ªvÀø©Î´£«eµ²§ôªvÀø¡C

(2)¦w¥þºÊ´ú©e­û·|«Øij¡G¦w¥þºÊ´ú©e­û·|«Øij¡AÄ~Äò¶i¦æÁ{§É¸ÕÅç¡A

¤£°µ¥ô¦ó½Õ¾ã¤H¼Æ¡C

(3)¥»¦¸¤ÀªR¨ÃµL¸Ñª¼¥BµL²Î­pµ²ªG¡A¬G¥»¤½¥q¹ï©óDSMC«ØijµLªk¦h§@¸àÄÀ¡C

6.¦]À³±¹¬I:µL

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¬ãµo·sÃĦWºÙ©Î¥N¸¹¡G¦¨¤Hºë¯«¤Àµõ¯g¥[¦¨ªvÀø·sÃÄNaBen (SND13)¡C

(2)¥Î³~¡GªvÀøºë¯«¤Àµõ¯g¡C(clinicaltrials.gov/ct2/show/

NCT02261519?term=NCT02261519&draw=2&rank=1)

(3)¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¦h°ê¦h¤¤¤ß¤G(b)/¤T´Á¤HÅéÁ{§É¸ÕÅç¡C

(4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

A.´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã/¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG/µo¥Í¨ä¥L

¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥ó¡G±µÀòDSMC´Á¤¤¤ÀªR«Øij¡C

B.¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¥¼¹F²Î­p¤W

ÅãµÛ·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G

¤£¾A¥Î¡C

C.¤w³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥i¡B¦U´Á¤HÅéÁ{§É¸ÕÅç(§t´Á¤¤¤ÀªR)µ²ªG¹F²Î­p¤WÅãµÛ

·N¸q©Îµo¥Í¨ä¥L¼vÅT·sÃĬãµo¤§­«¤j¨Æ¥óªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G±N«ùÄò½Õ¾ãÁ{§É¸ÕÅç

¤¤¤ß¡A¥[³t¦¬®×¡A¶i¦æÁ{§É²Ä¤G(b)/¤T´Á¸ÕÅç¡C±©´Á¤¤¤ÀªRµLªk¹w´Á³Ì²×¤§µ²ªG¡A

¨Ã¥BNaBen¤§Á{§É¬ãµo¶i®i¡A©MÃøªv«¬ºë¯«¤Àµõ¯f (Clozaben, SND12)¥H¤Î«C¤Ö¦~

ºë¯«¤Àµõ¯f (SND11)¬°¦P¤@­p¹º¡AµLªk¥H³æ¤@Á{§É¹êÅç¹w´ÁÃÄÃÒ¼f¬d¤§³Ì²×µ²ªG¡C

D.¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¬°ÁקK¼vÅT°ê»Ú±ÂÅv½Í§P¡A«O»Ù¤½¥q¤Î§ë¸ê¤HÅv¯q¡A

¤£¤©¤½¶}´¦ÅS¡C

(5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G

A.¹w­p§¹¦¨®É¶¡:¦ô­p2024¦~§¹¦¨¦¬®×¡A±©¹ê»Ú®Éµ{±N¨Ì°õ¦æ¶i«×¨M©w¬O§_½Õ¾ã¡C

B.¹w­pÀ³­t¾á¤§¸q°È¡GµL¡C

(6)¥«³õ²{ªp¡G

ºë¯«¤Àµõ¯g¦¨¤H±w¯f²v±µªñ1%¡A¦Û1993¦~²Ä¤G¥NÃĪ«Risperdal®Ö­ã¤W¥««á¡A±Nªñ¤T

¤Q¦~¨S¦³·s¾÷ÂàÃĪ«¡Cºë¯«¤Àµõ¯g¬OÄY­«¥¼ÀòÂåÀøº¡¨¬ªº¯e¯f¡A²{¦³ÃĪ«¹ï©óªø´Á

§xÂZ¯f±wªº­t©Ê¯gª¬¡B»{ª¾¥\¯à´î·l¤´µL¨}µ¦¡CSND13§í¨î¥k±ÛÓi°ò»Ä®ñ¤Æ»Ã¯À

(D-amino acid oxidase)¡A¥H´£°ª¥k±Ûµ·Ói»Ä(D-serine)¿@«×¡A¬¡¤Æ¤j¸£NMDA¨t²Î¡A

¦­´Á¤HÅéÁ{§É¸ÕÅçµo²{¥i¥H¦³®Ä§ïµ½¥¿©Ê¯gª¬¡B­t©Ê¯gª¬¡B»{ª¾¥\¯à´î·l¡C

(7)¤¤¼Ï¯«¸g·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{

­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/24 ¤U¤È 04:39:27²Ä 2351 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 07:04:07²Ä 2277 ½g¦^À³

®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C

--------------------------------------------------------------------------------------------------

¦]¬°FDAªº¤ÏõX¡AAdagio ¼È°±´£¥æ EUA ½Ð¨D->´N¬O¼È°±Step 4.

Ãø¥H¹w´ú¥xÆW¤§¥ú·|¤£·|¤£ºÞ¤T¤C¤G¤Q¤@©¹¤U¨«Step 4»PStep 5???

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/24 ¤U¤È 03:57:02²Ä 2350 ½g¦^À³
§â¦P¾Çª©¤ß®®whlin0168¤j:...ÁÙ¤Wºõ¤W­­¨ì¸Û«H¡A´N¤Ó¶W¹L¤F¡K«ç¤£¨£±z¥h°ê¹©»¡¡H¥L­Ì¨ºÃ䪺¤½¥q°ª¼h¤~¬O¯u¥¿§â¿ù»~µ²ªGµ¹§ë¸ê¤Hªº¤@¤è¡C±µ¤U¨Ó9/9ªºpre-EUAµ²ªG¡A§Úª½±µ§i¶D§Aµª®×¡A·|¹L¡A¦]¬°¦bpre-EUA¡A±q¹ê¾Þ¤WFDA¨Ã¤£·|ÀɧAªº±µ¤U¨ÓªºEUA¥Ó³ø¡A¦]¬°pre-EUAªº¥»·N¬O»²¾É¡A¤£¬Oµ¹µ²ªG...

----------------------------------------------------------------------------------------------------

®M¦bEUAªº¬yµ{7¨B¦±

Step 3: 9¤ë9¤é Pre-EUA Meeting¬O®Ñ­±¼f¬d.(±q¹ê¾Þ¤WFDA¨Ã¤£·|ÀɧAªº±µ¤U¨ÓªºEUA¥Ó³ø)->°ê¹©·|¦A©¹Step 4->Step 5(³o¨BFDA¤~·|µo¥X¥¿¦¡ªº§å­ãEUA©Î©Úµ´EUA)

µ²½×:9¤ë9¤é§O³Q­«°TÄF¤W¨®!!!

-------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/21 ¤W¤È 08:01:08²Ä 1807 ½g¦^À³

...

³o¬OEUAªº¬yµ{7¨B¦±!

Step 3: Pre-EUA Submission

Step 4: Submission of EUA This involves submitting an EUA request to be reviewed by the FDA.

Step 5: Approve/Reject EUA After reviewing the EUA application, the FDA issues a formal approval or rejection.

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦V«e¦æ10140498  µoªí®É¶¡:2022/8/24 ¤U¤È 02:59:46²Ä 2349 ½g¦^À³
¤j®a³£¦b¬Ý¥¼¨Ó

¤£¹L¡A·sÃĤ½¥q¬£ªººA«×¬O®ø·¥¡C

¿}°òªº°ò¥»­±¶i«×¦³¤ñ·sÃıj§_¡H

ªÑ»ù¦h¤F§Ö¦Ê¤¸

°ê³»¦³¤ñ·sÃıj§_¡H

¥_·¥ºA«×±j¦h¤F¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/8/24 ¤U¤È 02:11:30²Ä 2348 ½g¦^À³
¥ß¨¬ÂIÃn¥ú«×¤£¦P¡AªÑ»ù«ç¬Û¤ñ¡H¥b¦~«e¥_·¥¬PÁ`¤ñªYÄ£¤Ö10¤¸ªÑ»ù¡A²{¦b¤W¥««á¦h¥X50¤¸¡CªÑ»ù°ª§C°£¤W¥«Âd¦]¯À¥~¡A¤½¥q¹ê¤OÃn¥ú¦h¤Ö¡B©M³\¦h¦]¯À¢w¢w¡CÁ`»¡ªYÄ£²×±N¤@­¸½Ä¤Ñ¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦V«e¦æ10140498  µoªí®É¶¡:2022/8/24 ¤U¤È 01:15:49²Ä 2347 ½g¦^À³
ªÑ»ù¬O¥«³õ¨M©w

§Y¨Ï°ê³»¸ÕÅç¨S¹LÃö

¤H®aªÑ»ùÁÙ¬O°ª¹L·sÃÄ

¥u¯à»{¤F¦Û¤v¥Ø«e¤£ª§®ð

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/8/24 ¤U¤È 12:47:46²Ä 2346 ½g¦^À³
»¡­Ó¤£³ôªº¨Æ¡A¦b©MªB¤Í°Q½×°ê³»¡AÁ¿¨ì³Ì«áªB¤Í¸£²Û¦¨«ã¡A¤Ï¥¿°ê³»ªºªÑ»ù¤ñ·sÄ£°ª¡C«ç¼Ë!!!!!!
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/24 ¤U¤È 12:11:16²Ä 2345 ½g¦^À³
°ê¹©¯»¯uªº¬O¥i¯º¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/24 ¤W¤È 10:02:41²Ä 2344 ½g¦^À³
­û¡GROGER588910148151 µoªí®É¶¡:2022/8/17 ¤W¤È 08:55:50²Ä 2320 ½g¦^À³

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤W¤È 11:10:40²Ä 2291 ½g¦^À³

´¼Àº¤p²Ó­MªÍÀù¸Ñª¼©|¤£¯à¤U©w½×¡AmOS»PORR»PmPFS§¹¾ã¼Æ¾ÚÁÙ¨S¤½¥¬¡C

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/18 ¤U¤È 12:34:36²Ä 2243 ½g¦^À³

°²­Y´¼Àº¤½¥¬mOS p¦b0.06~0.08¡A¦Ó¦¸¼ÐORR¬O2­¿©óTopotecan-->ORR»¡¥Õ¸Ü:¥Î´¼ÀºÃĪ«ªvÀø¨Ï¸~½FÁY¤pªº±wªÌ¤H¼Æ¬OTopotecanªº2­¿¡AFDA·|¤£·|µoµ¹Ãįg???

µ²½×:±z¥i¥H¬ÝªÅ¡A¦ý¤£­n°µªÅ!

---------------------------------------------------------------------

°µªÅ´¼Àº À³¸Ó±¾¤F

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/24 ¤W¤È 05:47:53²Ä 2343 ½g¦^À³
9¤ë9¤é«á¡A¶Å¦³¶Å¥D¡AÂd¶R¤¤¤ß:[¦³¥¼¥R¤À´¦ÅS¸Ñª¼°T®§] ¤Î [¤½¶}»P¨Æ¹ê¤£²Å¤§¸ê®Æ±¡¨Æ¡C]

2022.8.23

Âd¶R¤¤¤ß³z¹L·s»D½Z«ü¥X....¥H¦¹¨Ó¬Ý¡A°ê¹©¥Í§Þ©ó111¦~1¤ë5¤é¶È¤½§i¥D­nµû¦ô«ü¼Ð¥ÎÃIJոê°T¡A¤Î111¦~3¤ë16¤é¥D±i¡u¥D­nµû¦ô«ü¼Ð¼Æ¾Ú¤ÀªR¬O¸ò°ò¦­È¤ñ¸û¡A¦]¦¹¨S¦³¯Ç¤J²Î­p¤ÀªRªºP­È¡v¤º®e¡A¦³¥¼¥R¤À´¦ÅS¸Ñª¼°T®§¤Î¤½¶}»P¨Æ¹ê¤£²Å¤§¸ê®Æ±¡¨Æ¡C

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/6/16 ¤W¤È 06:57:47²Ä 2086 ½g¦^À³

°ê¹©P­È«Üº}«G¶Ü???

NRX »sÃÄ [«ÅºÙ] ¼Æ¾Ú¹F¼Ð (P­È¹F¼Ð³QFDA§_¨MEUA) ¡A¤½¥qª£§@EUAÃD§÷¡AºG½ßªº§ë¸ê¤H¶°Åé´£§i¤½¥q©ÜÅS¤£¹ê¼Æ¾Ú¡K

ZYESAMI ¡K³o¨Ç±wªÌªº¥Í¦s¾÷²vÅãµÛ¼W¥[¡]P=0.006¡^¥|­¿¡F­·ÀI³Ì°ªªº±wªÌ¡]ÀH¾÷¤À²Õ®É¨Ï¥Î©I§l¾÷ªº±wªÌ¡^ªº¥Í¦s¾÷²v¼W¥[¤F 10 ­¿¡]P=0.03¡^¡C

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 12:18:10²Ä 2162 ½g¦^À³

¥h¦~¼W¦¬­«¯g±wªÌ¡A«¥¤w´£¥Xĵ¥Ü¬Ýªk¡C1¤ë5¤é¤U¤È 04:14:55¡A¦A½èºÃ¸Ñª¼¨S¦³¹ï·Ó²Õ¼Æ¾Ú!!!

1/21¶K¥X[ÃÒ¨é´Û¶B]«ß®v¨Æ°È©Ò¥Nªí§ë¸êªÌ«Å¥¬¹ï NRx ¶i¦æ½Õ¬d¡C

ºG½ßªº§ë¸ê¤H¸Ó«ç»ò°µ?

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/1/21 ¤W¤È 07:50:58²Ä 1611 ½g¦^À³

¸g¹L°ò¨È»P¯E¹©¨Æ¥ó«á¡A§ë¸ê¤H¹ï¥Í§ÞªÑ¯d¤U¤£¦nªº¦L¶H¡A¤£§Æ±æ¾ú¥v¨Æ¥ó­«ºt!

1. FDA©Úµ´NRxÃļtZyesami¥Î©óªvÀø¦M­«¯f±w¤§EUA

2. 2022.1.20ÃÒ¨é´Û¶B«ß®v¨Æ°È©Ò¥Nªí§ë¸êªÌ«Å¥¬¹ï NRx ¶i¦æ½Õ¬d2021 ¦~ 6 ¤ë¡ANRx «Å¥¬¦V¬ü°êFDA´£¥æ¥Ó½Ð¡A­n¨DÀò±oZYESAMIªººò«æ¨Ï¥Î±ÂÅvEUA¡A¥HªvÀø±w¦³©I§l°IºÜªº¦M­« COVID-19 ±wªÌ.

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/1/5 ¤U¤È 04:14:55²Ä 1548 ½g¦^À³

°ê¹©«ç¤£´£¨Ñ¹ï·Ó²Õ¼Æ¾Ú?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/23 ¤U¤È 05:01:16²Ä 2342 ½g¦^À³
ªGµM«ö¹H¤Ï±¡¸`»´­«¤À§O¥´150¤jªO»P50¤jªO!

2022.8.23Âd¶R¥«³õ¡n¹H¤Ï­«°T¥Ó³ø °ê¹©¾D³B¹H¬ùª÷150¸U¤¸

2022.8.23 ¤ß®®¹H¤Ï­«°T³W©w Âd¶R¤¤¤ß­«»@50¸U¤¸

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/3 ¤W¤È 09:42:57²Ä 2288 ½g¦^À³

·s«a3®a¸Ñª¼ª¬ªp:

1.°ê¹©1/5¸Ñª¼:ªø´ÁÄY­««K¯µ6­Ó¤ë¤SºÆ¨¥ºÆ»y(¯f¯g¤£©ú)

2.¤ß®®8/1¸Ñª¼:¥D­n/¦¸­n/p­È©Ô3¤é¤~°®²b(»´·L¸¡Âm©|¥i)

3.¶h¹F8/3¸Ñª¼:¥D­n/¦¸­n/p­È¤@¤Ñ´N°®°®²b²b(°·±d³Ì¨Î)

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/23 ¤U¤È 12:18:45²Ä 2341 ½g¦^À³
§Aªº³s½u¤£¬O¨p¤H³s½u

§ðÀ»ªÌ¥i¯à·|¸Õ¹Ï±q www.berich.com.tw ÅѨú§Aªº¸ê°T (¨Ò¦p±K½X¡B¶l¥ó©Î«H¥Î¥d¸ê®Æ)¡CÁA¸Ñ¸Ô±¡

NET::ERR_CERT_DATE_INVALID

-------------------------------------------------------------------------

¶i¨Ó³oÃä,¹q¸£µ¹§Ú´£¥Ü,©È©È?

§O©È¡A¦w¥þ©Ê¾ÌÃÒ¹L´Á½}¤F¡A¥¿­«·s¥Ó½Ð¤¤¡A½Ð¦w¤ß¨Ï¥Î¡AÁÂÁ¡IBY¥²´Iºôª©¥D

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/8/22 ¤U¤È 04:11:34²Ä 2340 ½g¦^À³
¤§«e¤]¦³°Ý¹L¥Í§Þ·~ªB¤Í³o°ÝÃD¡A¦¬Áʦn¹³¬O©MENDOºX¤Uªº¤l¤½¥qñªº¡A¤£½T©w°]°È¤Wªº¾Þ§@¬O«ç¼Ë?

·Q»¡¬°¤°»ò¤£©M·sģñ??

©ï·Lªº¾Þ§@¥u¯à»¡¨S¤ºÀ`§Ú¬O¤£¤Ó·Q«H ¤S¬O¤@­Ó©M¦w¥Í¤@¼Ë¤jªÑªF±j¦l¤pªÑªF

======================================

Endo ¦]Àn¤ùÃþ¤îµhÃÄ Opana ER ©x¥q½ßÀvª÷ÃBÃe¤j¦Ò¼{¯}²£¥Ó½Ð¡A¥x·LÅ骺 TLC599 ±ÂÅv·|¤£·|¯}§½¡H

With opioid litigation looming and $8B in debt, Endo looking at bankruptcy play: WSJ

¥X³B¡G

www.fiercepharma.com/pharma/endo-headed-bankruptcy-other-opioid-crisis-litigants-purdue-and-mallinckrodt-wsj

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¶ø¥ì´µ¯S10031727  µoªí®É¶¡:2022/8/22 ¤U¤È 03:43:34²Ä 2339 ½g¦^À³
Endo ¦]Àn¤ùÃþ¤îµhÃÄ Opana ER ©x¥q½ßÀvª÷ÃBÃe¤j¦Ò¼{¯}²£¥Ó½Ð¡A¥x·LÅ骺 TLC599 ±ÂÅv·|¤£·|¯}§½¡H

With opioid litigation looming and $8B in debt, Endo looking at bankruptcy play: WSJ

¥X³B¡G

www.fiercepharma.com/pharma/endo-headed-bankruptcy-other-opioid-crisis-litigants-purdue-and-mallinckrodt-wsj

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/8/22 ¤U¤È 12:25:14²Ä 2338 ½g¦^À³
¦X¤@±a°Ê¡A¦ýºâ®z
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/22 ¤W¤È 09:21:08²Ä 2337 ½g¦^À³
¤H©¹©¹¬O³æ¦V«äºû¦a¡Aµw±N¨Æ±¡©¹¦Û¤v§Æ±æªº¤è¦V¥h²z¸Ñ¡A¤@®Úµ¬¤£À´±oÂàÅs¡C

¥u¯àÅý®É¶¡§i¶D¥L¡AÅý³o¨Ç¤@®Úµ¬¦Û¥Í¦Û·À¡Aªº¤£¥h·sªº¤£¨Ó¡C

¡u³±¦b¶§¤§¤º¡A¤£¦b¶§¤§¹ï¡v¡A¦hťť¤£¤@¼ËªºÁn­µ¡A±q§ïÅܦۤv®Ú²`¸¦©Tªº·Qªk¶}©l¡A¤~¦³¾÷·|§ïÅܦۤvªº¤H¥Í¡C

ªÑ²¼§ë¸ê¦³¾÷·|Åý±z°]´I¦Û¥Ñ¡A¤]¦³¾÷·|Åý±z°f¦V°]´IÂk¹s!

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/1/5 ¤U¤È 05:04:51²Ä 1553 ½g¦^À³

¾À¥ß¤d¥Q¡A µL±ý«h­è¡C ®ü¯Ç¦Ê¤t¡A ¦³®e¤D¤j¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/21 ¤W¤È 10:33:45²Ä 2336 ½g¦^À³
Roger¤j¡C

¬Ý¨ì¨º¨Ç¤°»ò³£¤£À´ªº¹©¯»´N·Q¯º¦º¡C

·íªì³Û«n¥P¤¦ªº¹F¤H¡A¦­¶]¤F¡C

µ{«×¦³û{®t¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/21 ¤W¤È 06:56:24²Ä 2335 ½g¦^À³
¦X¤@¶Ë¤f¨Å»I ¬ü­ã¤W¥«--->¥Í§ÞªÑ¶g¤@¤S¬O­·­·¤õ¤õ½Ä«l¤Q¨¬!

¦Ü©ó¾Þ§ËÁ{§É¸ÕÅç¼Æ¾Úªº¼t®a¡A¤£¬O¤£³ø¡A®É¨°¥¼¨ì¡A¦]ªG¦ó´¿ÄǹL½Ö¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/21 ¤W¤È 06:37:56²Ä 2334 ½g¦^À³
ªYÄ£¦¶Á`:¦]¬°NAFLD¨Ã¤£¬O­P©Rªº¯e¯f¡A´NFDAªº¨¤«×¨Ó¬Ý¨Ã¤£·|¦P·NÁ{§ÉÃĪ«¥HNAFLD¬°¾AÀ³¯g¶i¦æ¸ÕÅç¡C

NAFLªº©w¸q¡G¦³¨x¯×ªÕÅܩʪºÃÒ¾Ú¡A¦ý©|¥¼¦³¨x²Ó­M·l¶Ë¡A¨äºtÅܦ¨¨xµw¤Æ©Î¨x°IºÜªº¦MÀI©Ê¸û§C¡C

NASHªº©w¸q¡G°£¤F¦³¨x¯×ªÕÅÜ©Ê¡A¥B¤w³y¦¨¤F¨x²Ó­M·l¶Ë¡A¥i¯à³y¦¨¨xµw¤Æ©Î¨x°IºÜ¡C

¤£¤F¸ÑÀq¨FªFªºÀY¹ïÀYªvÀø«D°sºë©Ê¯×ªÕ¨x¸ÕÅç¥Î·N?(«D°sºë©Ê¯×ªÕ¨xNAFLD³z¹L´îªÎ.¹B°Ê.¶¼­¹½Õ¾ã´N¯à°fÂà¡A¤£¶·¥ÎÃĪ«ªvÀø)¡A²ö«DFDAªº¥ß³õ§ïÅÜ¡A·|®Ö­ãNAFLDÃÄÃÒ???

---------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/20 ¤U¤È 04:53:08²Ä 2332 ½g¦^À³

ªvÀø«D°sºë©Ê¯×ªÕ¨x¡I

Àq¨FªFGLP-1/GCGRÂù­«¿E°Ê¾¯Efinopegdutide(ªá8.7»õ¬ü¤¸) ¬D¾Ô ¿Õ©M¿Õ¼wsemaglutide(GLP-1)

ÀY¹ïÀYP2Á{§É¸ÕÅç (±EÀu±E¦H«Ý´¦¾å!)

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/20 ¤U¤È 05:15:28²Ä 2333 ½g¦^À³
Semaglutide¤U¤@¤äÃĤý?

freewechat.com/a/MzI5NzY0NDQyNQ==/2247527375/1

...³o¦ì§Ó±o·Nº¡ªº¤¤¦~¨k¤l¡A§Ï©»¦b°Ý¦Û¤v¡G¡§Lipitor¤§«áªºÃĤý¬OHumira¡A±µ´ÀHumiraªº¤w¸g²@µLÄa©À·íÄÝKeytruda¡CKÃĤ§«á©O¡H§Ú­Ìªº³o´ÚGLP-1¿E°Ê¾¯Ozempic/Rybelsus¡]Semaglutide,¯Á°¨¾|肽¡^¥¼¨Ó±N·|¦b¦WÃıƦæº]¤W¦û¾Ú¤°»ò¼Ëªº¦ì¸m¡H

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/8 ¤W¤È 08:53:22²Ä 2306 ½g¦^À³

®Á¤F¬ü°êÂå«O°ê½Íªk®×¤@°O´e´Ò¡A[ÃĤý¶Ç©_]¦¹«áÃø¦³?!

..ªk®×ªº实¬I·N¨ýþÓ¹³Humira这ý©¦b¬ü国¥«场经¤[¤£°Iªº传©_¦¹¦Z³£难¦³¤F¡C

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤U¤È 07:24:51²Ä 2305 ½g¦^À³

2021¦~¿Õ©M¿Õ¼wGLP-1ÃþÃĪ«ºâ¤W´îªÎ»â°ì¦X­p°^ÄmÀ禬¹F95»õ¬ü¤¸!

­Y¦bNASH¤]®³¨ìÃÄÃÒ¡A¿Õ©M³o¤äGLP-1ÃÄ(¿}§¿¯f+´îªÎ+NASH)°ª®pÀ禬µ´¹ï¯}200»õ¬ü¤¸¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/20 ¤U¤È 04:53:08²Ä 2332 ½g¦^À³
ªvÀø«D°sºë©Ê¯×ªÕ¨x¡I

Àq¨FªFGLP-1/GCGRÂù­«¿E°Ê¾¯Efinopegdutide(ªá8.7»õ¬ü¤¸) ¬D¾Ô ¿Õ©M¿Õ¼wsemaglutide(GLP-1)

ÀY¹ïÀYP2Á{§É¸ÕÅç (±EÀu±E¦H«Ý´¦¾å!)

clinicaltrials.gov/ct2/show/NCT04944992?term=Efinopegdutide&draw=2&rank=1

...............................................................................................

·|­û¡GROGER588910148151 µoªí®É¶¡:2020/8/19 ¤W¤È 08:27:20²Ä 288 ½g¦^À³

­Ó¤H¾ã²z¥Xªº2019~2020 NASHÃĪ«±ÂÅvª÷¦æ±¡¡A¶È·J¾ã«¥¤§«e¦b¥»ª©¶K¥Xªº¸ê®Æ¡A«OÃÒÁÙ¦³¿òº|¤§¯]!

...............................................................................................

...

6.2020.08.05 NASH¥«³õ¤õ¼ö! Àq¨FªF8.7»õ¬ü¤¸¨ú±oÁú¬ü»sÃÄNASH·sÃÄ---P1?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/20 ¤U¤È 01:29:12²Ä 2331 ½g¦^À³
F2~F3Á{§É:clinicaltrials.gov/ct2/show/NCT02970942

Drug: Semaglutide

Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)

Drug: Placebo

Once daily administration subcutaneously ( s.c., under the skin)

----------------------------------------------------------

F4Á{§É:

Drug: Semaglutide

Drug: [Placebo (semaglutide)]

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/20 ¤U¤È 12:02:19²Ä 2330 ½g¦^À³
1.¥¢±Ñªº71¤HÁ{§É(F4¹ï·Ó²Õ(¦w¼¢¾¯)Àu©ó¥ÎÃIJÕ???)

clinicaltrials.gov/ct2/show/NCT03987451?term=NCT03987451&draw=2&rank=1

Drug: Semaglutide

Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks

Drug: Placebo (semaglutide)

Semaglutide placebo s.c. given once-weekly for 48 weeks

2.¦N§Q¼w»P¿Õ©M¿Õ¼w(Semaglutide)¦³¦X§@¤@­Ó¤G´ÁÁ{§É440¤HªºF4¶i¦æ¤¤

clinicaltrials.gov/ct2/show/NCT04971785

---------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 12:27:15²Ä 2205 ½g¦^À³

NASH«Í¾î¹M³¥¡C

¦³¬ð¯}©ÊÀøªkªº¿Õ©M¿Õ¼wsemaglutide¦bF4¸T°Ï±¾¤F!!!

2022.7.1 www.healio.com/news/gastroenterology/20220630/ozempic-boosts-cardiometabolic-markers-falls-short-for-fibrosis-in-nashrelated-cirrhosis

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¶ø¥ì´µ¯S10031727  µoªí®É¶¡:2022/8/20 ¤W¤È 09:55:53²Ä 2329 ½g¦^À³
Novo Nordisk (¿Õ©M¿Õ¼w)ªº semaglutide ¦b NASH F2/F3 stage ªí²{«G²´¡A¦ý F4 Á{§É¤G´Á¨S¦³¹F¼Ð¡C

In the study of 71 NASH patients with compensated cirrhosis (the F4 stage of the disease), only 10.6% of those who received a weekly 2.4 mg dose of semaglutide saw an improvement in liver fibrosis coinciding with no worsening of NASH. The figure for those on placebo was 29.2%.

As a secondary endpoint, 34% of patients on semaglutide saw a resolution of NASH¡Xwhich means improvement in liver inflammation and liver cell ballooning¡Xversus 20.8% on placebo.

¥þ¤å¥X³B¡G

www.fiercepharma.com/pharma/after-phase-2-flop-novo-nordisk-next-list-fail-nash

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/19 ¤U¤È 07:30:38²Ä 2328 ½g¦^À³
¤ñ°_2¦~«e¾D©Úªº¼Æ¾Ú¡AIntercept¬°¤F®øÀ±FDA¹ï©óªø´Á¨Ï¥Îªº¦w¥þ©ÊÅU¼{¡A³o¦¸¥Ó½Ð¬O¦³¦¬¶°¼Æ¾Ú¡C

ir.interceptpharma.com/news-releases/news-release-details/intercept-announces-positive-data-fibrosis-due-nash-new-analysis

...Safety was evaluated in 2,477 subjects who took at least one dose of study drug (placebo, OCA 10 mg, or OCA 25 mg). Compared to the original analysis, the safety population in this new interim analysis had significantly longer exposure to study drug (median 42 months vs. 15 months), yielding more than 8,000 total patient-years and 3.4 times more exposure. Nearly 1,000 subjects had been on study drug for four years.

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¶ø¥ì´µ¯S10031727  µoªí®É¶¡:2022/8/19 ¤U¤È 03:07:48²Ä 2327 ½g¦^À³
www.genetinfo.com/international-news/item/61022.html

¥H¤W­z³ø¾É¨Ó¬Ý Intercept ´£¥Xªº·s¤ÀªR¼Æ¾Ú¡A¦ü¥G¨S¦³¤°»ò«G²´ªº¦a¤è¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/19 ¤W¤È 04:59:40²Ä 2326 ½g¦^À³
Intercept¤µ¤Ñ¦¬19.7¡A´N®t0.8¤¸¯}52¶g°ª¡A¦ü¥G¦³À¸¥i¥H¬Ý?

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 04:48:53²Ä 2164 ½g¦^À³

Ocaliva[²×§½¤§¾Ô]´N¦b7¤ë! ²Ä1¤äNASHÃĪ«?

...

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/1/18 ¤W¤È 07:49:34²Ä 1600 ½g¦^À³

·Q[½ä]¤@©]­P´I?³o®aIntercept pharmaceuticalsªº[²×§½¤§¾Ô]¦³¼Éº¦10~20­¿ªº¹ê¤O»P¾÷·|?!

­ì¦]:

1.ªÑ»ù¾ú¥v°ª 2014.1.6 $497¡A¾ú¥v§C:2021.8.16 $11.6

2.¬Q¤é¦¬½Lº¦7.96% ¦¬$17.76----¬ü°ê§ë¸êªÌ¶}©l©ãª`Ocalivaªº[²×§½¤§¾Ô]

2022.1.7---2022 ¦~¤£¥i¿ù¹Lªº 3¶µ....¹ï©ó³o¨Ç»sÃÄ°Ó¨Ó»¡¡A³o¥i¯à¬O«D±`¿E°Ê¤H¤ßªº¤@¦~¡C

3.¤@¾Ô¨M¥Í¦º®É¶¡:2022¦~¤W¥b¦~

2021.12.20 Intercept ¥i¯à·|¦b 2022 ¦~¤W¥b¦~»P FDA ­«·s´£¥æ·|ij¡C

4.­Ó¤H¤£·|©ãª`³o³õ½ä§½¡A°lÂÜFDA§å­ãªº²Ä1¤äNASHÃĪ«¥Î¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/19 ¤W¤È 04:29:28²Ä 2325 ½g¦^À³
VERU¤µ¤Ñ¦hªÅ¥æ¾Ô¿E¯P±Y21.47%(¸³¨ÆMario Eisenberge¶g¤@½æªÑ¡A¿ðº¢¤µ¤Ñ¤ÏÀ³?)¡AªÅÀY³o»ò¸vµL§Ò¼ª?

¹ï¤ñ½÷·ç»PÀq§J»´¯gÃĪ«¡AFDA¹ï­«¯gÃĪ«EUA§å±o¦ü¥G¦³ÂIºC?

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/16 ¤W¤È 09:18:42²Ä 2316 ½g¦^À³

Veruªºeua±q6/7´£¥æ¤w¹L2­Ó¤ë¡A FDA¬°¦óÁÙ¤£§å?

¦s¦³20%¤£¹LÃöªº²z¥Ñ:

1.5/10 :Veru»PFDA¶}pre-eua meeting 6/7:Veru¤½§i°e¥Xeua¥Ó½Ð¡C

EUAÄÝ©óºu°Ê¦¡¥Ó½Ð¡A¶}pre-eua meeting®É¡A7/8ªÅ¤è©Ò½èºÃªº¼Æ¾Ú¬O¦³¥i¯àÁÙ¨S¦¬»ô´£¥æFDA¡C

2.[Sabizabulin ªvÀø²Õªº±wªÌ¼Æ¶q¬O¦w¼¢¾¯ªº1­¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84]»P[¦w¼¢¾¯²Õ¤¤¦³11.5%ªº±wªÌ¬OWHO 6 ±wªÌ¡A¦ÓSabizabulin²Õ¥u¦³ 5.1%]¡X¬Ý°_¨Ó¤£¹³¬OÀH¾÷???

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/18 ¤U¤È 12:44:04²Ä 2324 ½g¦^À³
¥k¤âÂå«O°ê½Íªk®×¤j¤M¬åÃÄ»ù¡A¥ª¤â¤Sµ¹¤F¥v¤W³Ì©ù¶QªºÃĪ«»ù280¸U¬ü¤¸!

2022.8.18 ¥v¤W³Ì©ù¶QªºÃĪ«©w»ù°ª¹F280¸U¬ü¤¸

¬ü°ê­¹«~ÃĪ«ºÞ²z§½(FDA)¶g¤T(17¤é)³q¹L¤Fbluebird bioªº°ò¦]ÀøªkÃĪ«¡A¥iªvÀø¨u¨£¯e¯f±wªÌ¡C·sÃÄ©w»ù°ª¹F280¸U¬ü¤¸¡A¬°¥v¤W³Ì©ù¶QªºÃĪ«¡C

MoneyDJ XQ¥þ²yĹ®a¨t²Î³ø»ùÅã¥Ü¡A17¤ébluebird bio´­¤É3.04%¡B¦¬6.78¬ü¤¸¡AIJ¤Î240¤é½u¡C

¸ô³zªÀ¡B µØº¸µó¤é³ø³ø¾É¡A·sÃĦW¬°¡uZynteglo¡v¡A¥Î¨ÓªvÀø»Ý©w´Á¿é¦åªº¤A«¬¦a¤¤®ü³h¦å(beta-thalassemia)±wªÌ¡CFDAªí¥Ü¡AZynteglo¬°­º´Ú¤A«¬¦a¤¤®ü³h¦åªº°ò¦]Àøªk¡C

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/8 ¤W¤È 08:53:22²Ä 2306 ½g¦^À³

®Á¤F¬ü°êÂå«O°ê½Íªk®×¤@°O´e´Ò¡A[ÃĤý¶Ç©_]¦¹«áÃø¦³?!

2022.8.5 ¬üª©¡§医«O国谈¡¨ªk®×¤L¥GªO¤W钉钉¡A业¬É¤@¤ù哗µM

www.phirda.com/artilce_28513.html?cId=1

...

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/8/17 ¤U¤È 01:52:20²Ä 2323 ½g¦^À³
ÄY­«¨xÅÖºû¤Æ±yÃö¥Í©R¦s¤`¡A¥²µM»ù­È¶W°ª¡Fµ¥¦P¬O¯«ÃįżƤ~¯à¦³¦p¦¹Àø®Ä¡F³o³¡¤À°Ó¾÷¤ñ²vÁö¤£ºâ¤Ó°ª¡A¦ýÁn¶Õ·|Ån¬A¨xÃĬɡA¥u­n¨S¤°°Æ§@¥Î¡A¥D­nÀø®Ä³¡¤À»â¥ý«e­±´XÁûÃÄ¡A¥¼¨Ó¼ÖÆ[¡C²Ä¤@­Ó¦X§@ÃļtÀt¤F¥b¤ÑÁÙ¤£±ÂÅv¡A¥L©ú©ú¨S¦³¤£±ÂÅv±ø¥ó¡m­Y¤£±ÂÅv¡A¦Ñ¹«¦Y´¶®³¯k¦º¥ú¹êÅç¬ã¨s¦ÛµM·|¤£¤p¤ßÃn¥ú¡Aº¡Áy¨§ªá¡n·l¥¢ºG­«¡CµL¬r¤îµh¾¯±ÂÅv®ø®§¦~©³«e¥i¯à·|¦³®ø®§¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/17 ¤U¤È 12:40:04²Ä 2322 ½g¦^À³
Roger¤j¡A¥«³õ¤j¡Aµ¥±ÂÅv¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/17 ¤W¤È 10:22:46²Ä 2321 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/17 ¤W¤È 07:42:01²Ä 2319 ½g¦^À³

Peter Lin¤j,±z·|³ßÅw°­¨û¤µ¤Ñªº³o¥y¡G[³o­Ó­««×¯×ªÕ¨x¦pªG¦¨¥\ªº¸Ü¡A©Ò¦³«e­±ªº¥[°_¨Óªº»ù­È³£¤£¤Î³o­Ó¡I²{¦bÁÙ¦­¡I]

-----------------------------------------------------------------------------------------------------

ªYÄ£¤pªÑ¥»¨­»´¦p¿P¡A¤@¤é¯×ªÕ¨xª¢NASHÃĪ«¦¨¥\¡A³o¥y¡§¤jÄP¤@¤é¦P­·°_,§ß·nª½¤W¤E¸U¨½¡C¡¨±N«Ü¶K¤Á¡C

§ë¸ê¤@©w¦³­·ÀI¡A§OÀ£¨­®a(ÁÙ¤£¨ì®É­Ô)!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/17 ¤W¤È 08:55:50²Ä 2320 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤W¤È 11:10:40²Ä 2291 ½g¦^À³

´¼Àº¤p²Ó­MªÍÀù¸Ñª¼©|¤£¯à¤U©w½×¡AmOS»PORR»PmPFS§¹¾ã¼Æ¾ÚÁÙ¨S¤½¥¬¡C

¤G½uÃĪ«´N2¤ä:Topotecan»PLurbinectedin ¡AÂå±w¥i¿ï¾ÜÃĪ«¤Ó¤Ö!

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/18 ¤U¤È 12:34:36²Ä 2243 ½g¦^À³

«¥¦³¤@­ÓP­È0.06·L¤j©ó0.05¡AFDAµoµ¹ÃÄÃÒ¦a®×¨Ò¦p¤U

1. 2020.12.12 www.fiercepharma.com/marketing/where-do-you-stand-fda-reviewers-argue-for-

novartis-entresto-committee-meeting-file

FDA staffers highlighted that the result¡¦s p-value, at 0.06, is ¡§only slightly above the 0.05

target¡¨ to achieve statistical significance, hinting that they¡¦re willing to give that miss a

pass.

---------------------------------------------------------------------------------------------------

¥D¼Ðp­È0.06¡AFDAµ¹ÃÄÃÒ!

°²­Y´¼Àº¤½¥¬mOS p¦b0.06~0.08¡A¦Ó¦¸¼ÐORR¬O2­¿©óTopotecan-->ORR»¡¥Õ¸Ü:¥Î´¼ÀºÃĪ«ªvÀø¨Ï¸~½FÁY¤pªº±wªÌ¤H¼Æ¬OTopotecanªº2­¿¡AFDA·|¤£·|µoµ¹Ãįg???

µ²½×:±z¥i¥H¬ÝªÅ¡A¦ý¤£­n°µªÅ!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/17 ¤W¤È 07:42:01²Ä 2319 ½g¦^À³
Peter Lin¤j,±z·|³ßÅw°­¨û¤µ¤Ñªº³o¥y¡G[³o­Ó­««×¯×ªÕ¨x¦pªG¦¨¥\ªº¸Ü¡A©Ò¦³«e­±ªº¥[°_¨Óªº»ù­È³£¤£¤Î³o­Ó¡I²{¦bÁÙ¦­¡I]

www.genetinfo.com/investment/featured/item/58585.html?start=2

...¤é«e¤w¦³¬ã¨s«ü¥XADI-PEG20¦b­««×¯×ªÕ¨x»P«D°sºë©Ê¨xª¢ªºªvÀø®ÄªG¨Î¡A­Y¥¼¨Ó¦³¾÷·|¥ç¥i´Â«DÀù¯g»â°ìÂX¤j¬ãµo....

---------------------------------------------------------------------------------------------------

·|­û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/6 ¤U¤È 01:51:41²Ä 2194 ½g¦^À³

ROGER¥S

°­¤â©ö¥Í.....¬O¬Ý¬Ý´N¦n¡A°£«D¤Q¤j°ê»ÚÃļt½Í±ÂÅvªº®ø®§¥X¨Ó¡A»ù­È¦ô¤£¥X¨Ó¡A§Ú¤£¸Iªº¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/16 ¤U¤È 04:27:24²Ä 2318 ½g¦^À³
§Ú·|¬°¡§¦n¬Ý¡¨¶R³æ´îªÎ!

¡§ÃC­È¸gÀÙ¡¨: ³o¬O¤@­Ó¬ÝÁyªº®É¥N¡A©ÎªÌ»¡¬ÝÃC­Èªº®É¥N¡C

m.21jingji.com/article/20210530/herald/fd370e54f45dfecbff7049c4877f2ec7_zaker.html

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¶ø¥ì´µ¯S10031727  µoªí®É¶¡:2022/8/16 ¤U¤È 01:47:04²Ä 2317 ½g¦^À³
´î­«Ãijq±`¤j¥b®³¤£¨ì«OÀIµ¹¥I¡A¨S·Q¨ì³ºµM¯à½æ³o»ò¦n¡A»á¤H¥O¤H·N¥~¡C ¬d¤F¤@¤U¡A­ì¨Ó¥xÆW¤w¸g¦³«Ü¦hÂå¥ÍÀ°·Q´îªÎªº¤H¨Ï¥Î¸zªc¯ÀÃĪ«(off lable use)¡A¥L­Ì³qºÙ½G½G°w¡A¤@¦~ªºÃĪ«¶O¥Î 8~10 ¸U¡C

Ò\«e¸pªø´¿°Ý¹L­J±Ð±Â¡ASNP-610/630 ¯à¤£¯à·í´îªÎÃĨϥΡA­J¯ºµÛ¦^»¡¤£¦æ¡C±µµÛ¤S»¡ªA¥Î SNP-610/630 ´Nºâ¦³¯×ªÕ¨x¤]¤£¦AÅܦ¨¯×ªÕ¨xª¢¡A¤£¥²´îªÎ¡C

¸zªc¯ÀÃĪ«¬O±q­°§C­¹¼¤¤Î©µ¿ð±ÆªÅ­G³¡ªº®ÄªG¨Ó¹F¦¨´îªÎªº®ÄªG¡A¦Ó SNP-610/630 ¬O´î¤Ö¯×ªÕ§Î¦¨¤ÎÂà´«¨x¯×ªÕªº¯S©ÊÅܦ¨¤£¶Ë¨x¡A¤£¬O±q¼ö¶qÄá¨ú·½ÀYµÛ¤â¡A§Ú²q®ÄªG¥i¯à¨S¦³¸zªc¯ÀÃĪ«¨ÓªºÅãµÛ´î¤ÖÅé­«¡A¦ýªÖ©w¬O¦³¨ó¦Pªº®ÄªG¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/16 ¤W¤È 09:18:42²Ä 2316 ½g¦^À³
Veruªºeua±q6/7´£¥æ¤w¹L2­Ó¤ë¡A FDA¬°¦óÁÙ¤£§å?

¦s¦³20%¤£¹LÃöªº²z¥Ñ:

1.5/10 :Veru»PFDA¶}pre-eua meeting 6/7:Veru¤½§i°e¥Xeua¥Ó½Ð¡C

EUAÄÝ©óºu°Ê¦¡¥Ó½Ð¡A¶}pre-eua meeting®É¡A7/8ªÅ¤è©Ò½èºÃªº¼Æ¾Ú¬O¦³¥i¯àÁÙ¨S¦¬»ô´£¥æFDA¡C

2.[Sabizabulin ªvÀø²Õªº±wªÌ¼Æ¶q¬O¦w¼¢¾¯ªº1­¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84]»P[¦w¼¢¾¯²Õ¤¤¦³11.5%ªº±wªÌ¬OWHO 6 ±wªÌ¡A¦ÓSabizabulin²Õ¥u¦³ 5.1%]¡X¬Ý°_¨Ó¤£¹³¬OÀH¾÷???

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/15 ¤U¤È 12:11:31²Ä 2315 ½g¦^À³
NovoªÑ»ù«l´­50%¡A¥»¯q¤ñ¸û¦P·~°ª¥X70%¡C§¨ÓªÑ»ù¬ù¬°300¬ü¤¸¡A¥»¯q¤ñ¬O¦P·~ªº¨â­¿¡C

2022.8.12

www.barrons.com/articles/buy-eli-lilly-novo-nordisk-stock-price-picks-weight-loss-drugs-51660319418?tesla=y

§¨Óªº¸zªc¯ÀÃĪ«¦W¬°tirzepatide¡C¾¨ºÞtirzepatide©|¥¼®Ö­ã¥Î©ó´îªÎ¡A³o´Ú·sÃĤwÅý§¨ÓÅD©~µØº¸µóªº³Ì·R¤§¤@¡C¥Ø«e§¨ÓªÑ»ù¬ù¬°300¬ü¤¸¡A¬O¥¼¨Ó12­Ó¤ë¬Õ¾l¹w´Áªº34­¿¡A¥»¯q¤ñ¬O¦P·~ªº¨â­¿¡C

----------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 04:11:51²Ä 2295 ½g¦^À³

§O§â´îªÎ¥«³õ¬Ý¤p¤F!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/15 ¤W¤È 08:33:31²Ä 2314 ½g¦^À³
2022.8.15 ·s´î­«ÃĮĪG¨Î ®Æ¦¨¥v¤W³ÌºZ¾PÃÄ Â§¨ÓªÑ»ù«N(§¨ÓºÙ·sÃÄ¥i¥Ï1/5Åé­« ®ÄªG¦p¤â³N)

ªÎ­D¬O¥þ²y¤j°ÝÃD¡A«Â¯Ù¨ì5»õ¤Hªº©Ê©R¡A¦p¤µ¥X²{¦w¥þ¦³®Äªº·sÃÄ¡A¯àÅý¤H´î±¼20%Åé­«¡A¥i±æ¦¨¬°¥v¤W³ÌºZ¾PÃĪ«¡C¬ãµoÃļtNovo Nordisk©M§¨Ó(Eli Lilly)±N¬O¶W¯ÅĹ®a¡C

Barron`s³ø¾É¡A¸zªc¯À(incretin)ªº´î­«®ÄªG«e©Ò¥¼¨£¡A¬ã¨sÅã¥Ü¡A¦¹ºØ·sÃįàÅý¥Á²³¦w¥þ¥Ï±¼1/5Åé­«¡A¦³±æÅD©~¥þ²yªº³Ì¼ö¾PÃÄ«~¡C¥~¬É¦ô­p¡A2030¦~°_¸zªc¯Àªº¦~«×¾P°â±N¬ð¯}500»õ¡B¬Æ¦Ü600»õ¬ü¤¸¡A¦¹¤@¥«³õ±N¥ÑNovo©M§¨Ó´x±±¡C

.....

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤W¤È 08:50:42²Ä 2302 ½g¦^À³

DGAT1§í¨î[´î¤Ö¯×ºw§Î¦¨] + Cyp2e1§í¨î[¯à¶q®ø¯Ó¼W¥[]

¤£±´¨sªÎ­DªvÀø(1+1>2¨ó¦P®ÄÀ³) ?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/13 ¤U¤È 05:35:14²Ä 2313 ½g¦^À³
²¦³ºVeruªº¼Æ¾Ú¯u¹ê©Ê¥ÑCRO¡BIDMC¡BFDAµû¼f¹L¡A«¥ªº«O¦u¥u¬O~100%´î¬°8¦¨·|¹L¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/13 ¤U¤È 05:09:16²Ä 2312 ½g¦^À³
Veru stock³o2¤éÃzº¦¡A¦³½g¸ê®Æ¥i¬Ý¤@¤U!

2022.7.18 Veru ªºP3¸ÕÅç¥X²{·sªº¦MÀI«H¸¹¡Aªí©ú FDA ¥i¯à·|©Úµ´

whitediamondresearch.com/research/new-red-flags-emerge-from-verus-phase-3-covid-trial-suggesting-an-fda-rejection-is-likely/

¦w¼¢¾¯²Õªº§C¦å®ñ¹¡©M«×

±q¤w¤½§Gªº¦w¼¢¾¯²Õ°ò½u¦å®ñ¹¡©M«×(OS)½d³ò¨Ó¬Ý¡A§Ú­Ìª¾¹D52¦W¦w¼¢¾¯±wªÌ¤¤³Ì§CªºOS¬OVeru¦P¦æµû¼f½×¤å¤¤ªº48¡C³oÅãµM¬O¤@­Ó¯f±o«Ü­«ªº¯f¤H¡A¤£ºÞªvÀø¦p¦ó¡A¥Lªº©R¹B´X¥G³£¬O²³©Ò©Pª¾ªº¡C

[Sabizabulin ªvÀø²Õ¾¨ºÞ±wªÌ¼Æ¶q¼W¥[¤F¤@­¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84¡C]

[Sabizabulin ªvÀø²Õ¾¨ºÞ±wªÌ¼Æ¶q¼W¥[¤F¤@­¿¡A¦ý¨S¦³¥ô¦ó¤Hªº OS §C©ó 84¡C]

...

¦w¼¢¾¯²Õ¤¤¦³ 11.5% ªº±wªÌ¬O WHO 6 ±wªÌ¡A¦Ó Sabizabulin ²Õ¥u¦³ 5.1%¡C³o¬O Veru «ù¤[¹B®ðªº¤@­Ó¨Ò¤l¡A

[³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C][³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C][³o¦b¾A·íªºÀH¾÷¤Æ¤U¬O¤£¥i¯àªº¡C]

µ²½×:¤£ª¾¹D¸ê®Æ¯u°°©Ê¡A«¥Âର«O¦u¬Ý«ÝEUA!

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 08:56:23²Ä 2262 ½g¦^À³

¶¢²áVERU ªñ´ÁªÑ»ùªí²{¤£¨Î¥i¯à­ì¦]?

2022.7.8: ½æªÅ¶°¹ÎCulper Researchµoªí¤F¤@¶µ·s¤ÀªR¡A¹ï¨ä³¡¤ÀÁ{§É¸ÕÅç¼Æ¾Ú´£¥X½èºÃ¡C

www.fool.com/investing/2022/07/08/why-veru-stock-got-dented-today/

--------------------------------------------------------------------------------------------------

µ²½×:1.Àò±oDSMBªº«Øij´£¦­µ²§ôÁ{§É¸ÕÅç¡A¶i¦æ¸Ñª¼¡C

2.5¤ë10¤éÁ|¦æFDAªº­±¹ï­±°Q½×·|ij¡AFDA¨S¦³­n¨D´£¨ÑÃB¥~¼Æ¾Ú¥B·í¤Ñ´N«ØijVERU»¼¥æEUA¥Ó½Ð¡C

3.6¤ë7¤éVERU«Å¥¬°e¥XEUA¥Ó½Ð

«¥»{¬°¹LÃö¾÷²v~100%¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/11 ¤U¤È 07:43:09²Ä 2311 ½g¦^À³
¥Ó½ÐPRE-EUA meeting»PEUA­nªá«Ü¦h¿ú¶Ü? (FDA:§K¶O §K¶O §K¶O)

¸ê®Æ¶}ªù¨£¤s¼gµÛ:FDA offers formal advice at no cost to developers of medicines regulated by both CDER and CBER, with the aim of supporting medicinal product development from Phase 1 through to marketing.

FDA§K¶O¬°¨üCDER©MCBERºÊºÞªºÃÄ«~¶}µo°Ó´£¨Ñ¥¿¦¡«Øij¡A¥Øªº¬O¤ä«ùÂåÃIJ£«~±q²Ä¤@¶¥¬q¨ì¤W¥«ªº¶}µo....

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/19 ¤W¤È 11:56:49²Ä 1804 ½g¦^À³

¡§³Õ¾Ç¤§¡A¼f°Ý¤§¡A·V«ä¤§¡A©ú¿ë¤§¡A¿w¦æ¤§¡¨

..¦Ü©ópre-EUA meeting¡AFDA´X¤Ñ¤º¸Ó°µ¥X¦^À³(»â®©¦b­Ó¤H):

www.scendea.com/making-the-most-of-opportunities-to-interact-with-the-us-fda

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/11 ¤W¤È 10:03:19²Ä 2310 ½g¦^À³
2022.8.10(¤j³°) ­º´Ú国产·s«a药ª«©wɲ¤£¨ì300¤¸¡A¥H¶q换ɲ¡Hwww.drugtimes.cn/2022/08/10/shoukuanguochanxinguanyaowudingjiabudao300yuanyilianghuanjia/

...

从ɲ®æ¤è­±来¬Ý¡A­º个国产§Ü·s«a¤fªA药ªº©wɲ仅为进¤f§Ü·s«a¤fªA药(辉·çPaxlovid)ªº约1/10¡C®ÚÕu¨C²~¤£¨ì300¤¸ªºÉ²®æ计ºâ

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/2 ¤W¤È 10:17:29²Ä 2286 ½g¦^À³

..¤»ºØª¢¯g«ü¼Ð¤¤ªº¤­ºØ¤¤¡A¤½¥q¨S¥æ¥N²M·¡5ºØp < 0.05¬O¨º´XºØ?(¤å·NÀ³¸Ó¤£¬O5ºØ)

¥t¥~¡A»´¯gÃĪ«ªº»ù®æ«ÜÃöÁä¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/8/10 ¤U¤È 03:42:31²Ä 2309 ½g¦^À³
·sÃĤñ¥É®i§C¡A§Ú¤£ªA!!!!

§Ö¯}¦Ê§r

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/9 ¤U¤È 05:22:55²Ä 2308 ½g¦^À³
50¥H¤U¦³º¡¤Àªº[¼É§Q¬ü¾Ç]! 2Ãä¶]¦³ÂI²Ö.

---------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤W¤È 10:38:08²Ä 1600 ½g¦^À³

·s«a¥¢ª¼¶^¶Õ¦³ÂI·N¥~ªº²`¡A¤½¥q®Ö¤ß»ù­È¦b2¤äBTDÃĪ«¡A50¥H¤U¥ýÅu¤@¨Ç¡C¾¬±æ¤ß®®¦¨¥\Åý«¥¸É¦^¨Ó¤@¨ÇÃĵتº¿ò¾Ñ¡C

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/3 ¤W¤È 11:15:22²Ä 1593 ½g¦^À³

À£·s«aªº¶}µPÂ÷³õ¡A§ÚÀ£2¤äBTD³o¶g¤J³õ¡AÅ¥µP¸Õ¤â®ð!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/9 ¤W¤È 10:58:56²Ä 2307 ½g¦^À³
Roger¤j, ¤ß®®§A¶iÔ·¨S¡H¤î¶^½L¤F¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/8 ¤W¤È 08:53:22²Ä 2306 ½g¦^À³
®Á¤F¬ü°êÂå«O°ê½Íªk®×¤@°O´e´Ò¡A[ÃĤý¶Ç©_]¦¹«áÃø¦³?!

2022.8.5 ¬üª©¡§医«O国谈¡¨ªk®×¤L¥GªO¤W钉钉¡A业¬É¤@¤ù哗µM

www.phirda.com/artilce_28513.html?cId=1

...

ªk®×ªº实¬I·N¨ýþÓ¹³Humira这ý©¦b¬ü国¥«场经¤[¤£°Iªº传©_¦¹¦Z³£难¦³¤F¡C

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/6 ¤U¤È 07:24:51²Ä 2305 ½g¦^À³

2021¦~¿Õ©M¿Õ¼wGLP-1ÃþÃĪ«ºâ¤W´îªÎ»â°ì¦X­p°^ÄmÀ禬¹F95»õ¬ü¤¸!

­Y¦bNASH¤]®³¨ìÃÄÃÒ¡A¿Õ©M³o¤äGLP-1ÃÄ(¿}§¿¯f+´îªÎ+NASH)°ª®pÀ禬µ´¹ï¯}200»õ¬ü¤¸¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/6 ¤U¤È 07:24:51²Ä 2305 ½g¦^À³
2021¦~¿Õ©M¿Õ¼wGLP-1ÃþÃĪ«ºâ¤W´îªÎ»â°ì¦X­p°^ÄmÀ禬¹F95»õ¬ü¤¸!

­Y¦bNASH¤]®³¨ìÃÄÃÒ¡A¿Õ©M³o¤äGLP-1ÃÄ(¿}§¿¯f+´îªÎ+NASH)°ª®pÀ禬µ´¹ï¯}200»õ¬ü¤¸¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/6 ¤U¤È 06:53:40²Ä 2304 ½g¦^À³
«¥ªº20»õ±o©¹¤W+17=37»õ¬ü¤¸¤F!

2022.3.8§â¿}§¿¯f药卖¦¨ú£ªÎ药¡I诺©M诺¼w2025¦~¡§发»}¡¨­n卖¨ì37亿¬ü¤¸

www.sohu.com/a/527948439_359980

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/5 ¤U¤È 04:54:17²Ä 2297 ½g¦^À³

´N¾Ì[¿Õ©M¿Õ¼w»¼¥æ¤F¤@±iÀu¥ý¼f¬d¾ÌÃÒ¡]PRV ,»ù­È>1»õ¬ü¤¸¡^¨Ó¥[³t´îªÎÃÄNDA¼f¬d(FDA§Ö³t¦b4­Ó¤ë¤º§å­ã¤W¥«]

³æ¬Ý´îªÎ¥ÎÃÄ¡A¥q¬ü®æ鲁肽ª`®g²GÃĮĴ20%+Åé­«(µ¥¦P´îªÎ¤â³N®ÄªG)¡A¥þ²y½æ­Ó20»õ¬ü¤¸¨S¤°°ÝÃD¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/6 ¤U¤È 06:46:31²Ä 2303 ½g¦^À³
¿Õ©M¿Õ¼w¥Ö¤Uª`®gªº­°¿}药ª«¦bªÀ¥æ¥­¥x¤W摇¨­¤@变¦¨¤F¡§ú£ªÎ¯«¾¹¡¨

2022.7.17 ¡§¤@针½G4¤ç¡Aªá费¤£¨ì3000¡¨

m.cyol.com/gb/articles/2022-07/17/content_O5W2YfWya.html

¥q¬ü¦b³¡¤À¦a区¥X现断货¡Cªñ¤é¡A¤¤·s经纬¥H®ø费ªÌ¨­¥÷«t询¤@¦ì药¥N¡A对¤è称¡G¡§经济条¥ó¤¹许ªº¦}¥B¨Ï¥Î过¥q¬üªº¡A¤@©w­n§y药¡I现¦b¥«场«Ü¤£稳©w¡A说¤£©w­þ¤Ñ断货¡A断¦h¤[¤]说¤£©w....

...¨ä风Ãû­ì¦]¡A¤@¤è­±¡A¦b¤_¨äú£ªÎ®ÄªG¡C¤W­z药¥Nªí¥Ü¡A®ÄªG¦]¤H¦ÓÉÝ¡A对¤_¤j°ò数ú£ªÎ§ó¦³®Ä¡A¨Ï¥Î©P´Á3-6个¤ë¡A¤§¦Z¤£会¤Ï弹¡A«e´Á½Gªº¬O¥Ö¤U¯×ªÕ¡A¦Z´Á¬O内脏¯×ªÕ¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/6 ¤W¤È 08:50:42²Ä 2302 ½g¦^À³
DGAT1§í¨î[´î¤Ö¯×ºw§Î¦¨] + Cyp2e1§í¨î[¯à¶q®ø¯Ó¼W¥[]

¤£±´¨sªÎ­DªvÀø(1+1>2¨ó¦P®ÄÀ³) ?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/6 ¤W¤È 08:38:30²Ä 2301 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2021/4/24 ¤U¤È 02:27:37²Ä 1062 ½g¦^À³

2020.05.13 »®»®¦³¦Wªº¬ü¤k¬ì¾Ç®a(¬ü°êÃÀ³N»P¬ì¾Ç°|¥~Äy°|¤h)¡AÃC¹ç½ÒÃD²Õ1­Ó¤ë®É¶¡¤º4½g³»¥Z¡C

´¦¥Ü¯×ªÕ¦X¦¨ÃöÁä酶DGAT1µ²ºc¤Î¶Ê¤Æ¾÷¨î

---------------------------------------------------------------------------------------------------

Nature¡G­«½S¡I¬ì¾Ç®a­º¦¸´¦¥Ü¤HÃþ¾÷Åé»s³y¥Ìªo¤Tà­ªº¤À¤l¾÷²z¡I

...

¬ã¨sªÌµo²{¡ADGAT1¯à¦b½¤¤¤§Î¦¨¤@ºØ¤jªº¡§·t¼Ñ¡¨¡A³oÅý¬ã¨s¤H­û«D±`¤£¥i«äij¡A³oºØ¡§¤ÏÀ³¼Ñ¡¨¯à¦b½¤¤º¤ÀÂ÷¥X¤@­ÓªÅ¶¡¡A±q¦ÓÀ°§U¶i¦æ¥Ìªo¤Tà­ªº酶Ãþ¦X¦¨¡C¤ÏÀ³ª«·|¦b¡§¤ÏÀ³¼Ñ¡¨¤¤¬Û¹J±q¦Óµo¥Í¤ÏÀ³¡AÀH«á¥Ìªo¤Tà­´N·|±q¯×ºwªº½¤¤¤²£¥Í¡A¦Ó¯×ºw¯à±N¥Ìªo¤Tà­±a¨ì²Ó­M»Ý­n¥¦­Ìªº¦a¤è¡C¦¹«e¬ã¨s¤H­û¨Ã¥¼¸Ô²Ó´¦¥Ü¹LDGAT1ªº3-Dµ²ºc¤Î¨ä§@¥Î¾÷¨î¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/6 ¤W¤È 08:28:27²Ä 2300 ½g¦^À³
DGAT1³Q认为¬O­«­nªºªv疗[ªÎ­D]¤Î¿}§¿¯fªº药ª«¹v点¡C

CYP2E1-PPAR £\¶b©w¸q¬°[ªÎ­D]ªvÀøªº·sªvÀø¹vÂI¡C

µ²½×:SNP·sÃĬODGAT1+CYP2E1§í¨î¡A¤£±´¨sªÎ­DªvÀø(1+1>2¨ó¦P®ÄÀ³) ?

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/4/24 ¤U¤È 02:27:37²Ä 1062 ½g¦^À³

2020.05.13 »®»®¦³¦Wªº¬ü¤k¬ì¾Ç®a(¬ü°êÃÀ³N»P¬ì¾Ç°|¥~Äy°|¤h)¡AÃC¹ç½ÒÃD²Õ1­Ó¤ë®É¶¡¤º4½g³»¥Z¡C

picture.iczhiku.com/weixin/message1592580325817.html

´¦¥Ü¯×ªÕ¦X¦¨ÃöÁä酶DGAT1µ²ºc¤Î¶Ê¤Æ¾÷¨î

...

DGAT1¦X¦¨¤T酰°ò¥Ìªoà­¡A¬O¤HÃþ¶¼­¹¯×ªÕ§l¦¬©M¯×ªÕ¦sÀx©Ò¥²»Ýªº¡C DGAT1Äݩ󽤵²¦XªºO-酰°òÂಾ酶¡]MBOAT¡^¶W®a±Ú¡A¨ä¦¨­û¦s¦b©ó©Ò¦³¥Í©R¤ý°ê¤¤¡A¨Ã°Ñ»P¯×½è©M³J¥Õ½èªº酰¤Æ§@¥Î¡C©|¤£²M·¡¤HÃþDGAT1©MMBOAT®a±Úªº¨ä¥L¦¨­û¦p¦óÃѧO¨ä©³ª«¨Ã¶Ê¤Æ¨ä¤ÏÀ³¡C¯Ê¥F¤Tºûµ²ºc¤]§«Ãª¤F¥X©óªvÀø¥Øªº¦X²z¹v¦VDGAT1¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/5 ¤U¤È 09:08:16²Ä 2299 ½g¦^À³
SNPÃĪ«ªº·s¾AÀ³¯gªÎ­DªvÀø?

³o¨Ç½×¤åµoªí³£¬Oªñ¦~ªº¿N¿S¿S~

-----------------------------------------------------------------------------------

2021.8.1 Áú°ê¤jªô¤j¾Çªº¬ã¨s

²Ó­M¦â¯À P450 2E1 (CYP2E1) ¥¿¦V½Õ¸`¯×½è¤À¸Ñ¥NÁ¨û¤¾É 3T3-L1 ¥Õ¦â¯×ªÕ²Ó­M½ÅÅÜ

www.sciencedirect.com/science/article/abs/pii/S0024320521006342

....§Ú­Ìªº¼Æ¾Ú´¦¥Ü¤F CYP2E1 ¦b 3T3-L1 ¥Õ¦â¯×ªÕ²Ó­M¤¤½Õ¸`½ÅÅܪº¤@ºØ¥ý«e¥¼ª¾ªº¾÷¨î¡Aªí©ú CYP2E1 ¬OªvÀøªÎ­D¤Î¨ä¬ÛÃö¯e¯fªº¦³§Æ±æªº¤À¤l¹v¼Ð¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/5 ¤U¤È 08:55:44²Ä 2298 ½g¦^À³
SNPÃĪ«ªº·s¾AÀ³¯gªÎ­DªvÀø?

--------------------------------------------------------------------------------------------

发¥¬时间¡G2022-07-08

¤ý©ý课题组¦bBiochem Pharmacol发ªí¬ã¨s论¤å¡G细­M¦â¯ÀP450 2E1°ò¦]ºV°£©Î§í¨î³q过调节¯à¶q®ø¯Ó预¨¾°ª¯×饮­¹诱导ªºªÎ­D

为¤°¤\¦³ªº¤H¤@¯ë饮­¹´N®e©ö发­D¡A¦Ó¦³ªº¤H«ç¤\¦Y³£¤£­D¡H这¥i¯à©MÊ^内CYP2E1¥N谢酶¬Û关¡CCYP2E1¬O¨x脏细­M¦â¯ÀP450¥N谢酶®a±Úªº­«­n¦¨员¡A调节药ª«ªº处¸m©M内·½©Êª«质ªº¥Íª«转¤Æ¡C虽µM¤§«eªº¬ã¨s发现CYP2E1ÉO¯à¶q¥N谢¦³关¡A¦ýCYP2E1¦b维«ù¯à¶q稳态¤¤ªº§@¥Î¤´¤£²M·¡¡C¥»¬ã¨sªí©ú¡A¤j¹«Cyp2e1°ò¦]¯Ê¥¢¥i¥H预¨¾°ª¯×饮­¹诱导ªºªÎ­D¡B¯×ªÕ¨x©M¯Ø岛¯À©è§Ü¡CÉó¨î¬ã¨sªí©ú¡ACyp2e1¯Ê¥F¤£仅¼W¥[´Ä¦â¯×ªÕ组织¡]BAT¡^©M¥Ö¤U¯×ªÕ组织¡]SAT¡^¤¤产热°ò¦]ªºªí达¡A¦Ó¥B«P进¨x脏©MBAT¤¤ªº¯×ªÕ»Ä¥N谢¡C¯S别¬O¡ACyp2e1¯Ê¥F³q过¼W¥[¨x脏¥Í¦¨ªº酰°ò¦×þé¦Ó¼W¥[¯à¶q®ø¯Ó¡A酰°ò¦×þé¥i¥H«P进´Ä¦â¯×ªÕ产热¦}¼W¥[£]-®ñ¤Æ¡C¦³½ìªº¬OCYP2E1§í¨î剂¡A¨Ò¦p双²¸仑¡A¥i¥H¥Î来预¨¾¤j¹«°ª¯×饮­¹诱导ªºªÎ­D¡C总ªº来说¡A¥»¬ã¨s¸Ñ释¤FCYP2E1ÉO¯à¶q¥N谢ªº关¨t¡A为ªÎ­Dªº预¨¾©Mªv疗´£¨Ñ¤F·sªº视¨¤¡C

--------------------------------------------------------------------------------------------

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/5 ¤U¤È 04:54:17²Ä 2297 ½g¦^À³
´N¾Ì[¿Õ©M¿Õ¼w»¼¥æ¤F¤@±iÀu¥ý¼f¬d¾ÌÃÒ¡]PRV ,»ù­È>1»õ¬ü¤¸¡^¨Ó¥[³t´îªÎÃÄNDA¼f¬d(FDA§Ö³t¦b4­Ó¤ë¤º§å­ã¤W¥«]

³æ¬Ý´îªÎ¥ÎÃÄ¡A¥q¬ü®æ鲁肽ª`®g²GÃĮĴ20%+Åé­«(µ¥¦P´îªÎ¤â³N®ÄªG)¡A¥þ²y½æ­Ó20»õ¬ü¤¸¨S¤°°ÝÃD¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/5 ¤U¤È 04:44:28²Ä 2296 ½g¦^À³
SNPÃĪ«ªº·s¾AÀ³¯gªÎ­DªvÀø?

杨¨q伟团队ªº½×¤å´N¬O2022.5¤ë³o½gwww.sciencedirect.com/science/article/pii/S2211383522000545

µ²½×:¦b¥»¬ã¨s¤¤....³o¨Çµo²{±N CYP2E1-PPAR £\¶b©w¸q¬°ªÎ­DªvÀøªº·sªvÀø¹vÂI¡C

---------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/27 ¤U¤È 12:18:28²Ä 2025 ½g¦^À³

µ²½×

¦b¥»¬ã¨s¤¤....³o¨Çµo²{±N CYP2E1-PPAR £\¶b©w¸q¬°ªÎ­DªvÀøªº·sªvÀø¹vÂI¡C

------------------------------------------------------------------------------------

SNP-610¬O CYP2E1§í¨î¡A¤£±´¨sªÎ­DªvÀø¤Ó¥i±¤¤F!!!

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/28 ¤W¤È 12:23:43²Ä 2029 ½g¦^À³

2003.12.30 ¤@½g¾Ç³N¬ã¨s¥ÎÁ{§É¸ÕÅç (16¦WªÎ­D¨ü¸ÕªÌ¶}­G´î­«¤â³N VS 16¦WÅé­«¥¿±`ªº¹ï·Ó²Õ)

±w¦³«D°sºë©Ê¯×ªÕ¨xªº¯fºAªÎ­DªÌ¦b´îªÎ«e«áªºCYP2E1¬¡©Ê

aasldpubs.onlinelibrary.wiley.com/doi/abs/10.1053/jhep.2003.50342

...Á`¤§¡A¦b¯fºAªÎ­D¨ü¸ÕªÌ¤¤¡A¨xŦ CYP2E1 ¬¡©Ê¤W½Õ¡C³N«e¯×ªÕÅܩʵ{«×»PCYP2E1¬¡©Ê¤§¶¡¥H¤Î³N«áªÎ­Dµ{«×»PCYP2E1¬¡©Ê¤§¶¡¦s¦b¥¿¬ÛÃö¡A³oªí©úCYP2E1ªº»¤¾É»P¯fºAªÎ­D¾É­Pªº¨xż¯fÅܦ³Ãö©Î¥Ñ¨ä¤Þ°_¡C

-----------------------------------------------------------------------------------------------

³o­Ó¤HÅé¸ÕÅçµ²ªG¡Aµ¹ªYÄ£ªºNASH (CYP2E1§í¨î)Á{§É¸ÕÅç¤j¥[¤À¡C

«Øij§âªÎ­D¥[¤JªvÀø¾AÀ³¯g!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/5 ¤U¤È 04:11:51²Ä 2295 ½g¦^À³
§O§â´îªÎ¥«³õ¬Ý¤p¤F!

1.2022.7.27 k.sina.com.cn/article_2051747990_7a4b309600101gc0y.html?from=health

[转]·s«¬¡uú£ªÎ药¡v卖断货¡H¦h®a药¥ø¥[³t¥¬§½

¦b诺©M诺¼w©xÊI¤W¡A¥Ø«e¥q¬ü®æ鲁肽ª`®g²G³¡¤À剂¶q¤w经显¥Ü货¶qµu¯Ê¡C诺©M诺¼w¦b声©ú¤¤写¹D¡G¡§¥q¬ü®æ鲁肽ªº»Ý¨D¤w经¶W过¤F¤§«e预¦ôªº¥«场»Ý¨D¡A¦P时¡A¦b±À¥X该产«~¦Z¤£¤[¡A诺©M诺¼w¦X§@ªºCMO¥X现问题¡A这¨Ç问题³£导­P¤F¨Ñ应µu¯Ê¡C¡¨

¦ýÕu业内¤H¤h¤ÀªR¡A¤j·§²vÉO¨ä³Q认¥iªº¡§ú£ªÎ¥\®Ä¡¨¦³关¡C

2. 2022.8.4 诺©M诺¼w2022H1¡G营¦¬113.8亿¬ü¤¸¡Aú£ªÎ药¤j卖¡Iwww.drugtimes.cn/2022/08/04/nuohenuode2022h1yingshou1138yimeiyuanjianfeiyaodamaikoufusim/

----------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/27 ¤U¤È 09:34:47²Ä 2028 ½g¦^À³

ªYÄ£ SNP-610»PSNP-820À³¸Ó±´¨sªvÀøªÎ­D¯g!

¿Õ©M¿Õ¼w»¼¥æ¤F¤@±iÀu¥ý¼f¬d¾ÌÃÒ¡]PRV ,»ù­È>1»õ¬ü¤¸¡^¨Ó¥[³t´îªÎÃÄNDA¼f¬d(FDA§Ö³t¦b4­Ó¤ë¤º§å­ã¤W¥«)

Àu¥ý¼f¬d¾ÌÃÒ¨S¦³¯d«ÝNASH NDA¼f¬d®É¦A¨Ï¥Î¡Aªí¥Ü´îªÎÃÄ°Ó¾÷¤]«Ü¤j¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/5 ¤W¤È 07:53:19²Ä 2294 ½g¦^À³
·Pı¨ºùةǩǦa!

¤@¬d¯u¬Ogeneonlineªº¤å¦r±Ô­z¤£ºë½T:FDA«ü¥X¡A¸ÓÃĪ«ªº¤¤¦ì¼ÆµL¯e¯f¦s¬¡²v¡]DFS¡^[¥¼¹F¼Ð·Ç]-->À³¸Ó§ï¦¨¤¤¦ìÀH³XªºDFS[©|¥¼]¹F¨ì¼Ð·Ç¡C

©³¤U¬O¸ÕÅç³Ì²×¼Æ¾Ú¤ÀªR:

www.onclive.com/view/adjuvant-atezolizumab-shows-improvement-in-dfs-time-to-relapse-in-pd-l1-stage-ii-iiia-nsclc-subgroups

... DFS ¬° 42.3 ­Ó¤ëP=.02¡C

µ²½×:ÀH³X(¸ÕÅç)µ²§ô«áªºDFS¬O¦³¹F¨ì¼Ð·Ç¡C

--------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/4 ¤U¤È 12:26:30²Ä 2293 ½g¦^À³

¥D­n«ü¼Ð¥¼¹F¼Ð·Ç!FDAÁÙ¬O®ÖµoTecentriq«D¤p²Ó­M»²§UÀøªkÃÄÃÒ!

2021.10.18 geneonline.news/tecentriq-fda-nsclc/

FDA «ü¥X¡A¸ÓÃĪ«ªº¤¤¦ì¼ÆµL¯e¯f¦s¬¡²v¡]DFS¡^¥¼¹F¼Ð·Ç(¥D­n«ü¼Ð³á!)¡A¦]¬°¬Û¤ñ¹ï·Ó²Õ¡ATecentriq ¯à­°§CII-IIIA ´Á¨ü¸ÕªÌ34% ªºÀù¯g´_µo»P¦º¤`­·ÀI!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/4 ¤U¤È 12:26:30²Ä 2293 ½g¦^À³
¥D­n«ü¼Ð¥¼¹F¼Ð·Ç!FDAÁÙ¬O®ÖµoTecentriq«D¤p²Ó­M»²§UÀøªkÃÄÃÒ!

2021.10.18 geneonline.news/tecentriq-fda-nsclc/

FDA «ü¥X¡A¸ÓÃĪ«ªº¤¤¦ì¼ÆµL¯e¯f¦s¬¡²v¡]DFS¡^¥¼¹F¼Ð·Ç(¥D­n«ü¼Ð³á!)¡A¦]¬°¬Û¤ñ¹ï·Ó²Õ¡ATecentriq ¯à­°§CII-IIIA ´Á¨ü¸ÕªÌ34% ªºÀù¯g´_µo»P¦º¤`­·ÀI!

clinicaltrials.gov/ct2/show/NCT02486718?term=impower010&draw=2&rank=1

----------------------------------------------------------------------------------------

©Ò¥H´¼Àº©|¤£¯à¤U©w½×!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/4 ¤W¤È 11:20:06²Ä 2292 ½g¦^À³
2018¦~12¤ëFDAµoªí¡u¥Î©ó®Ö­ã§ÜÀùÃÄ«~¤Î¥Íª«»s¾¯ªºÁ{§É¸ÕÅçÀø®Ä«ü¼Ð¡v«ü¤Þ

«ÈÆ[¤ÏÀ³²v(Objective response rate¡AORR)¡G©w¸q¬°¸~½FÁY¤p¹F¥ý«e©w¸q¶q¨Ãºû«ù¤@¬q®É¶¡¤§[¯f¤H¤ñ¨Ò]¡A¬°§¹¥þ½w¸Ñ

(CR)©M³¡¤À½w¸Ñ(PR)¤§Á`©M¡C

´¼Àº¦b³o­Ó«ü¼Ð¬O2­¿©óTopotecan!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/4 ¤W¤È 11:10:40²Ä 2291 ½g¦^À³
´¼Àº¤p²Ó­MªÍÀù¸Ñª¼©|¤£¯à¤U©w½×¡AmOS»PORR»PmPFS§¹¾ã¼Æ¾ÚÁÙ¨S¤½¥¬¡C

¤G½uÃĪ«´N2¤ä:Topotecan»PLurbinectedin ¡AÂå±w¥i¿ï¾ÜÃĪ«¤Ó¤Ö!

­Wµ¥20¦~¡A¤p细­MªÍÀù终¤_¬ß来·s¤Æ疗药Lurbinectedin

zhuanlan.zhihu.com/p/107950829

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/8/4 ¤W¤È 09:42:12²Ä 2290 ½g¦^À³
©ö¤â°­¥Í³o¤UªÝ¤ñQ¤F¡C

.... ....

Q:´¼Àº¤p²Ó­MªÍÀù¸Ñª¼¯à¥H¥¢±Ñ½×?

A:³o¬O¸ò¤W¥«¤ÆÀøÃÄTopotecan§@[ÀY¹ïÀY]¸ÕÅç¡A¥D­n»P¦¸­n³£¹F¼Ð®É¡A¥s§@§¹³ÓÁÓÀ£(Àu®Ä©Ê)¡C

±q

[´¼Àº±j½Õ¡A¡u¦w¯à±o¡v¤p²Ó­MªÍÀùªºÁ{§É¸ÕÅçµ²ªG¡A¤´±N¥H¦¸­n«ü¼Ð¤Î²Ä¤T«ü¼Ðª§¨ú¥Ó½ÐÃÄÃÒ]

«¥»{¬°¬O¥D¼ÐmOS(¼Æ¾Ú¨S¤½¥¬)¤ñTopotecan·L¦n¦ý¤£ÅãµÛ(³o¥s¥­¤À¬î¦â)¡A¦Ó¦¸¼Ð«ÈÆ[½w¸Ñ²v(ORR)¬OTopotecanªº2­¿(³o¥s¥e¤W­·)¡C

µ²½×:¤£±Æ°£®³¨ì¤p²Ó­MªÍÀùÃįg!(Åý±wªÌ»PÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃĪ«)

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 06:22:25²Ä 2260 ½g¦^À³

Àu®Ä©Ê¡]superiority¡^¸ÕÅç:¦b©óÃÒ¹ê·sÃĤñÂÂÃÄ¡]©Î¦w¼¢¾¯¡^¦³®Ä¡A¥H«K©ó¥H·sÃĥΨӨú¥NÂÂÃÄ¡C

µ¥®Ä©Ê¡]equivalence¡^¸ÕÅç:·s¡BÂÂÃĮĬ۷í¡A¦¹ºØ¬ã¨s³]­p±`³Q®³¨Ó»P¡u«D¦H©Ê¸ÕÅç¡v¤@°_°Q½×¡C

«D¦H®Ä©Ê¡]non-inferiority¡^¸ÕÅç: ¥Øªº¦b©óÀË©w·sÃÄÀø®Ä¦Ü¤Ö¤£¿éÂÂÃÄ¡AÅýÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃÄ

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/4 ¤W¤È 06:22:03²Ä 2289 ½g¦^À³
Q:´¼Àº¤p²Ó­MªÍÀù¸Ñª¼¯à¥H¥¢±Ñ½×?

A:³o¬O¸ò¤W¥«¤ÆÀøÃÄTopotecan§@[ÀY¹ïÀY]¸ÕÅç¡A¥D­n»P¦¸­n³£¹F¼Ð®É¡A¥s§@§¹³ÓÁÓÀ£(Àu®Ä©Ê)¡C

±q

[´¼Àº±j½Õ¡A¡u¦w¯à±o¡v¤p²Ó­MªÍÀùªºÁ{§É¸ÕÅçµ²ªG¡A¤´±N¥H¦¸­n«ü¼Ð¤Î²Ä¤T«ü¼Ðª§¨ú¥Ó½ÐÃÄÃÒ]

«¥»{¬°¬O¥D¼ÐmOS(¼Æ¾Ú¨S¤½¥¬)¤ñTopotecan·L¦n¦ý¤£ÅãµÛ(³o¥s¥­¤À¬î¦â)¡A¦Ó¦¸¼Ð«ÈÆ[½w¸Ñ²v(ORR)¬OTopotecanªº2­¿(³o¥s¥e¤W­·)¡C

µ²½×:¤£±Æ°£®³¨ì¤p²Ó­MªÍÀùÃįg!(Åý±wªÌ»PÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃĪ«)

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/26 ¤W¤È 06:22:25²Ä 2260 ½g¦^À³

Àu®Ä©Ê¡]superiority¡^¸ÕÅç:¦b©óÃÒ¹ê·sÃĤñÂÂÃÄ¡]©Î¦w¼¢¾¯¡^¦³®Ä¡A¥H«K©ó¥H·sÃĥΨӨú¥NÂÂÃÄ¡C

µ¥®Ä©Ê¡]equivalence¡^¸ÕÅç:·s¡BÂÂÃĮĬ۷í¡A¦¹ºØ¬ã¨s³]­p±`³Q®³¨Ó»P¡u«D¦H©Ê¸ÕÅç¡v¤@°_°Q½×¡C

«D¦H®Ä©Ê¡]non-inferiority¡^¸ÕÅç: ¥Øªº¦b©óÀË©w·sÃÄÀø®Ä¦Ü¤Ö¤£¿éÂÂÃÄ¡AÅýÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃÄ

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/3 ¤W¤È 09:42:57²Ä 2288 ½g¦^À³
·s«a3®a¸Ñª¼ª¬ªp:

1.°ê¹©1/5¸Ñª¼:ªø´ÁÄY­««K¯µ6­Ó¤ë¤SºÆ¨¥ºÆ»y(¯f¯g¤£©ú)

2.¤ß®®8/1¸Ñª¼:¥D­n/¦¸­n/p­È©Ô3¤é¤~°®²b(»´·L¸¡Âm©|¥i)

3.¶h¹F8/3¸Ñª¼:¥D­n/¦¸­n/p­È¤@¤Ñ´N°®°®²b²b(°·±d³Ì¨Î)

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/3 ¤W¤È 08:49:50²Ä 2287 ½g¦^À³
·|­û¡G¶ø¥ì´µ¯S10031727 µoªí®É¶¡:2022/7/31 ¤W¤È 10:55:14²Ä 2271 ½g¦^À³

¦b¤U¤~²¨¾Ç²L¡A¤£¸Ñ¦p¦¹ªºÁ{§É¼Æ¾Ú¡A¤½¥q¦ó¨Ó«i®ð°e¥ó¥Ó½Ð EUA ¡H

------------------------------------------------------------------------------------------------

Àu®ÄÂùª¼¸ÕÅ窺¸Ñª¼¯à­ê¦i©Ò«ä»¡¥X:­p¹º®Ñªº­¶­±¨ÃµL´£¤Î¥D­n«ü¼Ð­n¸ò¦w¼¢¾¯¤ñ¸û¡C

·Q·íµMº¸¬O­p¹º®Ñªº­¶­±¨ÃµL´£¤Î»Ý¦³²Î­p¾Ç¤Wªº·N¸q¤~¯à´£¥X¥Ó½Ð¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/2 ¤W¤È 10:17:29²Ä 2286 ½g¦^À³
S¤jªº¸ÑªR¨¬¨o¡A«¥´N¬Ý¨º2­ÓBTDÃĪ«¡C

¤»ºØª¢¯g«ü¼Ð¤¤ªº¤­ºØ¤¤¡A¤½¥q¨S¥æ¥N²M·¡5ºØp < 0.05¬O¨º´XºØ?(¤å·NÀ³¸Ó¤£¬O5ºØ)

¥t¥~¡A»´¯gÃĪ«ªº»ù®æ«ÜÃöÁä¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦N¦Ì¦Ï10000583  µoªí®É¶¡:2022/8/2 ¤W¤È 09:53:32²Ä 2285 ½g¦^À³
¤£ª¾R¤j¹ï©ó¤ß®®·s«a¤G´Á¸Ñª¼¡A¥D­n«ü¼Ð¯f¬r¶q¥¼¦³ÅãµÛ®t²§¡A¦ýª¢¯g§ïµ½«o¦³¦h¶µ¹F¼Ð¦³¦ó¨£¸Ñ¡H
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/2 ¤W¤È 09:53:29²Ä 2284 ½g¦^À³
[©Ò¦³¾Ö¦³2­Ó©Î§ó¦hBTDªº¤½¥q³£³Q¤j»sÃĤ½¥q§]¨Ö¤F]-³o­Ó¤~¬O«¥§ë¸ê¤ß®®­ì¦]¡A¦Ó¤£¬O·s«aÃĪ«¡A¬Q¤é½¶Â«á¤w¶R¤J¤p³¡¦ì¡Aµø9¤ëªìªºÁ{§É¤ÀªRµ²ªG¦A°Ê§@¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/2 ¤W¤È 09:37:12²Ä 2283 ½g¦^À³
ÅS¥XÀ£½c3¦~ªºBTD»ù­ÈÂÃÄ_¹Ï¬O¹w®I¥ñµ§¡A¥´ºâ¤é«á³o®a¤½¥q[¯u]³Q¨ÖÁʮɮ³¨ÓÄmÄ_»¡¼L¡A¨S·Q¨ì¤@²{¥@¡AÃѳfªÌ°®©[¤j®¿²¾XX·|¡A¬JµM¦p¦¹«¥¤]´N¶¶¤ô±À¦à¡A©Ò¿×2­ÓBTDªº¤½¥q¬O«ü¤ß®®¡C

--------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 10:22:06²Ä 2281 ½g¦^À³

©Ò¦³¾Ö¦³2­Ó©Î§ó¦hBTDªº¤½¥q³£³Q¤j»sÃĤ½¥q§]¨Ö¤F...¥ô¦ó¾Ö¦³2­Ó©Î§ó¦hBTDªº¤½¥q³£±N³B©ó³Q¦¬Áʪº¼öªù°Ï°ì¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦V«e¦æ10140498  µoªí®É¶¡:2022/8/1 ¤W¤È 10:30:38²Ä 2282 ½g¦^À³
°ê³»ªº¥D­n¥Ø¼Ð¥¼¹LªùÂe

ªÑ»ù¥¼½ö¥­¡A³ºµM¦p¦¹¤§±j¡C

·sÃÄ¡A°ò¥»­±¸ò¨ä¬Û¤ñ¤j³Ó¡C

ªÑ»ù¤§®z¡A¤]µLªk¬Û¤ñ¡C

©Î³\¬O¡F®É¶¡¥¼¨ì¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/1 ¤W¤È 10:22:06²Ä 2281 ½g¦^À³
©Ò¦³¾Ö¦³2­Ó©Î§ó¦hBTDªº¤½¥q³£³Q¤j»sÃĤ½¥q§]¨Ö¤F...¥ô¦ó¾Ö¦³2­Ó©Î§ó¦hBTDªº¤½¥q³£±N³B©ó³Q¦¬Áʪº¼öªù°Ï°ì¡C

All the companies with 2 or more BTDs were gobbled up by big pharma. This list essentially represents low hanging fruit for a Big Pharma acquisition. Any company with 2 or more BTDs would be in the hot zone for acquisition.

------------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 09:36:25²Ä 2279 ½g¦^À³

µ²½×:¥i¯d·N¦³2­ÓBTDªº¤½¥q!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/8/1 ¤W¤È 10:03:03²Ä 2280 ½g¦^À³
¬Ý¬Ý³o°ê¤§¤j¹© ííªº¯}¦Ê²Ä¥S!!!¤Ó±j¤F

¦A¬Ý¬Ý·sÄ£ ¯uªºµLªk¤F¸Ñ

¤Õ©ú¥S¤]«Ü·|ª£ ¾Ç¤@¤UÆp¥Û

============================================

³o¦³¨S¦³§®ªÑ°ÝÃD??¦pªG©ú©úª¾¹D°T®§½T¤£¤½¥¬

§ó¥¿:

1. 2022.1.5¸Ñª¼:¥D­nµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ97.9%(¹ï·Ó²Õ¨S»¡)¡C

2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨ç­n¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0%

2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100%

2. ¥D­nµû¦ô«ü¼Ð¨S¦³²Î­pÅãµÛ·N¸q¡]P=0.5304¡^

--------------------------------------------------------------------------------------------------

¼Æ¾Ú¤@ÅܦAÅÜ¡A¤½¥q«HÅA±½¦a!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/1 ¤W¤È 09:36:25²Ä 2279 ½g¦^À³
¬ð¯}©ÊÀøªk»{©wªº¯u¥¿»ù­È

seekingalpha.com/article/4314267-real-value-of-breakthrough-therapy-designation

...

Takeover offers typically increase with breakthrough therapy designations.

Takeover offers for a company with 2 breakthrough therapy designations increase significantly and quickly.

------------------------------------------------------------------------------------------------

µ²½×:¥i¯d·N¦³2­ÓBTDªº¤½¥q!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/1 ¤W¤È 07:17:07²Ä 2278 ½g¦^À³
¡uª¾¤vª¾©¼¡A¦Ê¾Ô¤£¬p¡v

§¨ÓBebtelovima ¹ïOmicron¦³Àø®Ä¡A©Ò¥H®³¨ìEUA¡C

Adagio ADG20Àø®Ä¦³²Î­p¾Ç·N¸q¡A¦ý¹ïOmicronÀø®Ä¼Æ¾Ú©Ê¤£¨¬¡A¼È°±´£¥æ EUA ½Ð¨D¡C

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/31 ¤U¤È 11:06:36²Ä 2276 ½g¦^À³

®³Â§¨ÓªºBebtelovima EUA°µ¹ï·Ó¡A¥u¯à»¡¤½¥q¨S¥Í§Þ¤H¤~¤F.

---------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/8/1 ¤W¤È 07:04:07²Ä 2277 ½g¦^À³

®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/8/1 ¤W¤È 07:04:07²Ä 2277 ½g¦^À³
°ê¹©¤G´ÁÁ{§É¼Æ¾Ú¤£¨ã¦³²Î­p¾Ç·N¸q¡AOmicron¯f¨Ò¤H¼Æ¦³¦h¤Ö?

BA.2ÅÜÅé¬O«üOmicron.

2022.4.14 Adagio ¼È°±EUA½Ð¨D(AdintrevimabÀø®Ä¬O¨ã¦³²Î­p¾Ç·N¸q¦a!)

­ì¦]:®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C

®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C

®Ú¾Ú FDA Ãö©ó adintrevimab ¯Ê¥F¹ï BA.2ÅÜÅ骺¤¤©M¬¡©Êªº¤ÏõX¡AAdagio ±N¼È°±´£¥æ EUA ½Ð¨D¡C

markets.businessinsider.com/news/stocks/adagio-pauses-fda-emergency-use-request-for-its-covid-19-therapy-1031357425

---------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/4/3 ¤U¤È 01:50:12²Ä 1859 ½g¦^À³

...2022.3.30 Adagio «Å§G ADG20¡]adintrevimab )Àø®Ä¹F¼Ð¡A²Ä2©u¦VFDA´£¥æEUA¥Ó请!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/31 ¤U¤È 11:06:36²Ä 2276 ½g¦^À³
®³Â§¨ÓªºBebtelovima EUA°µ¹ï·Ó¡A¥u¯à»¡¤½¥q¨S¥Í§Þ¤H¤~¤F.

°ê¹©¤G´ÁÁ{§ÉOmicron¯f¨Ò¤H¼Æ?

---------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/4/3 ¤U¤È 01:50:12²Ä 1859 ½g¦^À³

..®t²§¦h¤j¦Û¤v¥h¬Ý¬ü°êÃļt¬O¦p¦ó¤½¥¬¼Æ¾Ú¹F¼Ð¡AÁÙ¦³¬°¤°»ò²{¦b¥Ó½ÐEUA¼Æ¾Ú¤À¦¨Omicron[«e]»P[«á]¥Î·N???(³o´N¬O§Ú¦b1/22´£°Ý°ê¹©¤G´ÁÁ{§ÉOmicron¯f¨Ò¤H¼Æªº­ì·N)

2022.3.30 Adagio «Å§G ADG20¡]adintrevimab )Àø®Ä¹F¼Ð¡A²Ä2©u¦VFDA´£¥æEUA¥Ó请!

www.thepharmaletter.com/article/strong-showing-for-adagio-s-adg20-in-pre-and-post-exposure-settings-for-covid-19

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/1/22 ¤U¤È 02:22:40²Ä 1614 ½g¦^À³

¶K´X«h°T®§¡A§ë¸ê¤H[¿W¥ß«ä¦Ò]²´¤UFDA±ÂÅvEUA¦a±ø¥ó???

1.°ê¹©¤G´ÁÁ{§ÉOmicron¯f¨Ò¤H¼Æ?

2. ¬ü°ê¦b2021.11.27«eOmicron¯f¨Ò 0¡A

¬ü°êÁp¨¹¯e¯f¨¾ªv¤¤¤ß(CDC)ºI¦Ü2022.1.1¤é°ê¤º95.4%ªº·s¯f¨Ò¡ADeltaÅܺدf¬r«h³QÀ£ÁY³Ñ¤U4.6%

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/31 ¤U¤È 11:01:32²Ä 2275 ½g¦^À³
§¨ÓªºBebtelovimaÁ{§É(©Û¦¬1755¦W)

FDA EUA :www.fda.gov/media/156151/download

Á{§É: clinicaltrials.gov/ct2/show/NCT04634409?term=blaze+4&draw=2&rank=1

------------------------------------------------------------------------------------------------

®ÉªÅ­I´º:

2021.11¤ë©³Omicron³vº¥¨ú¥NDletaÅܦ¨¬ü°ê¥D­n¬y¦æ¯f¬r®è¡A¦Ó¨ä¥L®aªº³æ§Ü¹ïOmicron¥¢®Ä¡A©Ò¥HBebtelovima®³¨ìEUA.

±q®É¶¡¤W±ÀÂ_°ê¹©¦¬ªvªº124¦W±wªÌÀ³¸Ó¬O·¥¤Ö¬Æ¦Ü¨S¦³Omicron±wªÌ?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/31 ¤U¤È 09:51:11²Ä 2274 ½g¦^À³
¸Ñª¼®É©~»¡»¡¥~¦æ¸Ü:¥D­n«ü¼Ð¤W¡u¨S¦³¼g»¡­n¸ò¦w¼¢¾¯¤ñ¸û¡C¡v

2022.7.31¸É¥R¤½§i:¦Ó­p¹º®Ñ¦b¥D­n«ü¼Ðªº­¶­±¨ÃµL´£¤Î­n»P¹ï·Ó²Õ¬Û¤ñ¡A¦]¦¹·í®É»{¬°¤£»Ý­n»P¹ï·Ó²Õ¬Û¤ñ¡C

[¤§«á»PCRO¤½¥q¶}·|°Q½×±oª¾¥»¸ÕÅç¥D­n«ü¼Ð»Ý»P¹ï·Ó²Õ¬Û¤ñ¸û¡C]

[¤§«á»PCRO¤½¥q¶}·|°Q½×±oª¾¥»¸ÕÅç¥D­n«ü¼Ð»Ý»P¹ï·Ó²Õ¬Û¤ñ¸û¡C]

¤t´¶·|ðݦºXXXX!---XXXX¸Ñ½X---¤t´¶·|ðݦº°ê¹©¯SÅv(¤£¥Î­n¸ò¦w¼¢¾¯¤ñ¸û)¡C

---------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/29 ¤W¤È 08:00:29²Ä 2266 ½g¦^À³

¤t´¶¤O±Àªº¡u¯«ÃÄ¡v¡A¥@½Ã¥s°±ªº¡u¬rÃÄ¡vßm´â喹¡A¦b¥D­n«ü¼Ð¤W¡u¨S¦³¼g»¡­n¸ò¦w¼¢¾¯¤ñ¸û¡C¡v

¦]¬°²Î­p¤ÀªR¨S¹F¼Ð¥¢±Ñ¡A¤t´¶·|ðݦºXXXX!

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/4/5 ¤W¤È 10:46:00²Ä 1864 ½g¦^À³

°ê¹©¥i¥H®³¥XFDA¯S­ã¼Æ¾Ú¤£¥Î»P¦w¼¢¾¯PK¤å¥ó¶Ü?(¬JµM§¹¥þ²Å¦X¬ü°êFDA µo¥¬©ó2020¦~5¤ëªº·s«aªÍª¢Á{§É«ü¾É³W©w)

...°ê¹©¥Í§ÞÁ{§ÉÂå¾Ç³¡³¯¨Ø©gÂå®v«ü¥X...§¹¥þ²Å¦X¬ü°êFDA µo¥¬©ó2020¦~5¤ëªº·s«aªÍª¢Á{§É«ü¾É³W©w¡A°w¹ïÃļt¶}µo·s«aªÍª¢ªºªvÀø©M¹w¨¾ÃĪ«¤Î¥Íª«»s¾¯ªº«ü¾É¡A³W©w¶·±Ä¥Î³Ì°ª¯Åªº³]­p¡A¤]´N¬OÁ{§É¸ÕÅ窺³]­p¥²¶·¬°ÀH¾÷¡BÂùª¼¡B¦Ó¥B¦³¦w¼¢¾¯¹ï·Ó(randomized, placebo-controlled, double-blind clinical trials)ªº¸ÕÅç¡A¤~¬O¥\®Ä©ÊÅçÃҳ̥i«HªºÃÒ¾Ú

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/31 ¤U¤È 07:48:31²Ä 2273 ½g¦^À³
7/30«e³£¬O¥ÎÃIJÕ(97.9%©Î100%)·L¦n©ó¹ï·Ó²Õ¡A½Ö®Æ¨ì³Ì²×¼Æ¾Ú¬O¹ï·Ó²Õ100%[°fÂà]Àu©ó¥ÎÃIJÕ97.9%¡Aªí©ú¤½¥q¤§«e©ÜÅS¤£¹ê¼Æ¾Ú¡A³o¬O[«D±`] [«D±`] [«D±`] ÄY­«ªº¸Û«H°ÝÃD!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/7/31 ¤U¤È 06:21:17²Ä 2272 ½g¦^À³
³o¦³¨S¦³§®ªÑ°ÝÃD??¦pªG©ú©úª¾¹D°T®§½T¤£¤½¥¬

§ó¥¿:

1. 2022.1.5¸Ñª¼:¥D­nµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ97.9%(¹ï·Ó²Õ¨S»¡)¡C

2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨ç­n¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0%

2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100%

2. ¥D­nµû¦ô«ü¼Ð¨S¦³²Î­pÅãµÛ·N¸q¡]P=0.5304¡^

--------------------------------------------------------------------------------------------------

¼Æ¾Ú¤@ÅܦAÅÜ¡A¤½¥q«HÅA±½¦a!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¶ø¥ì´µ¯S10031727  µoªí®É¶¡:2022/7/31 ¤W¤È 10:55:14²Ä 2271 ½g¦^À³
¦b¤U¤~²¨¾Ç²L¡A¤£¸Ñ¦p¦¹ªºÁ{§É¼Æ¾Ú¡A¤½¥q¦ó¨Ó«i®ð°e¥ó¥Ó½Ð EUA ¡H

Æp¥Û¥Í§Þ¿³Âdªk»¡·|¡AÆp¥Û¥Í§Þ©xºô¦³¼v¹³ÀÉ¡A¥i¥H¥hťť¥L­Ì¬O«ç»òµû»ù¤@¶¡¤½¥q¯à¤£¯à§ëªº¡A­Ó¤Hı±o³o¬O«Ü¦nªº¾Ç²ß¨å½d¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/31 ¤W¤È 07:05:18²Ä 2270 ½g¦^À³
¦]¬°¿ï¾Üªº¨Æ«á¤ÀªR¡A¥i¯à·|¨ü¨ì¡u·Q¦¨¥\¡vªº¼¤±æ©ÒÁÍ¡A¨äµ²ªG¥i¯à·|¦³©Ò°¾®t¡C

-------------------------------------------------------------------------------

¦b¥D­nÀø®Ä¤ÀªRµ²ªGµ²½×¬°¡u¥¢±Ñ¡v®É¡AFDA±µ¨ü¨Æ«á¤ÀªR¯S©wªºµû¦ô«ü¼Ð¡A¨º¯E¹©OBI-822ªº¸Ñª¼´N¬Oªk³W¤W¦¨¥\¥B¬ì¾Ç¤W¦¨¥\!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/30 ¤U¤È 09:27:38²Ä 2269 ½g¦^À³
·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/28 ¤W¤È 09:12:02²Ä 2264 ½g¦^À³

FDAÁ{§ÉªvÀø²×ÂI«ü¾É­ì«h:

..¦¸­n«ü¼Ðªº¥¿¦Vµ²ªG¡A¶È¦³¦b¥D­n«ü¼Ð®a±ÚªºÀø®Ä¤w¸gÀò±oÃÒ©ú®É¤~¥i¸ÑŪ

--------------------------------------------------------------------------------------------

¦b¬ü°êFDA¤§¦h­«µû¦ô«ü¼Ð«ü¤Þ¯ó®×¤¤©ú½T³¯­z¡A³æ¾Ì¨Æ«á¤ÀªR(post-hocanalyses)µ²ªG¡A¬OµLªkÃÒ©úÃÄ«~ªºÀø®Ä¡C¥ç§Y¡A·í¸ÕÅç¥D­nÀø®Ä¤ÀªRµ²ªGµ²½×¬°¡u¥¢±Ñ¡v®É¡A¨Æ«á¤ÀªR¯S©wªºµû¦ô«ü¼Ð¡A¤]³\¦³§U©ó±N¨Ó¥i¯à¶i¦æªº°²»¡ÀË©w¡A±©µLªk»{©w¬°¸ÕÅ礧½T»{©Êªºµ²ªG¡F¦]¬°¿ï¾Üªº¨Æ«á¤ÀªR¡A¥i¯à·|¨ü¨ì¡u·Q¦¨¥\¡vªº¼¤±æ©ÒÁÍ¡A¨äµ²ªG¥i¯à·|¦³©Ò°¾®t¡C

©Ò¥H¦p°ª¦åÀ£ (Antroquinonol 38.7% vs. ¹ï·Ó²Õ22.6%) ©M¿}§¿¯f(Antroquinonol 24.2% vs.¹ï·Ó²Õ14.5%)¥H¤Î¨k©Ê±wªÌªº¤ñ¨Ò§ó°ª---­Y³o¨Ç«ü¼Ð¬O¨Æ«á¤ÀªR¦aµ²ªG¡AFDA«ç»ò¬Ý?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/30 ¤U¤È 08:19:46²Ä 2268 ½g¦^À³
§ó¥¿:

1. 2022.1.5¸Ñª¼:¥D­nµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ97.9%(¹ï·Ó²Õ¨S»¡)¡C

2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨ç­n¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0%

2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100%

2. ¥D­nµû¦ô«ü¼Ð¨S¦³²Î­pÅãµÛ·N¸q¡]P=0.5304¡^

--------------------------------------------------------------------------------------------------

¼Æ¾Ú¤@ÅܦAÅÜ¡A¤½¥q«HÅA±½¦a!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/30 ¤U¤È 08:06:06²Ä 2267 ½g¦^À³
¨â­Ó«GÂI:

1. 2022.1.5¸Ñª¼:¥D­nµû¦ô«ü¼Ðªº²Ä14¤Ñ±d´_²v¡A¥ÎÃIJÕ100%(¹ï·Ó²Õ¨S»¡)¡C

2022.3.15 ¨ÌÂd¶R¤¤¤ß¨Ó¨ç­n¨D¡A¤½§i:¥ÎÃIJÕ100%¡A¹ï·Ó²Õ96.0%

2022.7.30:¥ÎÃIJÕ97.9%¡A¹ï·Ó²Õ100%

2. ¥D­nµû¦ô«ü¼Ð¨S¦³²Î­pÅãµÛ·N¸q¡]P=0.5304¡^

-------------------------------------------------------------------------------------------

1.¨Æ¹êµo¥Í¤é:111/07/30

2.¤½¥q¦WºÙ:°ê¹©¥Íª«¬ì§ÞªÑ¥÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

°ê¹©¥Í§Þ©ó111¦~07¤ë30¤é¦¬¨ì©Ò©e°U¤§CRO¤½¥q¤§³Ì²×CSR(clinical study report)¡A

¨Ì¾Ú¸ÓCSR­«ÂI¤º®e¤Î¾ãÅéµ²½×»¡©ú¦p¤U:

(1)¸ÕÅçÃĪ«¦WºÙ: Antroquinonol (Hocena)

(2)¸ÕÅç­pµe¥N¸¹: GHCovid-2-001

°ê¹©¥Í§Þ·s«aªÍª¢(COVID-19)¬ãµo¤¤·sÃÄAntroquinonol©ó¬ü°ê¡B¯µ¾|¤Îªü®Ú§Ê©Ò

¶i¦æªº¤HÅé¤G´ÁÁ{§É¸ÕÅç¡AÁ`¦@¦¬ªv124¦ì¯f±w¡C¸Ó¸ÕÅç¬O±ÄÀH¾÷¡BÂùª¼¡B¦w¼¢¾¯

¹ï·Ó¬ã¨s¡A¥Î©ó¦]·s«aªÍª¢¦Ó¦í°|ªº»´«×¦Ü¤¤«×±wªÌ¤§¦w¥þ©Ê©M¦³®Ä©ÊªºÅçÃÒ¬ã¨s¡A

±wªÌ¨Ã±N±µ¨ü¤@¤Ñ¨â¦¸¤fªA100mg Antroquinonol©Î¦w¼¢¾¯¡AÁp¦X¼Ð·ÇªvÀø(SoC)

Á`¦@14¤Ñ¡C

(3)¥»¸ÕÅç¼Æ¾ÚÅã¥Ü:

¥D­nµû¦ô«ü¼Ð¡G±d´_²v(recovery ratio)¡A¦b²Ä14¤Ñ¦s¬¡¥BµL©I§l°IºÜªº±wªÌ¤ñ¨Ò¡C

¸ÕÅçµ²ªGÅã¥Ü¡A¦bAntroquinonolªvÀø«áªº²Ä 14 ¤Ñ¦] COVID-19¾É­PªÍª¢¦í°|±wªÌ

¦s¬¡¥BµL©I§l°IºÜªº¤ñ¨Ò¬°97.9%¡A¦Ó¦b¹ï·Ó²Õªº¤ñ¨Ò¬°100%¡A³oºØ¤ñ¸û¨S¦³²Î­p

ÅãµÛ·N¸q¡]P=0.5304¡^¡CµM¦Ó¡A»P¹ï·Ó²Õ¬Û¤ñ¡AAntroquinonol²Õªºcomorbidities

¦X¨Ö¯g¡A¦p°ª¦åÀ£ (Antroquinonol 38.7% vs. ¹ï·Ó²Õ22.6%) ©M¿}§¿¯f

(Antroquinonol 24.2% vs.¹ï·Ó²Õ14.5%)¥H¤Î¨k©Ê±wªÌªº¤ñ¨Ò§ó°ª¡A³o¨â­Ó¦]¯À³£

·|ÅãµÛ¼W¥[·s«aªÍª¢´c¤Æ¬°­«¯g(©I§l°IºÜ)©Î¦º¤`ªº¤ñ¨Ò¡F¦AªÌ¡A¸ÕÅ窺²Ä¤@¤Ñ¦b

Antroquinonol²Õ´N¦³6­Ó¨ü¸ÕªÌ´c¤Æ¬°©I§l°IºÜ¡A¦Ó¹ï·Ó²Õ¬Û¹ï¸û¤Ö¥u¦³1­Ó©I§l

°IºÜ¡C

¦¹¥~¡A¹ï·Ó²Õ±µ¨ü¥Ö½èÃþ©T¾J©M·ç¼w¦è­³§@¬°¼Ð·ÇªvÀø( SoC )ªvÀøªº±wªÌ¦Ê¤À¤ñ

°ª©óAntroquinonol²Õ¡C¥H¤W¦]¯À¥i¯à¬O¾É­P¥D­n²×ÂI¦³®Ä©Ê¤£©ú½Tªº­ì¦]¡A§Y«K

¦p¦¹¡A¦b¥»¸ÕÅç´Á¶¡¥HDelta¬°¥D­n·s«aÅܲ§¯f¬rªº±¡ªp¤U¡AAntroquinonol²Õ¦b

²Ä14¤Ñ¥H«á¡A§Y¥¼¥X²{©I§l°IºÜ¡A¤]¨S¦³¥X²{¦º¤`¡A¨ä±d´_²v¬°¦Ê¤À¤§¦Ê¡C

(4)¦¸­nµû¦ô«ü¼Ð¡G

¥»¬ã¨sÁö¥¼Åã¥ÜAntroquinonol²Õ¬Û¹ï©ó¹ï·Ó²Õªº­«¤jÀu¶Õ( superiority )¡A

³o¥i¯à¬O¥Ñ©ó¬ã¨s¤H¸s¦b¸ÕÅç¨â²Õ¤¤³£±µ¨ü¤F¼Ð·ÇÀøªk( SoC )ªºªvÀø¡A¥B¹ï·Ó²Õ

¦³¸û§Cªº­·ÀI¦]¤l¡C§Y¨Ï¦p¦¹¡A¥»¸ÕÅ礴µM¦b·s«aªÍª¢( COVID-19 )¦í°|±wªÌªº

¤@¨Ç¯gª¬¤W¡AÆ[¹î¨ì§Q©óAntroquinonol ªº§ïµ½ÁͶաA¥]¬A¤¤¦ì¼Æ¦í°|®É¶¡´î¤Ö¤F

1 ¤Ñ¡A¥@¬É½Ã¥Í²Õ´¤§Á{§ÉÅܤƵû¤À§ïµ½¨ì¹sªº¤¤¦ì¼Æ®É¶¡¤]´î¤Ö¤F 2 ¤Ñ¡A¦Ó­«¯g

¥[Å@¯f©Ðªº¦í°|®É¶¡§ó¬O´î¤Ö¤F 9.5¤Ñ¡C³Ìªñ¡A¦b COVID 19 ·P¬VªÌ¤¤³ø§i¤F

COVID 19 ªø´Á¼vÅT(Long COVIDªø´Á·s«a¯gª¬) ªº¥D­n¯gª¬¡A¥]¬A©I§l§xÃø¡B¦Ù¦×

µmµh©M¨ýı©Î¶åı³à¥¢¡C¯÷¤À§O»¡©ú¦p¤U:

©I§l§xÃø: ¸ÕÅçµ²ªG²Ä28¤Ñ¤´¦³¦¹¯gª¬ªº¯f¤H¤À§O¬OAntroquinonol²Õ¦³6.1%¡A

¹ï·Ó²Õ«h¦³17.8%ªº¯f¤H(P=0.0327)¡C

¦Ù¦×µmµh: ¸ÕÅçµ²ªG²Ä7¤Ñ¤´¦³¦¹¯gª¬ªº¯f¤H¤À§O¬OAntroquinonol²Õ¦³3.6%¡A

¹ï·Ó²Õ«h¦³11.8% (P-value=0.0525)¡C

¶åı©Î¨ýı³à¥¢: ¸ÕÅçµ²ªG²Ä28¤Ñ¤´¦³¦¹¯gª¬ªº¯f¤H¤À§O¬O: ¥ÎÃIJզ³0%¡A¹ï·Ó²Õ

«h¦³6.7%ªº¯f¤H(P-value=0.1059)¡AAntroquinonol²Õªº¨ü¸ÕªÌ³£

¨S¦³¨ýı©Î¶åıªº³à¥¢¤F¡C

¥H¤WÁö¥¼¦³²Î­pÅãµÛ·N¸q¡A²Ä28¤Ñªº©I§l§xÃø(P=0.0327)©M²Ä7¤Ñªº¦Ù¦×»Äµh

(P=0.0525)³£Åã¥ÜAntroquinonol¦³§Q©ó¿n·¥´î¤Ö¯gª¬ªºÁͶաC

­«¯g¥[Å@¯f©Ð(ICU)ªºªvÀø®É¶¡: ¸ÕÅçµ²ªGAntroquinonol²Õªº¯f¤H¤¤¦ì¼ÆªvÀø¤Ñ¼Æ

¬°13.5¤Ñ¡A¹ï·Ó²Õ¬°23¤Ñ(P-value=0.5404)¡C

¦í°|®É¶¡: ¸ÕÅçµ²ªGAntroquinonol²Õªº¯f¤H¤¤¦ì¼Æ¦í°|®É¶¡¬°4¤Ñ¡A¹ï·Ó²Õ¬°5¤Ñ

( P-value=0.9951 )¡C

WHO§Ç¼Æ¶qªí´ú¶qªºÁ{§ÉÅܤƵû¤À§ïµ½®É¶¡:¸ÕÅçµ²ªGAntroquinonol²Õªº¯f¤H§ïµ½¨ì

scale¬°0ªº¤¤¦ì¼Æ¤Ñ¼Æ¬°29¤Ñ¡A¹ï·Ó²Õ

¬O31¤Ñ(P-value=0.7034)¡C

²M°£¯f¬rªº®É¶¡: ¸ÕÅçµ²ªGAntroquinonol²Õªº¤¤¦ì¼Æ¤Ñ¼Æ¬°14¤Ñ¡A¹ï·Ó²Õ¬O15¤Ñ

(P- value= 0.5422)¡C

¥H¤WÁö¥¼¦³²Î­pÅãµÛ·N¸q¡A¦b¦³«e­z¨â²Õ¶¡ªº¤£¹ïµ¥­·ÀI¦]¤l¤§¤U¡A©M¹ï·Ó²Õ¬Û¤ñ¡A

Antroquinonol²Õªº¤¤¦ì¼Æ¦í°|®É¶¡¤´µM´î¤Ö¤F 1 ¤Ñ¡AWHOÁ{§ÉÅܤƵû¤À§ïµ½¨ì¹sªº

¤¤¦ì¼Æ®É¶¡¤]´î¤Ö¤F 2 ¤Ñ¡A¦Ó­«¯g¥[Å@¯f©Ðªº¦í°|®É¶¡§ó¬O´î¤Ö¤F 9.5 ¤Ñ¡C

(5)¦w¥þ©Ê¤è­±: ¯f¤H­@¨ü©Ê¨}¦n¡AµL»Ý­n¶i¤@¨B±´°Qªº¦w¥þ©ÊijÃD¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/29 ¤W¤È 08:00:29²Ä 2266 ½g¦^À³
¤t´¶¤O±Àªº¡u¯«ÃÄ¡v¡A¥@½Ã¥s°±ªº¡u¬rÃÄ¡vßm´â喹¡A¦b¥D­n«ü¼Ð¤W¡u¨S¦³¼g»¡­n¸ò¦w¼¢¾¯¤ñ¸û¡C¡v

¦]¬°²Î­p¤ÀªR¨S¹F¼Ð¥¢±Ñ¡A¤t´¶·|ðݦºXXXX!

--------------------------------------------------------------------------------------------------

www.sciencedirect.com/science/article/pii/S2589537021000535

...For all analyses, two-sided p-values<0.05 were considered significant.

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/28 ¤U¤È 04:21:51²Ä 2265 ½g¦^À³
Á{§É¸ÕÅ礧µû¦ô«ü¼Ð¡Aªk³W­n¨Dªº½d³ò(Âù§Àp­È<0.05)

-------------------------------------------------------------------------------------------------

Á{§É¸ÕÅ礧µû¦ô«ü¼Ð¡A±N®Ú¾Ú«ü¤Þªº©w¸q¤À§O¦CÄݤT­Óµû¦ô«ü¼Ð®a±Ú(¥D­nµû¦ô«ü¼Ð®a±Ú¡B¦¸­nµû¦ô«ü¼Ð®a±Ú¡B±´¯Á©Êµû¦ô«ü¼Ð®a±Ú)¡A¨Ã¨Ì´`«ü¤Þ©Ò«Øij¤§²Î­pÀË©wµ¦²¤¡A±±¨î¾ãÅéType I Error©óªk³W­n¨Dªº½d³ò¤º(Âù§Àp­È<0.05)

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/28 ¤W¤È 09:12:02²Ä 2264 ½g¦^À³
FDAÁ{§ÉªvÀø²×ÂI«ü¾É­ì«h:

2017¦~FDA¨î©wMultiple Endpoints in Clinical Trials Guidance for Industry¡A

­«ÂI¦b±±¨îÁ{§É¸ÕÅ窺¥D­n«ü¼Ð©M¦¸­n«ü¼ÐªºType I Error, Type II Error, and p-value !

­«ÂI¦b±±¨îÁ{§É¸ÕÅ窺¥D­n«ü¼Ð©M¦¸­n«ü¼ÐªºType I Error, Type II Error, and p-value !

1.FDA Multiple Endpoints in Clinical Trials Guidance for Industry

www.fda.gov/files/drugs/published/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-

Industry.pdf

2.°]¹Îªk¤HÂåÃÄ«~¬dÅ礤¤ß¦ÒFDA¨î©w¤§ Draft Guidance for Industry: Multiple Endpoints in Clinical Trials

(2017)¨î©w¡uÁ{§É¸ÕÅç¦h­«ÀË©w¦Ò¶q¡v«ü¾É­ì«h¡A§@¬°Á{§É¸ÕÅç³]­p»P³W¹ºªº­«­n°Ñ¦Ò¨Ì¾Ú¡C

www.cde.org.tw/Content/Files/Knowledge/%E8%87%A8%E5%BA%8A%E8%A9%A6%E9%A9%97%E5%A4%9A%E9%87%8D%E6%8C%87%E6%A8%99%E4%B9%8B%E7%B5%B1%E8%A8%88%E6%8C%87%E5%B0%8E%E5%8E%9F%E5%89%87_%E7%AC%AC%E4%B8%80%E7%89%88.pdf

¦¸­n«ü¼Ðªº¥¿¦Vµ²ªG¡A¶È¦³¦b¥D­n«ü¼Ð®a±ÚªºÀø®Ä¤w¸gÀò±oÃÒ©ú®É¤~¥i¸ÑŪ

3.¬ü°êFDA¡uÁ{§É¸ÕÅç¦h­«µû¦ô«ü¼Ð«ü¤Þ¯ó®×¡v¤¤¤åª©

www3.cde.org.tw/Content/Files/Knowledge/068bfcb1-e8d9-4b17-857e-13c08a3159a8.pdf

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/7/27 ¤U¤È 12:53:45²Ä 2263 ½g¦^À³
ªñ´Á°ê¤H¦ÛÄ@ÀË´ú¯×ªÕ¨xª¢¡A¿©±w²v³º°ª¹Fªñ7¦¨¡AÂå¥Í¹w´ú¨x¯×ª¢±N¬O°ê¯f¡CÁö¤£¯àµø¬°±`ºA¦ý¤@©w·|¶WÅD¦¶¸³¹w¦ôªº2¦¨5¡F¦Ó2¦¨5¦ô¥@¬É¿©±w²v¼ç¦b°Ó¾÷¹F7¤d7¦Ê»õ¬ü¤¸¡A¦]¦¹¨x¯×ª¢¥ÎÃÄ¥«³õ«D±`¤j¡F§Æ±æ¦n¥Î§Ö³tÀË´ú¤èªk¥[³t6¨t¬ãµo¡AÅýÀuµ¥¥Í¶W³t¡I¥[ªo¡I
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/26 ¤W¤È 08:56:23²Ä 2262 ½g¦^À³
¶¢²áVERU ªñ´ÁªÑ»ùªí²{¤£¨Î¥i¯à­ì¦]?

2022.7.8: ½æªÅ¶°¹ÎCulper Researchµoªí¤F¤@¶µ·s¤ÀªR¡A¹ï¨ä³¡¤ÀÁ{§É¸ÕÅç¼Æ¾Ú´£¥X½èºÃ¡C

www.fool.com/investing/2022/07/08/why-veru-stock-got-dented-today/

--------------------------------------------------------------------------------------------------

µ²½×:1.Àò±oDSMBªº«Øij´£¦­µ²§ôÁ{§É¸ÕÅç¡A¶i¦æ¸Ñª¼¡C

2.5¤ë10¤éÁ|¦æFDAªº­±¹ï­±°Q½×·|ij¡AFDA¨S¦³­n¨D´£¨ÑÃB¥~¼Æ¾Ú¥B·í¤Ñ´N«ØijVERU»¼¥æEUA¥Ó½Ð¡C

3.6¤ë7¤éVERU«Å¥¬°e¥XEUA¥Ó½Ð

«¥»{¬°¹LÃö¾÷²v~100%¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/26 ¤W¤È 06:30:15²Ä 2261 ½g¦^À³
·í»¡´N»¡¤£¥Î¿ß°_¨Ó!

¤§«e»EµJ¦b°ê¹©¥Ó½ÐPRE-EUA meeting¦A¤T©µ¿ðªº®É¶¡©Ê¡AµÛ¹ê¨S¯d·N¨ìFDA©xºô¦³¬q[Requests for Type B and Type B (EOP) meetings will be honored except in unusual circumstances.Generally ]¡A·N§YFDA³q±`¤£·|©Úµ´Type B»PType B (EOP)ªº·|ij¥Ó½Ð¡C

----------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/19 ¤W¤È 11:56:49²Ä 1804 ½g¦^À³

..¦Ü©ópre-EUA meeting¡AFDA´X¤Ñ¤º¸Ó°µ¥X¦^À³(»â®©¦b­Ó¤H):

www.scendea.com/making-the-most-of-opportunities-to-interact-with-the-us-fda

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/26 ¤W¤È 06:22:25²Ä 2260 ½g¦^À³
FDA¤£·|¦Û¥´¼L¤Ú¡A¹O¶V¦Û­qªºÁ{§É«ü¾É³W©w: ªvÀøCOVID-19ªºÃĪ«À³±Ä¥Î[Àu®Ä©Ê³]­p]ªº [ÀH¾÷]¡B[¦w¼¢¾¯¹ï·Ó]¡B[Âùª¼]Á{§É¸ÕÅç¶i¦æµû¦ô¡C

ºK¦Û°ê¹©¦Û®aªº¦õÃÒ¸ê®Æ:

°ê¹©¥Í§ÞÁ{§ÉÂå¾Ç³¡³¯¨Ø©gÂå®v(¼B¸³¤k¨à?)«ü¥X¡A°ê¹©ªº·s«aªÍª¢´ÁÁ{§É¬O¥¿¦¡ªº¤G´ÁÁ{§É¡A§¹¥þ²Å¦X¬ü°êFDA µo¥¬©ó2020¦~5¤ëªº·s«aªÍª¢Á{§É«ü¾É³W©w¡A°w¹ïÃļt¶}µo·s«aªÍª¢ªºªvÀø©M¹w¨¾ÃĪ«¤Î¥Íª«»s¾¯ªº«ü¾É¡A³W©w¶·±Ä¥Î[³Ì°ª¯Å]???ªº³]­p¡A¤]´N¬OÁ{§É¸ÕÅ窺³]­p¥²¶·¬°[ÀH¾÷]¡B[Âùª¼]¡B¦Ó¥B[¦³¦w¼¢¾¯¹ï·Ó]ªº¸ÕÅç¡A¤~¬O¥\®Ä©ÊÅçÃҳ̥i«HªºÃÒ¾Ú¡A«áÄò¤~¥i½×¤Î¥Ó½Ð¬ü°êºò«æ¨Ï¥Î±ÂÅv(EUA)

-----------------------------------------------------------------------------------------

FDA·s«aªÍª¢Á{§É«ü¾É³W©w­ì¤å: FDA strongly recommends that drugs to treat COVID-19 be evaluated in randomized, placebo-controlled, double-blind clinical trials using a [superiority design].

¦Ó [superiority design]¬O³Ì°ª¯ÅÁÙ¬OÀu®Ä©Ê?

3ºØÁ{§É¸ÕÅç³]­p:

Àu®Ä©Ê¡]superiority¡^¸ÕÅç:¦b©óÃÒ¹ê·sÃĤñÂÂÃÄ¡]©Î¦w¼¢¾¯¡^¦³®Ä¡A¥H«K©ó¥H·sÃĥΨӨú¥NÂÂÃÄ¡C

µ¥®Ä©Ê¡]equivalence¡^¸ÕÅç:·s¡BÂÂÃĮĬ۷í¡A¦¹ºØ¬ã¨s³]­p±`³Q®³¨Ó»P¡u«D¦H©Ê¸ÕÅç¡v¤@°_°Q½×¡C

«D¦H®Ä©Ê¡]non-inferiority¡^¸ÕÅç: ¥Øªº¦b©óÀË©w·sÃÄÀø®Ä¦Ü¤Ö¤£¿éÂÂÃÄ¡AÅýÂå¥Í¦h¤@ºØ¥i¿ï¾Ü¤§ÃĪ«¡Aµ¹¤©¬Û¦P¯e¯f¤§¤£¦P±wªÌ¡C

µ²½×: ÃĪ«¸ÕÅçÀø®Ä«ÜÅãµÛ¡ADSMBªº«Øij¡A¸Ó¬OVERU»P¥_·¥¬Pªº´£¦­µ²§ôÁ{§É¸ÕÅç¡A¶i¦æ¸Ñª¼¡C

«¥¤p½¼¦ÌÁÙ·í¤£¤F§ßÀs¤ý¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/24 ¤W¤È 08:02:40²Ä 2259 ½g¦^À³
§ó¥¿:2006¦~µÜ´µ¤º½×¤å¬Oµo¦b³»¦y´Á¥Z¡mNature¦ÛµM¡n¤W¡A²{¦b¥t¤@³»¦y´Á¥Z¡mScience¬ì¾Ç¡n½ðÃz½×¤å¥i¯à³y°²¡C

³y°²³¡¤À¬O§âWestern blot½Æ»s¶K¤W¡A£]¾ý¯»¼Ë³J¥ÕÁÙ¬O¦³¨Ç¤H­«½Æ°µ±o¥X¡C

¨Æ¥ó¸òÁú°ê¶À¬ê¿üªº½Æ»s·F²Ó­M³y°²(§O¤H¨Sªk½Æ»s­«²{µ²ªG)¦³©Ò¤£¦P¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/24 ¤W¤È 07:30:45²Ä 2258 ½g¦^À³
2022.7.22 ¬ì¾Ç¬ÉÅå¤ÑÁà»D¡I

ªü¯÷®üÀq¯gÃöÁä½×¤åºÃ³y°² »~¾É¥~¬É16¦~

...½ðÃzµÜ´µ¤º½×¤åªº¤j¶q¹Ï¤ù¥i¯à³y°²¡A­Y½T¹ê¦p¦¹¡A¨º»ò¾Ç¬É¹ï©óªü¯÷®üÀq¯gªº¬ã¨s¤è¦Vµ¥©ó¬O³Q»~¾É¤F16¦~¤§¤[¡C

µ²½×:[·L]­×¹Ïªí«Ü¥¿±`°Ú¡C¦ýµo¦b³»¦y´Á¥Z¡m¬ì¾Ç¡nªº­«¤j»P·N¸q¥i´N¤£¤@¼Ë!

---------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/23 ¤U¤È 10:56:57²Ä 2257 ½g¦^À³

¥Ñª¢¯g¤¶导ªºCYP2E1ªº变¤Æ¦b[¨x]内ªº调±±Éó¨î¤w较为©úÚÌ¡A¦ý¬O对[¤¤枢内] CYP2E1ªº变¤Æ±¡úG¬ã¨s较¤Ö¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/23 ¤U¤È 10:56:57²Ä 2257 ½g¦^À³
¥Ñª¢¯g¤¶导ªºCYP2E1ªº变¤Æ¦b[¨x]内ªº调±±Éó¨î¤w较为©úÚÌ¡A¦ý¬O对[¤¤枢内] CYP2E1ªº变¤Æ±¡úG¬ã¨s较¤Ö¡C

-------------------------------------------------------------------------------------------

2016¦~ 脑CYP2E1参ÉO¯×¦h¿}诱导ªº¯«经¤¸损伤 html.rhhz.net/ZGYLXTB/html/201607010.htm

¬ã¨s´£¥Ü¡A©¬ª÷´Ë¯f¡Bªüûدý®üÀq¯f¡B¦h发©Êµw¤Æ¡B¦Ùµä缩侧¯Áµw¤Æ¯gµ¥¯«经°h¦æ©Ê¯e¯fªº¯f²z¥Í²z学§ï变ÉO«ù续ªºª¢¯g¤Ï应过µ{±K¤Á¬Û关[1-3]¡AµM¦Ó¨ä¯f²zÉó¨î©|»Ý²`¤J¬ã¨s¡C

细­M¦â¯ÀP450¡]cytochrome P450¡ACYP¡^¶W®a±Ú酶¨t参ÉO内·½©Êª«质¡]¦p¯×ªÕ»Ä¡B维¥Í¯À¡B胆»Ä¡^©M¥~·½©Êª«质¡]¦p药ª«¡B¬rª«¡B«e­PÀùª«¡^ªº¥N谢¥¢¬¡¤Î¬¡¤Æ¡CCYP¶W®a±Ú酶¨t虽¥D­nªí达¦b¨x脏¡A¦ý¤]ªí达¤_¨x¥~¾¹©x¡A¦p脑¡C¦bCYP亚«¬¤¤¡ACYP2E1³J¥ÕªÅ间结Ìۨ㦳¥i变©Ê¡A

...¦Ó°ªªí达CYP2E1¥i¥[­«LPS©Ò­P¯«经¤¸损伤¡C¥Ø«e¡A¥Ñª¢¯g¤¶导ªºCYP2E1ªº变¤Æ¦b¨x内ªº调±±Éó¨î¤w较为©úÚÌ¡A¦ý¬O对¤¤枢内CYP2E1ªº变¤Æ±¡úG¬ã¨s较¤Ö¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/23 ¤U¤È 10:48:06²Ä 2256 ½g¦^À³
ªñ¦~¨Ó¡A²Ó­M¦â¯À P450 酶 (CYP) ªº­«­n©Ê¤w¶W¥X¨ä¦b¨xŦ¤¤ªº§@¥Î???

CYP2E1 ¬O¤@ºØ¤½»{ªº°Ñ»P¦UºØ¤º·½©Ê©M¥~·½©Êª«½è¥NÁªº³æ¥[®ñ酶¡A¦b¯A¤Î©¬ª÷´Ë¯fµo®iªº¤j¸£¤¤°_µÛ¦ÜÃö­«­nªº§@¥Î¡C

CYP2E1ªº [¹Lªí¹F]¦ü¥G¹ï¦h¤ÚÓi¯à¯«¸g¤¸¦³®`¡C

----------------------------------------------------------------------------------

2021.07.29 www.eurekaselect.com/article/116960

­I´º¡Gªñ¦~¨Ó¡A²Ó­M¦â¯À P450 酶 (CYP) ªº­«­n©Ê¤w¶W¥X¨ä¦b¨xŦ¤¤ªº§@¥Î¡C¿ò¶Ç¡BÀô¹Ò¬r¯À¡BÃĪ«¥Íª«Âà¤Æ©M¼ç¦b¯e¯fµ¥¦]¯À¤¶¾É¤F³o¨Ç酶ªºªí¹F¡C¦b CYP 酶¤¤¡ACYP2E1 ¬O¤@ºØ¤½»{​​ªº°Ñ»P¦UºØ¤º·½©Ê©M¥~·½©Êª«½è¥NÁªº³æ¥[®ñ酶¡A¦b¯A¤Î©¬ª÷´Ë¯fµo®iªº¤j¸£¤¤°_µÛ¦ÜÃö­«­nªº§@¥Î¡C CYP2E1 ªºªí¹F¦b¤£¦Pªº¤j¸£°Ï°ì¤¤¦³©Ò¤£¦P¡A¨Ï±o¬Y¨Ç°Ï°ì¤ñ¨ä¥L°Ï°ì§ó¯Ü®z¡C CYP2E1 ªí¹F¬O¥i»¤¾Éªº¡A¥¦²£¥Í¾É­P®ñ¤ÆÀ³¿E¡B½u²ÉÅé¥\¯à»Ùê©M³Ì²×¯«¸gÅܩʪº²Õ´·l¶Ë¦Û¥Ñ°ò¡C

¥Øªº¡G¹ï CYP2E1 ¦b¤¤¼Ï¯«¸g¨t²Î¤¤ªº§@¥Î¤F¸Ñ¸û¤Ö¡A¦]¦¹¥»¬ã¨sªº¥Øªº¬O±´°Q»P©¬ª÷´Ë¯f¬ÛÃöªº CYP2E1 酶ªºªí¹F»P¬¡©Ê¤§¶¡ªºÃö«Y¡A¨Ã½T©w CYP2E1 ªºªí¹F¬O§_¼W¥[¡C»P¯«¸g°h¤Æ¦³Ãö¡C

¤èªk¡G¥»¬ã¨sªº¥Ø¼Ð¬O³q¹L±Ä¥Î¤@ºØ«D¨t²Îªººî¦X¤åÄmºî­z¤èªk¨Ó¹ê²{ªº¡A¦b¸Ó¤èªk¤¤¡A¤åÄm³Q©w©Ê¤ÀªR¡B§å§P©Êµû»ù¡A¨Ã´£¥X¤F¤@ºØ¹ï¾÷¨î¦³¾ãÅé¬Ýªkªº·s²z½×¡C

µ²ªG¡Gµo²{ CYP2E1 ¦b©¬ª÷´Ë¯fµo®i¤¤ªº°^Äm¬OÅãµÛªº¡A¦]¬° CYP2E1 ªº­t­±¼vÅT±»»\¤F¨ä«OÅ@©Ê¸Ñ¬r§@¥Î¡C

µ²½×¡GCYP2E1ªº¹Lªí¹F¦ü¥G¹ï¦h¤ÚÓi¯à¯«¸g¤¸¦³®`¡A¦]¦¹¡A¬°¤F§JªA³o¤@ÂI¡A»Ý­n¦X¦¨¥Í¤Æª«½è¡A³o¬°¶i¤@¨B¬ã¨s©M¶}µo¦³»ù­Èªº¥Íª«¤À¤lçE¥­¤F¹D¸ô¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/7/22 ¤W¤È 11:59:54²Ä 2255 ½g¦^À³
¨º­Ó¦a¤Ñ®õ§â·|²£¥ÍºÒ±Æªº¦³¾÷¼o±óª«§Ö³tµo»Ä(3¤p®É)¬°¦³¾÷ªÎ¡A¥i¥H©TºÒ¡A§â®ðºAºÒ©TºÒ¦^¤gÄ[¡A¤S¯à°ö¨|¦a¤O¡A«e´º¬Û·í¤£¿ù¡C

µ¥·Å«Ç®ðÅé´î¶q¤ÎºÞ²zªk­×¥¿¯ó®×¹L¤F¡A¦³ºÒÅv¥i¥H½æ¡A´N¦³»¤¦]¤j¦¨ªø¡C

enews.epa.gov.tw/DisplayFile.aspx?FileID=26E59EF644F21D93

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/7/22 ¤W¤È 11:53:30²Ä 2254 ½g¦^À³
roger¤j.

¥Ã¥Í²Ó­M¤]¬O¤£¿ùªº¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/21 ¤U¤È 08:47:42²Ä 2253 ½g¦^À³
2022.7.21Æp¥Û¥Í§Þ7/25µn³°¿³Âd ¥Ø¼Ð°ö¨|¦h®a¥Í§Þ¿W¨¤Ã~

...Æp¥Û¥Í§Þ¦@¦³ 10 ®aÂà§ë¸ê¤½¥q¡A°£¤F¦X¤@¡BÁÞ°ò¥~¡A¸ô¤Õ©ú¬Ý¦n¡A¤U¤@¶¥¬q¥HªYÄ£¥ÍÂå»P¥Ã¥Í²Ó­Mªº¦¨ªø©Ê³Ì¨ü´Á«Ý¡AªYÄ£¬°·sÃĶ}µo¤½¥q¡A§Y±N±q¿³ÂdÂà¤WÂd¡B¥Ã¥Í²Ó­M»P¦a¤Ñ®õ¹A·~¥Í§Þ¤]¦³¾÷·|¦b©ú¡B«á¦~¶i¤J¸ê¥»¥«³õ¡C

-------------------------------------------------------------------------------------------------

¸ô¤Õ©ú¬Ý¦n¡A¤U¤@¶¥¬q¥HªYÄ£¥ÍÂå»P¥Ã¥Í²Ó­Mªº¦¨ªø©Ê³Ì¨ü´Á«Ý????

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/20 ¤U¤È 09:09:34²Ä 2252 ½g¦^À³
·Q¾x±oº¡«°­·«BÁÙ¬O¥­ÀR¸¨¹õ? ¼Æ¾Ú¥æªk°|¤½¶}»{ÃÒ? Âd¶R¤¤¤ßµL¥¢Â¾?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G±iÄ£¤¯10152866  µoªí®É¶¡:2022/7/20 ¤U¤È 07:38:56²Ä 2251 ½g¦^À³
§A²ö¦W¨ä§®¡A¦bªYÄ£³oÃä¡A³y°ê¹©ªºÁÁ¡I

¦s¤ß¤£¨}¡A¤p¤ß¦V°ê¹©ÀËÁ|§A¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦V«e¦æ10140498  µoªí®É¶¡:2022/7/19 ¤U¤È 03:05:02²Ä 2250 ½g¦^À³
¹ï©ó¥Í§Þ¤p¼t¨Ó»¡

¦æ¾P¬O«Ü§xÃøªº

¤j¼t¦­´N§G«Ø³q¸ô

­nµØÃĪº¦æ¾P¦ÒÅç¤~­è­n¶}©l

¥Ø«eªºÀ禬¬O¤£¬O¥ª¤â´«¥k¤â¡H

©|«Ý¥¼¨ÓªºÅçÃÒ¡I

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/7/19 ¤U¤È 02:05:31²Ä 2249 ½g¦^À³
¯à¼W¸êÂX¤j§Q¼í¬O­Ó¤H«ä¦Ò¸ô½u¡A¦Ü©ó§xÃø«×¹ê¦b¤£²M·¡¤]¤£À´¡F¥»ª©¦Ü²{¦b³£¨S¦³¤H»¡ªYÄ£·|¬OªÑ¤ý¡A¤j®a³£¥H¥i¯à¬OªÑ¤ý¹w¦ô²q´ú¡C¨ä¹ê¥|ÁûÃĶW¹L10»õ¬ü¤¸¹w¦ô¬Û·í«O¦u¡A®M¤W°ê»ÚºâªkªÑ»ù´N¬O2000¤¸¡A¥ú¾a±ÂÅv´N¬OªÑ¤ý¡F­Y¥H¤À¼íª÷¦ôªÑ»ù§ó°ª¡C­Y¥H§ë¸ê¨¤«×¬Ý¡AÃĵØÃĬO«Ü¬Ý¦n¨S¿ù¡A¦ý§ë¸ê³ø¹S²vªYÄ£¥i¯à°ª«Ü¦h¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G½²ºû¤¯10143700  µoªí®É¶¡:2022/7/19 ¤U¤È 12:13:25²Ä 2248 ½g¦^À³
ªYÄ£±N¨Ó­Y¯à¦A100¤¸¼W¸ê10»õ¤¸¦@Äw¸ê100»õ¤¸¡A¥H¥R¸Î¸êª÷¨«¦V¦Û¤v³c°â¤§¸ô¡A«K¯àÀ½¨­§ó°ª§Q¼íÃļt¤§¦C¡A´Á«Ý¡C
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/19 ¤W¤È 10:03:20²Ä 2247 ½g¦^À³
Æ[¹î¦¹ª©µo¨¥ªÌ¡A¤£¥~¥G2ºØ¥i¯à©Ê:¤@¦³ªYÄ£¡A¤G¦³°ê¹©¡C

¶À°ê­ÛÃã¥ô¸³¨Æ¡AEUA¨Æ¥ó¦pªG¾É­P¨p¶Ò¤£¦¨ ¡A°ê¹©¦ó¥h¦ó±q?

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/6/21 ¤W¤È 08:11:06²Ä 2130 ½g¦^À³

¤é ´Á¡G2022¦~06¤ë20¤é

¤½¥q¦WºÙ¡G°ê¹© (4132)

¥D ¦®¡G°ê¹©¸³¨ÆÃã¥ôº[¸³¨ÆÅܰʹF¤G¤À¤§¤@

------------------------------------------------------------------------------------

¦M¨o!!!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G§d°ê¥°10151930  µoªí®É¶¡:2022/7/19 ¤W¤È 09:31:52²Ä 2246 ½g¦^À³
ªYÄ£½Íªº¬O±ÂÅvª÷

¥ú¾Ì³o¤@ÂI´N­n·í¤WªÑ¤ý¨º¬O¤£¥i¯àªº¨Æ

6446¥L¬O¥þ²y¿W¤@µL¤Gªº¦åÀù¥ÎÃÄ

¦Û¤vª¾¹D¦Û¤v¾P°â

¥L·í¤WªÑ¤ý¤ñ¸û¦³¾÷·|

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/19 ¤W¤È 06:46:00²Ä 2245 ½g¦^À³
1.CYP®a±Úªº±ÂÅv®×¡A³æ³æñ¬ùª÷´N®³¤F2.9»õ¬ü¤¸(Á`¨½µ{ª÷¤£ª¾)¡A[¤Û·Q]SNP¨t¦CªºCYP2E1§í¨î¤]¯à¬Ý»ô!

2.«Dªü¤ù类镇µh·s药JMKX000623 ¦b¤j¤¤华区¥H¥~ªº开发¡B¥Í产¤Î°Ó业¤Æ权§Q¡A预¥I´Ú1500ÉE欧¤¸¡A总权¯qª÷数额¥i观

------------------------------------------------------------------------------------------------

2022.7.13--2.9亿¬ü¤¸预¥I´Ú¡IÀq§J©M Orion «Å¥¬´N ODM-208 (CYP11A1) ªº开发©M°Ó业¤Æ开®i¥þ²y¦X§@www.phirda.com/artilce_28325.html?cId=1

...ªñ´Á¡AOrionÉO济¥Á¥i«HºX¤U¤l¤½¥q¤W®ü济·Ô达¦¨¤@项独®a¦X§@协议¡A获±o¤W®ü济·Ô¦Û¥D¬ã发ªº«Dªü¤ù类镇µh·s药JMKX000623 ¦b¤j¤¤华区¥H¥~ªº开发¡B¥Í产¤Î°Ó业¤Æ权§Q¡A预¥I´Ú1500ÉE欧¤¸¡A总权¯qª÷数额¥i观

ªñ´Á¡AOrionÉO济¥Á¥i«HºX¤U¤l¤½¥q¤W®ü济·Ô达¦¨¤@项独®a¦X§@协议¡A获±o¤W®ü济·Ô¦Û¥D¬ã发ªº«Dªü¤ù类镇µh·s药JMKX000623 ¦b¤j¤¤华区¥H¥~ªº开发¡B¥Í产¤Î°Ó业¤Æ权§Q¡A预¥I´Ú1500ÉE欧¤¸¡A总权¯qª÷数额¥i观

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/18 ¤U¤È 12:42:05²Ä 2244 ½g¦^À³
FDA COVID-19ÃĪ««ü«nwww.fda.gov/media/137926/download

FDA ¡§±j¯P«Øij¨Ï¥Î [Àu®Ä©Ê] ³]­pªºÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B[Âùª¼] Á{§É¸ÕÅçµû¦ô¥Î©óªvÀø©Î¹w¨¾ COVID-19 ªºÃĪ«¡¨¡A¨ÃÀ³¦b©Ò¦³ªvÀø¤è®×¤¤¨Ï¥Î¼Ð·ÇÅ@²z

-----------------------------------------------------------------------------------------

·s«aÃĪ«Á{§É¸ÕÅç·ÓFDA«ü«n³]­p:ÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡BÂùª¼»P¨Ï¥Î¼Ð·ÇÅ@²z¡A¨º»ò¼Æ¾Ú¹F¼Ð­n¨D´N¬O[Àu®Ä©Ê]!

¤£À´[Àu®Ä©Ê]? ¸Û¤ß«Øij»·Â÷·sÃħë¸ê!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/18 ¤U¤È 12:34:36²Ä 2243 ½g¦^À³
¬Ý¨ì¤@­Ó¤£¿ù¦a°ÝÃD¡A ¤âÄo¦^µª¤@¤U!

¦Ü©óµoÃÒ¸Ô²Ó²z¥Ñ¡A¦³¿³½ì¦Û¤v¬d¡A§K±o¨S§¹¨S¤F!

---------------------------------------------------------------------------------------------

Q:¦P¾Ç·|¦³¤H°Ý¦³Á{§Ép­È¤j©ó0.05~0.5¡A FDA¤´µMµ¹ÃÄÃÒ¡BEUAªº®×¨Ò¶Ü¡H

A:«¥¦³¤@­ÓP­È0.06·L¤j©ó0.05¡AFDAµoµ¹ÃÄÃÒ¦a®×¨Ò¦p¤U¡A ¨S¬Ý¹LµoEUA¦a!

1. 2020.12.12 www.fiercepharma.com/marketing/where-do-you-stand-fda-reviewers-argue-for-

novartis-entresto-committee-meeting-file

FDA staffers highlighted that the result¡¦s p-value, at 0.06, is ¡§only slightly above the 0.05

target¡¨ to achieve statistical significance, hinting that they¡¦re willing to give that miss a

pass.

2.2021.2.17 ¤ß°I­«½S®ø®§¡I¬ü国FDA§å­ã诺华Entresto(诺ªY§´)¡Gªv疗®g¦å¤À数«O¯d¤ß¤O°IºÜ(HFpEF)ªº药ª«!

news.bioon.com/article/6784283.html

Entresto¬O²Ä¤@个¤]¬O°ß¤@¤@个³Q§å­ã¥Î¤_ªv疗«ü«n©wú媺¤ß¤O°IºÜ±wªÌªºªv疗¤èªk¡A¥]¬A®g¦å¤À数­°§Cªº¤ß¤O°IºÜ±w

ªÌ¡]HFrEF¡^©M®g¦å¤À数­°§Cªº¤ß¤O°IºÜ±wªÌ¡]HFpEF¡^¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/15 ¤W¤È 07:54:51²Ä 2242 ½g¦^À³
¤£²Å¦XFDAªºCOVID-19ÃĪ««ü«nªº¸ÕÅçµ²ªG(¤£¨ãÀu®Ä©Ê»P«DÂùª¼)¡A¥Ó½ÐEUA´N¬O½t¤ì¨D³½!

°ê¹©¥Í§ÞÁ`¸g²zĬ¸g¤ÑÂÔ·Vªí¥Ü¡A·|¥ý¦VFDA¥Ó½Ð¡uPre-EUA¡vªº·|ij¡C³o­Ó³Qµø¬°¥Ó½ÐEUA«e [¿Ô¸ßªº¦æ°Ê]....

[¿Ô¸ßªº¦æ°Ê][¿Ô¸ßªº¦æ°Ê][¿Ô¸ßªº¦æ°Ê]

VS.

¦pªG¸Á»e¸ÕÅç°e¥X¤å¥ó¥Ó½ÐPRE-EUA meeting[¿Ô¸ßªº¦æ°Ê]¡A¨Ì©x¤è¤å¥ó¦¬µo³W©w¡A¤@¼Ëµo­Ó¤å¸¹µ¹±z¡Aªí¥Ü¦³¦¬¤å¥ó¡C

µM«áFDAªº¼f¾\¤H¥´¶}¸ê®Æ®Éªºµe­±-->ÀY¤W¯Q¾~­¸¹L¡A¸£¸ÌXXX¡C

ÀH«áµo¥÷[COVID-19ÃĪ««ü«n]¥s±z¦n¦n¬ãŪ¡A§O½M·d!

------------------------------------------------------------------------------------------------

FDA COVID-19ÃĪ««ü«nwww.fda.gov/media/137926/download

FDA ¡§±j¯P«Øij¨Ï¥Î [Àu®Ä©Ê] ³]­pªºÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B[Âùª¼] Á{§É¸ÕÅçµû¦ô¥Î©óªvÀø©Î¹w¨¾ COVID-19 ªºÃĪ«¡¨¡A¨ÃÀ³¦b©Ò¦³ªvÀø¤è®×¤¤¨Ï¥Î¼Ð·ÇÅ@²z

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/14 ¤W¤È 10:25:18²Ä 2241 ½g¦^À³
«¥¦³¬ö¿ýªº!

¨ä¹êFDA¦³CTAP¡]«aª¬¯f¬rªvÀø¥[³t­pµe¡^¡A¥[³t¼f¬d¦b24¤p®É¤º§Y¦^ÂÐ(±ÀÂ_Veru¬O¦b24¤p®É¤º±o¨ìFDA¦P·N¶}·|)

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤U¤È 04:11:11²Ä 2212 ½g¦^À³

¥u¦³¼Æ¾ÚÁà¤~·|ÂÃþÓ±³þÓ©È别¤Hª¾¹D!!!

¼B¸³¦b¸Ñª¼°OªÌ·|»¡­n¥Ó½ÐEUA¡A¦A±À°U¤£°e¥ó¡A§ë¸ê¤H¤@©w·|´£§i!

±µ¤U¨ÓFDA¦b21¤Ñ¤º·|µ¹¥X¦P·N©Î¤£¦P·N¶}pre-EUA meeting¡A³o³õEUA¾x¼@¤]´N¸¨¹õ¤F¡C

¤§«á¨p¶Ò¸U¤@¨S¦¨¡A³o®a¤½¥q¤j·§´N¥h¤F¤F!

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/19 ¤W¤È 11:56:49²Ä 1804 ½g¦^À³

¡§³Õ¾Ç¤§¡A¼f°Ý¤§¡A·V«ä¤§¡A©ú¿ë¤§¡A¿w¦æ¤§¡¨

..¦Ü©ópre-EUA meeting¡AFDA´X¤Ñ¤º¸Ó°µ¥X¦^À³(»â®©¦b­Ó¤H):

www.scendea.com/making-the-most-of-opportunities-to-interact-with-the-us-fda

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦N¦Ì¦Ï10000583  µoªí®É¶¡:2022/7/14 ¤W¤È 10:19:05²Ä 2240 ½g¦^À³
R¤j¡A§Aªº®É¶¡ÂI¦ü¥G¤ñ¸û¼e¤j³á¡Aªþ¤WS¤j¤À¨Éªº¸ê°T

Suggested dates and times (e.g., morning or afternoon) for the meeting ( «Øij·|ijªº¤é´Á©M®É¶¡¡]¨Ò¦p¡A¤W¤È©Î¤U¤È¡^)

TYPE B Meeting ªº³W©w

Confirmation of scheduling : 21 days ( ½T»{®É¶¡ªí : 21 ¤Ñ )

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/14 ¤W¤È 10:17:18²Ä 2239 ½g¦^À³
¸Á»e¸ÕÅç¼Æ¾ÚÅã¥ÜÀu®Ä©Ê¹F¼Ð¡A«¥¬°¦ó»¡¸Á»eÁ{§É¥Ó½Ð¤£¤FEUA ¡C

ÃöÁä´N¦b¸Á»eÁ{§É¤£¬OÂùª¼(¸Á»e¤ôªº¨ý¹D¤ÓÃø±»¹¢¤F)¡AOpen-label¤£²Å¦XFDAªºCOVID-19ÃĪ««ü«n¡C

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/22 ¤W¤È 09:09:37²Ä 1809 ½g¦^À³

...2020.5.11 FDA COVID-19ÃĪ««ü«nwww.fda.gov/media/137926/download

...FDA ¡§±j¯P«Øij¨Ï¥Î [Àu®Ä©Ê] ³]­pªºÀH¾÷¡B¦w¼¢¾¯¹ï·Ó¡B[Âùª¼] Á{§É¸ÕÅçµû¦ô¥Î©óªvÀø©Î¹w¨¾ COVID-19 ªºÃĪ«¡¨¡A¨ÃÀ³¦b©Ò¦³ªvÀø¤è®×¤¤¨Ï¥Î¼Ð·ÇÅ@²z¡C

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/1/16 ¤U¤È 08:08:06²Ä 1599 ½g¦^À³

°ê¹©¼B³Ó«i:¦ý¬O¤W¬ü°ê°ê®a½Ã¥Í¬ã¨s°|NIHºô¯¸¥h¬d¡A°ê¹©³Q®Ö­ã¶i¦æªº·sÃÄAntroquinonol¤G´Á¸ÕÅç´N¦b¤W­±¡C¡v

­±¹ï¥~¬Éªº¤@¨Ç§åµû¡A¼B³Ó«iªí¥Ü¡A¥L»Ý­n¹ï¥~»¡©ú¡A¸ÕÅç¤H¼Æ¯à¤£¯à¦³¥Nªí©Ê¡A´N¬ÝFDA¬O§_³q¹L®Ö­ãÅý°ê¹©¶i¦æ¤G´Á¸ÕÅç¡AÃĪ«¦³¨S¦³®Ä¡A´N¬ÝFDA¬O§_¦P·NÅý°ê¹©¨ú±oEUA¡C

----------------------------------------------------------------------------------------------------

¯º¸Ü!

¦bÄY­«¯f¨Ò¤¤,¸Á»e¥ÎÃIJկf¨Ò¦b²Ä10¤Ñ¥X°| PK °ê¹©¥ÎÃIJժºªvÀø®É¶¡ÁYµu¤F9.5¤Ñ¡C

§Ú¤]¥i¥H»¡¸Á»eÀø®Ä¹F¼Ð¡A°ê¹©¨S¦³¤½¥¬§¹¾ã¼Æ¾Ú¡A´N¬O¤½»¡¤½¦³²z¡A±C»¡±C¦³²zªºª§°õ¤£¤U¡C

(¸Á»eÁ{§É¥Ó½Ð¤£¤FEUA)

¸Á»e³Q®Ö­ã¶i¦æªvÀø·s«aªÍª¢Á{§É¤]¦bNIHºô¯¸¡A¤£¶È¬O¤T´Á¡A¹ï·Ó²Õ¼Æ¾Ú³£¦³!

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/1/5 ¤U¤È 04:14:55²Ä 1548 ½g¦^À³

°ê¹©«ç¤£´£¨Ñ¹ï·Ó²Õ¼Æ¾Ú?

©³¤U¸Á»e©M¶ÂºØ¯ó¡]¤]ºÙ¬°¶Â§¶µM¡^3´ÁÁ{§É¸ê®Æ(µLªk½Æ»s¶K¤W«¥¤j·§¼g¤@¤U):

»P¹ï·Ó²Õªº7¤Ñ»P13¤Ñ¬Û¤ñ,µo²{¥ÎÃIJզb¤¤¦Ü­«¯g¯f¨Ò¤¤¤À§O¦b4¤Ñ»P6¤Ñ¤º½w¸Ñ·s«a¯gª¬(P<0.0001)¡C

»P¹ï·Ó²Õ¬Û¤ñ,¥ÎÃIJզb¤¤¦Ü­«¯g¯f¨Ò¤¤ªº¯f¬r²M°£¤]´£¦­4¤Ñ¡C

¥ÎÃIJÕÁÙ­°§C¤F­«¯g¯f¨Òªº¦º¤`²v(P=0.029)

¦b¤¤«×¯f¨Ò¤¤,96.26%ªº¤¤«×¯f¨Ò±wªÌ¦b²Ä10¤é«ì´_¤é±`¬¡°Ê,¦Ó¹ï·Ó²Õ¬°68.93%¡C

¦bÄY­«¯f¨Ò¤¤,¥ÎÃIJկf¨Ò¦b²Ä10¤Ñ¥X°|,¦ÓÆ[¹î¨ì¹ï·Ó²Õ¤´»Ý¦í°|ªvÀø»P»Ý­n®ñ®ð¡C

¹ï·Ó²Õªº30¤Ñ¦º¤`²v¬°18.87%, ¦Ó¥ÎÃIJլ°4%¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/14 ¤W¤È 08:57:06²Ä 2238 ½g¦^À³
1¶g¤F¡A¾÷²v³Ñ94%¡C

¥Ó½ÐPRE-EUA¯Âºé¬OÀ³¥I1/5¸Ñª¼¦¨¥\»P6¤ëªÑªF·|ªºµªÂСA¦ý¼B¸³¦b1¤ë5¤é»¡ªº[¸Ñª¼¦¨¥\]±N¥Ó½ÐEUA·|¦p¦P²î¹L¤ôµL²ª???

P­ÈÂÃþÓ±³þÓ¬O­nÃh­L10­Ó¤ë¤~¥Í±o¥X¨Ó???

---------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/8 ¤W¤È 09:36:36²Ä 2204 ½g¦^À³

...¤£¤NÃø¼B¸³¡A¯à»PFDA¶}pre-EUA meeting¾÷²v¡A©ú¤é°_ºâ1¤Ñ´î1%¡Aº¡¦Ê¤é«h¾÷²v¬°0¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/12 ¤W¤È 10:35:36²Ä 2237 ½g¦^À³
2022.7.12 «ôµn¬F©²±N©µªø COVID ¬ðµo¤½¦@½Ã¥Í¨Æ¥ó

7/15 PHE¨ì´Á100%®i©µ¡A¿ïÁ|«á¤~µ²§ôPHE¡C

-------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/6/25 ¤W¤È 08:48:35²Ä 2140 ½g¦^À³

¿ï²¼¦Ü¤W!!!

2022.6.23 «ôµnªº¤ä«ù²v³sÄò²Ä¥|©P¤U­°¡A³Ð¤U¾ú¥v·s§C

³o¬O¤@­Óĵ§i«H¸¹¡Aªí©ú¥L©ÒÄݪº¥Á¥DÄÒ¥i¯à¦b 11 ¤ë 8 ¤éªº¤¤´Á¿ïÁ|¤¤¥¢¥h¹ï¬ü°ê°ê·|ªº±±¨î¡C

7/15 PHE¨ì´Á~100%¦A®i©µ¡A¿ïÁ|«á¤~µ²§ôPHE¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/12 ¤W¤È 09:52:26²Ä 2236 ½g¦^À³
¦³¤Ö¼Æ¤p¤À¤lÃĦX¦¨¨BÆJ¦h¥B²£²v·¥§C¡A¦¨¥»°ª©ó¤j¤À¤lÃÄ!(SNP-630«ÜÃø¦X¦¨!!!)

¨Ò¦p:

µµ§ü¾J­ì®Æ»ù®æ±q­è¶}©lªº¨C¤½§J¤K¦Ê¬ü¤¸¡A·Æ¸¨¨ì¥Ø«eªº¤T¦Ê¬ü¤¸...¡C

2021.8.4àF´£·ÒªvÀùª«½è¡uµµ§ü¾J¡v§lª÷¤W»õ¤¸¡@¤ÑÀº¥Í§Þ­t³d¤H§P¦D©wù©www.ettoday.net/news/20210804/2047435.htm

¶}µo¤¤°ê®aªº§åµo¦¨¥»¨C100²@§J¬ù¬°7.06¦Ü13.48¬ü¤¸(*10­¿=70.06~130.48/§J)¡A¦Ó¦b­^°ê«h¬ù¬°66.85­^Âé¡]¬ù88¬ü¤¸*10­¿=880¬ü¤¸/§J¡^¡C

VS.

¤j³W¼Ò¥Í²£®É¡A³æ®è§ÜÅ骺¥Í²£¦¨¥»³q±`§C©ó¨C§J100¬ü¤¸

VS.

®Ö»Ä¾AÅé¥i¥H©T¬Û¦X¦¨§Þ³N¥Í²£¡A¥Í²£®É¶¡¬ù¼Æ¤p®É¡A¥Í²£¦¨¥»¨C§J¶È50¬ü¤¸

-------------------------------------------------------------------------------------------------

·|­û¡GPeter Lin10152815 µoªí®É¶¡:2022/7/10 ¤U¤È 03:59:31²Ä 2220 ½g¦^À³

¥t¥~SNP³£¤p¤À¤lÃĪ«¡A¦¨¥»À³¸Ó¨ã¦³¶W¯Å¤jªºÀu¶Õ¡C

----------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2021/5/7 ¤U¤È 05:44:04²Ä 1099 ½g¦^À³

Q2:ª¾¹DSNP-630«ÜÃø¦X¦¨¡A»s³y¦¨¥»¨s³º¦h°ª?

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/12 ¤W¤È 08:56:07²Ä 2235 ½g¦^À³
¨S¦³¹ï·Ó²Õ¬Ý¤£¥X¼Æ¾Ú®t²§!

1.®Ú¾Ú²Î­p¼Æ¾Ú¡A¥þ²y¦@¦³4.44»õNASH±wªÌ¡C

VS.

2.¨Ì·Ó¥@¬É½Ã¥Í²Õ´¡]WHO¡^¦ô­p¡A¥þ²y¨C¦~¬ù¦³300¦Ü400¸U¤H·P¬VC«¬¨xª¢¯f¬r¡A¬ù¦³1.3¦Ü1.7»õ¤H¤f±w¦³ºC©ÊC«¬¨xª¢¡C

VS.

3.®Ú¾Ú¥@¬É½Ã¥Í²Õ´2019¦~ªº¦ô­p¡A¥Ø«e·R´þ¯f±wªÌ³Ì¦hªº¦a°Ï¬O«D¬w¦a°Ï¡A¥þ²y¦³¶W¹L3,800¸U¤H·P¬V¤F·R´þ¯f¬r¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/12 ¤W¤È 08:47:50²Ä 2234 ½g¦^À³
¬ü°êNASH±wªÌ±q800¸U¤H§ó·s¬°1700 ¸U¤H

1.¦Ü¤Öªá8.7»õ¬ü¤¸ªºBI¡A¤j¼Æ¾Ú¦¬¶°:

®Ú¾Ú²Î­p¼Æ¾Ú¡A¥þ²y¦@¦³4.44»õNASH±wªÌ¡A¥Ø«e©|¥¼¦³¥i¦æªºªvÀø¤è®×¡Cwww.boehringer-

ingelheim.tw/nash

2.½÷·çºô­¶:...¬ü°ê¬ù¦³ 1700 ¸UNASH±wªÌ

----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2020/8/19 ¤W¤È 08:27:20²Ä 288 ½g¦^À³

4.2019-07-03 Boehringer Ingelheim»PÁú°êYuhanñ­q8.7»õ¬ü¤¸¦X¦P---[Á{§É«e]

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/10 ¤U¤È 10:49:57²Ä 2221 ½g¦^À³

...C¨x¦b¬ü°ê¬ù1%ªº¤H¿©±w(400¸U)¡A«D°sºë©Ê¯×ªÕ¨xª¢NASHªº¤ñ¨Ò°ª¹F2%+(¬ü°ê´N¦³600~800¸U¤H»ÝªvÀø)¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦V«e¦æ10140498  µoªí®É¶¡:2022/7/12 ¤W¤È 07:54:11²Ä 2233 ½g¦^À³
­Ó¤H¤]Æg¦P²{¦b¬OªÅÀY¥«³õ¡A«X¯Q¾Ôª§¦s¦b¥¨¤jªºÅܼơC

¿ú¬O¦Û¤vªº¡A¨º¸Ì¸Ó¶R¸Ó½æ¥»´N¸Ó¦Û§Úµû¶q¡C

170¤¸ªºªYÄ£¤W§ð¦³5¤d±i¦¨¥æ¶q¡A²{¤µ¥¼¥X²{¹L2¤d±i¡C

¥ú¦¨¥æ¶q´N©úÅ㤣¨¬¡A¦ó¨Óªºª£¡H°£«D¦n®ø®§¤w²{¡Aª½±µ¸õ¹L¡C

²{¤µ¡A®ÉªÅ­I´º¤S¤£¦P¤F¡A¦ó®É¤~¥X²{¡u¨}¾÷¡v¨S¤H»¡ªº·Ç¡C

ÁÙ¬O¶Ì¶ÌªººCºCµ¥¡AÄ~Äò°µ¬ü¹Ú¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¯È¤W´I¶Q10134993  µoªí®É¶¡:2022/7/12 ¤W¤È 01:59:18²Ä 2232 ½g¦^À³
¦³¨Ç¤H¯u¬O¤õ®ð«Ü¤j ®ð¼P¼P ¤£ª¾¹D¦b®ð¤°»ò

§Ú¥u¬O»¡ªÅÀY¥«³õºÉ¶q§C±µ ¤£°l°ª §Ú¨SÁ¿¡§§CÂI¡¨³o2¦r§a

¿ú¬O¡§·Q¡¨¥X¨Óªº¡H§Ú¥uª¾¹DªÑ»ù¬O¿ú°ï¥X¨Óªº

´I¶Q¡§ÀI¡¨¤¤¨D¡H§Ú¤ñ¸û³ßÅw´I¶Qí¤¤¨D

§Ú¤£¬O¨S²¼ªº»Ä»Ä §Ú«ùªÑªYÄ£ ±q2x¨ì²{¦b

¤§«eª£¨ì§Ö180¤S«ç¼Ë Á{§É¨S¤jÅD¶i ¤j¼t¤]¤£Ã±¬ù

ÁÙ¤£¬O±o¦^¨Ó

§ÚÁÙ¯u´Á«Ý«Ü¦h´I¤H¥Î·Qªº §âªÑ»ùª£¨ì1000

§Ú³o½a¤H·|«Ü¼Ö·N½æµ¹´I¤H

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¤p«Ó­ô10152857  µoªí®É¶¡:2022/7/11 ¤U¤È 11:57:04²Ä 2231 ½g¦^À³
®@Åý§A»~·|¤F,§Ú¤£¬O¦b¦^À³¦V¤j~

¥u¬Oı±o¬Y¼Ó«Ü§®,¶R½æªÑ²¼Áٻݭn¤H´£¿ôÅý§Ú¤£¸T¯º¤F

¦³¨S¦³­nª£.¦³¨S¦³ÃD§÷,©|»Ý®É¶¡ÃÒ©ú

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GNtumgk10151447  µoªí®É¶¡:2022/7/11 ¤U¤È 10:44:03²Ä 2230 ½g¦^À³
¦V¤jµL»Ý¤¶·N¡A²ö¦W¨ä§®¼J¿Ø§¹§O¤H¦A¸É¤@¥y¦@«j¤§¶W¯ÅµL¨¥ªº¡K
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¤p«Ó­ô10152857  µoªí®É¶¡:2022/7/11 ¤U¤È 10:31:13²Ä 2229 ½g¦^À³
«¢«¢«¢,§CÂI??10¤¸¶Ü??

´²¤á¹w´Á¤ß²z´N¬OªÅÀY¥«³õ

¦bªÅÀY¥«³õ«o¯à¤@ª½©¹¤Wöt?

§A«ç»ò·Q??

¿ú¬O·Q¥X¨Óªº,´I¶QÀI¤¤¨D,¦³¿ú¤H©M½a¤HªºÆ[ÂI¥Ã»·¤£¦P

³o¤]´N¬O¬°¤°»ò½a¤H´N½a¤@½ú¤l,´I¤H¦b®À±Ñ«á©¹©¹ÁÙ¬O´I¥i¼Ä°ê

¦@«j¤§~

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¦V«e¦æ10140498  µoªí®É¶¡:2022/7/11 ¤U¤È 09:43:26²Ä 2228 ½g¦^À³
¶R¥Í§ÞªÑ¥»¨Ó´N¸Ó¦Û¦æ¿Å¶q­·ÀI

ÃĵØÃĦ³¥¦ªº½æÂI

ªYÄ£¦³¦Û¤vªº½æÂI

·Qªø§ë¡B·mµu¡B§C±µ¡A¥ô§g¿ï¾Ü¡C

ªYÄ£ªº810¡B610¦³¦Û¤vªº°ò¥»­±¦b

¥«³õ¦Û·|¤ÏÀ³¸Ó¦³ªº»ù­È

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¯È¤W´I¶Q10134993  µoªí®É¶¡:2022/7/11 ¤U¤È 05:53:12²Ä 2227 ½g¦^À³
ªÅÀY®É´Áª£¥Í§Þ¶Ü

¨º±o­n¦³ÃD§÷

6¨t¦CÁ{§É¶i«×ÁÙ¦b2b ¨ÖÁʥثe¨S¸ñ¶H

8¨t¦C¥Î¤w®³¨ìªºotcÃÄÃÒ§ð¬ü °£«D¤j¼tñ¬ùª½±µ®³¥¦ªºÃÄ¨Ó½æ ¤£µM§Ú¬Ý·¥«×Ãø ¤j¼t²{¦b¤]¨S«æ­¢©Ê

§O¬ÝÃĵإثe¥»¯q¤ñµL­­¤j ¥¦ªº¥¼¨Ó¥Ø«e¬O¬Ý±o²M·¡ªº

ªYÄ£¥Ø«e«h¬OÂaÄg¬ü

¦b³oºØ±¡ªpµwª£ ¥i¯à¹ï¤w«ùªÑ¤j¤á¤]¤£¬O¦n¨Æ

³o¬O§Ú­Ó¤H¤p´²¤á±qªÑ»ùÆ[ÂI¨Ó¬Ý¦Ó¤w

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/7/11 ¤U¤È 02:17:55²Ä 2226 ½g¦^À³
¥»¨Ó·Q¥Î®ã¤õ¥[½X¡A·Q»¡ªÅÀY¤]­nª£ªÑªº¡A¥Í§Þ¦nµo´§

Å¥¯È¤jªº¡A§Ú85¥X¤@¨Ç¦n¤F¡A¤£µM¤S¬O¯È¤W´I¶Q

==================================================

§Ú­Ó¤H¬O»{¬°¦³¿³½ì§ë¸êªº¤H ÁÙ¬OºÉ¶q§C±µ¬°­ì«h

²¦³º6¨t¦CÁ{§ÉÁÙ¦b2b °£«D¦³¤º½u ª¾¹D¥¦·|³Q¨ÖÁÊ ¦ý©Z¥Õ»¡¬Ý°_¨Ó¥Ø«e¨S³o²{¶H

¦Ó8¨t¦C°£«D2¤j¼t¤¤¨ä¤¤¤@¼t«Å§Gñ¬ù ¨Ã¥Î8¨t¦C¥þ­±´À´«ÂÂÃÄ ¤£µM¾a8¨t¦C­nÁÈ¿ú ¤]¬O»»»»µL´Á

¦b¥Ø«eªÅÀY¥«³õ ÁÙ¬O¯à§C±µ´N§C±µ

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¯È¤W´I¶Q10134993  µoªí®É¶¡:2022/7/11 ¤U¤È 01:38:18²Ä 2225 ½g¦^À³
§Ú­Ó¤H¬O»{¬°¦³¿³½ì§ë¸êªº¤H ÁÙ¬OºÉ¶q§C±µ¬°­ì«h

²¦³º6¨t¦CÁ{§ÉÁÙ¦b2b °£«D¦³¤º½u ª¾¹D¥¦·|³Q¨ÖÁÊ ¦ý©Z¥Õ»¡¬Ý°_¨Ó¥Ø«e¨S³o²{¶H

¦Ó8¨t¦C°£«D2¤j¼t¤¤¨ä¤¤¤@¼t«Å§Gñ¬ù ¨Ã¥Î8¨t¦C¥þ­±´À´«ÂÂÃÄ ¤£µM¾a8¨t¦C­nÁÈ¿ú ¤]¬O»»»»µL´Á

¦b¥Ø«eªÅÀY¥«³õ ÁÙ¬O¯à§C±µ´N§C±µ

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/7/11 ¤W¤È 11:55:43²Ä 2224 ½g¦^À³
·sÃĤñ¥É®i®t??¾~¤ùÃþ¦¨Å}??¤Ó¤£­È¤F!!!!!¥[ªo§r
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/7/11 ¤W¤È 11:10:00²Ä 2223 ½g¦^À³
µ²ªGÁÙ¬OBBQ¤F¡A¦³¥´¦^¦A±µ¡I³q¸ô¥ý¥X¤@¥b¤F!²KÂI®ã¤õ
¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡Gdk10140377  µoªí®É¶¡:2022/7/11 ¤W¤È 09:44:05²Ä 2222 ½g¦^À³
¬Ý¨ÓÁÙ¬O¦P¾Ç¨º§Q®`¡A¤@©I¦Ê±i

³o¨½ÁÙ¬O¤Ó§N²M¡A¨S¥D¤O¬Ý

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/10 ¤U¤È 10:49:57²Ä 2221 ½g¦^À³
GLP1¦³¤@­Ý¤GÅU¡AºN¸Ä¥J­Ý¬~¿ÇªºÀuÂI¡A¤£¤ÖNASH±wªÌ¤]¬O¿}§¿¯f±w¡A³o®ÉGLP1ÃÄ´N¬O­º¿ï¡C

³æ³æ±q±wªÌ¤H¼Æ»PªvÀø®É¶¡¬Ý¥«³õ¡ANASHºC©Ê¯f¤j©óC¨x(ªv¡)ÃĪ«¥«³õ!

C¨x¦b¬ü°ê¬ù1%ªº¤H¿©±w(400¸U)¡A«D°sºë©Ê¯×ªÕ¨xª¢NASHªº¤ñ¨Ò°ª¹F2%+(¬ü°ê´N¦³600~800¸U¤H»ÝªvÀø)¡C

¬ü°êªº«D°sºë©Ê¯×ªÕ¨x¯fNAFLD(¥¼¨ÓªºNASH±wªÌ)¡A¿©±w²v§ó°ª¹F30%~40%¡C

----------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 01:35:37²Ä 2163 ½g¦^À³

...¥¼¨ÓNASH»â°ì¯à¥´±o¦h¤õ¼ö? ¥i¥H°Ñ¦Ò´X½gC¨xÃĪ«ªº¬G¨Æ:

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GPeter Lin10152815  µoªí®É¶¡:2022/7/10 ¤U¤È 03:59:31²Ä 2220 ½g¦^À³
²{¦b³o»ù®æÀ³¸ÓSNP8¨t¦C´N­È¤F¡C

SNP610ªºPH2b§@§¹¤j·§«á¦~¡A­è¦nNASH¤õÃz°_¨Ó¡A¥u­n°Æ§@¥Î¤p¤S¦³®Ä¡A¤£©È¨S¤H­n¡C

¥t¥~SNP³£¤p¤À¤lÃĪ«¡A¦¨¥»À³¸Ó¨ã¦³¶W¯Å¤jªºÀu¶Õ¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/10 ¤U¤È 02:51:24²Ä 2219 ½g¦^À³
Intercept·Q¤jº¡³e¨úÃÒ¡A´N¬O­nÁpÃĪvÀø!

°ê¥~±À¦ôOcaliva¦bF2~F3®³ÃÒ¾÷²v60%(«¥¥[1¤À=¤C¤À¾a¥´«÷)

F4ªºREVERSE study¦bQ3·|¥X¨Ó(¦]¨x¬r©Ê¡AF4®³ÃÒ¾÷²v§C=3¤À¤Ñª`©w=¤Hºâ¤£¦p¤Ñºâ)

-----------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/7 ¤U¤È 12:23:54²Ä 1938 ½g¦^À³

¦pªG§Ú¬OIntercept¤½¥qCEO¡A¦b®³¨ì²Ä1±iNASHÃÄÃÒ«á¸êª÷¤ô¦ìº¡·¸¡A­nµÛ¤âOcalivaªº¤U¤@¥N·sÃÄ(§ó¨ã¦w¥þ©Ê»PÀø®Ä)¡A

¨º»òª½¨úSNP-630§@ÁpÃĶ}µo´N¬O³Ì¨Î³Ì§Ö³t¿ï¶µ¤§1 !

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/5/7 ¤W¤È 10:02:17²Ä 1935 ½g¦^À³

FDA¹ïOcalivaªººÃ¼{¦b¦w¥þ©Ê(¨x¬r)!

Ocaliva +SNP-630ÁpÃĦ³ÅãµÛªº¨ó¦P§@¥Î¡AOcaliva ¾¯¶q­°§C¡AÀø®Ä»P¦w¥þ©Ê§ó°ª§ó¨Î!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡G¶ø¥ì´µ¯S10031727  µoªí®É¶¡:2022/7/10 ¤U¤È 02:00:52²Ä 2218 ½g¦^À³
GLP1©MFGF21 ¹vÂIªºÃÄ¡A¥Ø«e¦³¤j¤À¤l¤Î¤p¤À¤lÃÄ¡C¤j¤À¤l³q±`³£¬Oª`®g¾¯«¬¡A³oºØ¥ÎÃĤ覡¦b¤j¶q¥B»Ýªø´Á¨Ï¥ÎªººC©Ê¯f¨Ó»¡¡A¸û¤£°Q³ß¡A°£«DÃĮīD±`«D±`ÅãµÛ¥[¤W»¡ªø¶g´Á¡A»¤¦]¥i¯à·|¤j¤@ÂI¡C

GLP1©MFGF21­Y§ï¦¨¤p¤À¤l(¤fªA)¡A¥ÍÅé¥i§Q¥Î²v·|¤U­°¡A©Ò¥H¦PÀø®Ä¤U¾¯¶qªÖ©w­n¥[¤j¡A¦ý¦¹Á|°Æ§@¥Î·|§ó©úÅã¡A©Ò¥H

SNP-6 ¨t¦C­Y°Æ§@¥Î»´·L«Ü¾A¦X»P GLP1©MFGF21 ¤p¤À¤lÃIJզX¥ÎÃÄ¡A¦p¦¹¥i´î¤Ö GLP1 ©M FGF21 ¤p¤À¤lªº¥Î¶q¡A¥H­°§C°Æ§@¥Î¡A¦P®É¦h¹vÂIªvÀø¥[­¼¤]¯à´£¤ÉÀø®Ä¡C

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
·|­û¡GROGER588910148151  µoªí®É¶¡:2022/7/10 ¤W¤È 09:27:33²Ä 2217 ½g¦^À³
KRAS¦­´Á´ºªp¦p¦PNASH²{¤µªº«Í¾î¹M³¥¡AÅý§ë¸êªÌ»D¤§¦âÅܤ£´±§ë¸ê...µM«áFDA®Ö­ã²Ä1¤äÃĪ«¥«ªp¦A¤«¼Q¡C

«ø¥Ø¥H«Ýµ¥FDA®Ö­ã²Ä1¤äNASHÃĪ«¡A¤ÞÃzNASH»â°ì!!!

------------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/7/2 ¤U¤È 01:35:37²Ä 2163 ½g¦^À³

·í²Ä¤@­ÓNASHÃĪ«¤W¥«¡ANASH»â°ì´N·|¯u¥¿ªº¤õÃz°_¨Ó¡C

-----------------------------------------------------------------------------------------------

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/1 ¤W¤È 11:22:42²Ä 1762 ½g¦^À³

¥h¬Ý¬Ý¦b¥þ²y­º´ÚKRAS¹v¦V药AMG-510(Sotorasib)¾_¾Ù¤W¥««á¡AKRASÅܦh¼öªù!(ÁÙ¦³¤@°ïÁ{§É«eªº¨S¯B¤WÂi­±)

从¤£¥i¦¨药¨ì¬ã发¦¨ªG¡§¤«喷¡¨¡A细说KRAS

www.drugtimes.cn/2021/10/29/congbukechengyaodaoyanfachengguojingpenxishuokras/

----------------------------------------------------------------------------------------------

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶

·|­û¡GROGER588910148151 µoªí®É¶¡:2022/3/1 ¤W¤È 11:01:40²Ä 1761 ½g¦^À³

DGAT1´¿¬O¥D¬y¹vÂI¡AKRAS¤§«e¤]¬O¸ó¤£¹L»Ùê¡A¤]³Q»{¬°¤£¯à¦¨ÃÄ¡C

²{¦b¤S¤@°ïÃĪ«¹v¦VKRASÅo!

¦^ÂÐ¥»¤å ¦^¿³Âd°Q½×°Ï1­¶
²Ä¤@­¶¤W¤@­¶5678910111213¤U¤@­¶¤U¤Q­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

ªYÄ£¥ÍÂå

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!